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Abstract 
The fundamental function of the Endoplasmic Reticulum (ER) is to process nascent 
membrane and secretory proteins in a calcium-dependent manner.  Disruption of ER 
function by the depletion of ER calcium results in ER stress, which triggers apoptosis if 
prolonged.  ER stress has been shown to play a role in the pathogenesis of Motor 
Neuron Diseases (MNDs) and CAG-repeat disorders. Kennedy’s Disease (KD) is an X-
linked neurodegenerative disease that is classified as both a MND and CAG-repeat 
disorder. In this Thesis I investigate whether ER Stress also plays a role in the 
pathogenesis of KD.  
Using a mouse model of KD, primary motoneuron cultures from both KD and wild-type 
(WT) embryos were established. Confocal microscopy was used to infer ER calcium 
levels, and markers of ER stress and ER stress-induced apoptosis were examined 
using western blot analysis and immunocytochemistry.    
KD motoneurons were found to have reduced levels of ER calcium and elevated levels 
of markers of ER stress and ER stress-induced apoptosis relative to WT controls. ER 
stress-induced apoptosis appears to contribute to the motoneuron death observed in 
KD mice,  since inhibition of ER stress with Salubrinal increases ER Ca2+, decreases 
ER stress-induced apoptosis and consequentially improves KD motoneuron survival.   
Examination of markers of ER stress in the spinal cord of KD mice revealed higher 
expression levels compared to WT controls, with the most significant increase detected 
between E13 and 3 months of age i.e. pre-symptomatically. Mitochondrial dysfunction 
and impaired mitochondrial biogenesis was also observed in KD motoneurons. 
However, increasing mitochondrial biogenesis was not as effective as inhibition of ER 
stress in improving KD motoneuron viability. 
These results show that ER stress may play an early, causal role in the pathogenesis 
of KD and suggest that inhibition of ER stress may be a potential therapeutic strategy 
for the treatment of KD. 
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1.1. Kennedy’s disease 
1.1.1 Introduction 
Kennedy’s Disease (KD), otherwise known as Spinal and Bulbar Muscular Atrophy 
(SBMA), is an adult onset, X-linked neurodegenerative disease that can be classified 
as both a Motor Neuron Disease (MND) and Polyglutamine (CAG-repeat) disorder 
(Gallo 2001). The prevalence of KD varies in different parts of the world. In regions of 
Italy for example, the prevalence of KD is 3.3 in 100,000 (Guidetti et al, 2001), which is 
lower than the prevalence of other inherited MNDs such as Amyotrophic Lateral 
Sclerosis (ALS). In regions of Finland however, the prevalence of KD is 13 in 85,000, 
which exceeds that of ALS (Udd et al, 1998).  
1.1.2 History 
Although Kennedy’s Disease was first described by William R Kennedy in 1968 
following a study of 11 patients from two families (Kennedy, 1968), the precise genetic 
defect underlying the disease was not identified for another 23 years. The initial 
suggestion that the underlying cause of KD was genetic came in 1982 (Fischbeck, et 
al, 1982), however it wasn’t until nine years later, in 1991, that a CAG-repeat 
expansion in the Androgen Receptor (AR) gene was identified as the genetic trigger 
(La Spada et al, 1991). Advances in our understanding of KD pathogenesis progressed 
quite rapidly following the discovery of the AR mutation. Within a year, a correlation 
between the CAG repeat number and the severity and onset of symptoms had been 
identified (Igarashi et al, 1992) and within three years, the first mouse model of 
Kennedy’s Disease had been developed, which has been a critical tool in identifying 
cellular processes that are impaired in the disease (Bingham et al, 1995). 
1.1.3 Etiology & Genetics of Kennedy’s Disease 
Kennedy’s Disease is thus caused by a Polyglutamine (CAG-repeat) expansion in exon 
1 of the AR gene on chromosome Xq-11-12 (La Spada et al, 1991). Repeat numbers of 
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greater than 40 result in disease manifestation, although there is some variation 
between individuals (Sinclair et al, 2007). Various aspects of the disease are 
modulated by the CAG-repeat number. It is generally accepted that the greater the 
number of CAG-repeats, the earlier the onset of disease symptoms (Katsuno et al, 
2008). It has also been suggested that a higher repeat number increases the likelihood 
of future generations possessing a greater number of CAG-repeats (Katsuno et al, 
2008). Dominant symptom type and symptom severity also appear to be dependent on 
the CAG repeat number (Suzuki et al, 2008). Motor-related symptoms for example, 
appear to be more severe in individuals possessing a higher repeat number, whereas 
sensory symptoms are thought to be more pronounced in patients with a lower number 
of CAG-repeats (Suzuki et al, 2008). 
At a protein level, the CAG-repeat is located in the N-terminal of the AR (Chamberlain 
et al, 1994). In normal individuals, the repeat number ranges between 9 and 36 (Sulek 
et al, 2005). A repeat number of greater than 40 however, results in a gain-of-function, 
mis-folded protein toxicity, accompanied by loss of normal protein function (Palazzolo 
et al, 2008). 
 
1.1.4 Histopathology 
1.1.4.1 Neuronal histopathology 
A fundamental feature of KD is the loss of spinal and bulbar motoneurons, particularly 
those originating from the anterior horn of the spinal cord and the brainstem nuclei 
(Sobue et al, 1989). Cranial nerves III (Oculomotor), IV (Trochlear) and VI (Abducens), 
which innervate extraocular muscles (Chilton and Guthrie, 2004) however, appear to 
remain unaffected in the disease (Sobue et al, 1989).  An important feature of KD is 
that upper motoneurons appear to remain unaffected, although this suggestion has 
recently been challenged following electrophysiological studies of KD patients, which 
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suggest sub-clinical involvement of upper motoneruons (Pachatz et al, 2007, Eisen, 
2007).  
At a cellular level, a hallmark of all CAG-repeat diseases is the presence of mutant 
protein Nuclear Inclusions (Yamada et al, 2000). KD is no exception to this, with 
Nuclear Inclusions (NIs) containing the mutant AR present in residual brainstem and 
anterior horn motoneurons (Figure 1.1) and testes of KD patients (Suzuki et al, 2007, 
Adachi et al, 2007). Structural information about the NIs found in KD tissue has come 
from the use of antibodies that are targeted to specific areas of the AR. When the 
antibodies used are targeted to the N-terminal of the AR as well as the CAG-repeat 
region specifically, NI staining is positive (Tahiri et al, 2001). However, when antibodies 
are targeted to the C-terminal of the AR, the NIs are no longer detectable (Tahiri et al, 
2001). This indicates that the formation of NIs either leads to the truncation of the C-
terminal or physically conceals it, which suggests that the normal ligand-binding 
function of the AR C-terminal (discussed in Section 1.3.1.4) is impaired in KD. 
The precise nature of the role of NI formation in disease pathology has yet to be 
determined. Although their presence is a key feature of Polyglutamine Diseases and 
their suggested structure implies that protein function is impaired, NIs containing the 
mutant AR are observed in cells in areas that remain unaffected in KD. For example, 
both the Basal Ganglia and Hypothalamus, which are not affected in KD, appear to 
contain NIs (Adachi et al, 2005). 
As well as the accumulation of the mutant AR protein, the accumulation of 
phosphorylated- and non-phosphorylated neurofilament proteins and synaptophysin is 
also observed in distal motor axons of KD mice, which could reflect a defect in axonal 
trafficking (Katsuno et al, 2006). However, as discussed below (Section 1.4.2), it has 
recently transpired that axonal transport defects may not play a substantial role in KD 
pathogenesis (Malik et al, 2011). 
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Figure 1.1: Nuclear Inclusions are observed in the anterior horn of KD patient 
spinal cord 
Nuclear Inclusions are a histopathological feature of Kennedy’s Disease.  (A) 
Immunohistochemical analysis of the accumulation of the Androgen Receptor protein, 
using an anti-CAG-repeat antibody, shows aggregation in the motoneuron nuclei (white 
arrows) of the anterior horn of KD patients. The image is taken from Suzuki et al, 
2007).  When the relationship between CAG repeat number and nuclear accumulation 
of the AR protein is observed, as shown in the graph (B), taken from Adachi et al, 
2005, there appears to be a positive correlation.  
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1.1.4.2 Muscle histopathology 
Characteristic myogenic histopathology has also been observed in KD patients and 
skeletal muscle from mouse models of KD.  
It has been suggested that myogenic events may be as important as neuronal events 
in KD pathogenesis. For example, in an animal model of KD in which the mutant AR 
protein is expressed in muscle tissue exclusively, the same neuromuscular phenotype 
was apparent as that observed in animal models expressing the mutant AR in both 
motoneurons and muscle even though no motoneuron degeneration was observed 
(Dupuis et al, 2010). This suggests that myogenic events play a pivotal role in KD 
neuromuscular pathology. 
In some respects the muscle histopathology that is associated with KD is not typical of 
MNDs because the severity of the myogenic histology does not appear to directly 
correlate with the duration of the disease (Soraru et al, 2008). In a study based on 8 
KD patients in which muscle biopsies were examined, it was found that 6 out of 8 
patients possessed myogenic anomalies including fibre splitting and scattered 
basophilic fibres (Soraru et al, 2008). There also appeared to be variation amongst 
patients with respect to muscle histology, with the fibre size varying significantly 
(Soraru et al, 2008). The abnormalities however, did not appear to correlate with 
disease duration, despite appearing to be more prominent with increasing patient 
disability (Soraru et al, 2008). Myogenic pathology also appears to be wide-spread in 
KD, with progressive atrophy of all three types of muscle fibre (Type 1, 2a and 2b) 
being observed (Greenland & Zajac 2004). 
As is the case with motor axons, the accumulation of phosphorylated and non-
phosphorylated neurofilaments and synaptophysin also appears to occur in skeletal 
muscle of AR97Q KD mice and KD patients, as shown by immunohistochemistry, 
suggesting that axonal transport could be impaired in this cell type (Katsuno et al, 
2006).  However it appears unlikely that the presence of the mutant AR directly disrupts 
19 
 
cellular transport. Indeed, when -bungarotoxin was used to label neuromuscular 
junctions, it was found that neurofilaments and synaptophsyin accumulated at the most 
distal end of the motor axon in both mice and KD patients whereas the mutant AR 
accumulated in the nucleus. Thus a physical association between the mutant AR and 
these proteins seems unlikely and therefore it is also unlikely that the mutant AR 
directly disrupts axonal transport (Katsuno et al, 2006, Malik et al, 2011). 
1.1.5 Clinical Features of KD 
1.1.5.1 Manifestation in affected males 
The symptoms that are associated with KD can be classified as motor, sensory, or 
endocrine. Motor symptoms arise as a result of spinal and bulbar motoneuron 
degeneration (Suzuki et al, 2008). The most common motor symptoms include 
weakness and wasting of bulbar, facial and limb muscles (for review see Greenland & 
Zajac, 2004).  Symptoms tend to begin in male carriers of the mutant AR gene between 
the third and fifth decade of life (Suzuki et al, 2008), although some mild symptoms, 
such as muscle weakness and hand tremors, have been reported by patients in their 
teenage years (Greenland & Zajac, 2004). The first disease manifestations include 
postural tremor, flexor muscle cramps and a hanging jaw (Larsen et al, 2005). Proximal 
flaccid weakness also occurs, usually in lower limbs before upper limbs. In 
approximately one third of KD patients, rapid muscle fatigability is also reported to be 
an early clinical manifestation (Lee et al, 2005). All of these initial symptoms remain 
throughout the disease and deteriorate with disease progression (Larsen et al, 2005). 
With time, bulbar symptoms also appear, for example, difficulty swallowing, which 
occurs as a result of wasting of the tongue, jaw and throat muscles (Greenland & 
Zajac, 2004). 
KD progresses relatively slowly compared to other MNDs. In a study of 223 patients, 
motor symptom progression was observed and found to deteriorate over a period of 10 
years (Atsuta et al, 2006). For example, the median age at which patients required the 
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assistance of a handrail to climb stairs was found to be 49 years of age, however it 
wasn’t until the age of approximately 61 that most patients had such severe motor 
defects that they were confined to a wheelchair (Atsuta et al, 2006). Kennedy’s 
Disease does not appear to directly affect the life-span of patients, although sufferers 
are more prone to complications that increase the risk of mortality, such as aspiration 
pneumonia and choking as a result of severe bulbar effects (Larsen and Smith, 2005). 
Sensory symptoms that often accompany these motor symptoms were initially thought 
to be relatively minor in severity. However, it now appears that in some cases, sensory 
symptoms can be just as severe as motor symptoms and the original concept that 
sensory symptoms were mild in KD patients was a result of relatively insensitive 
diagnostic tools as well as incorrectly identifying the peak time at which such symptoms 
occur (Polo et al, 1996). Indeed, a small-scale electrophysiological study of both male 
patients and female carriers revealed that sensory deficits peak at earlier stages of the 
disease (Polo et al, 1996). A larger scale, electrophysiological study of over 100 
patients showed pathological lesions in the Dorsal Root Ganglion (DRG). Furthermore, 
the F-wave latency was significantly longer in patients than in controls and the 
maximum F-wave conduction velocity was significantly lower in patients, most 
predominantly in upper limbs, indicating that cervical neurons that innervate upper 
limbs could be affected more severely than lumbar neurons innervating lower limbs 
(Suzuki et al, 2008). Other studies have also revealed that in a small number of 
patients, the tendon reflex is absent and the trigeminal reflex is severely abnormal 
(Antonini et al, 2000). 
It has been suggested that such sensory symptoms are more dominant in patients with 
lower CAG-repeat numbers (Adachi et al, 2005). This could be due to the effect that 
the CAG-repeat length appears to have on the distribution of the mutant AR within the 
neuron (Adachi et al, 2005). For example, ARs containing a longer CAG-repeat tend to 
exist relatively diffusely in the nucleus, whilst AR proteins containing shorter CAG-
repeats, associated with dominant sensory symptoms, tend to form cytoplasmic 
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aggregations (Adachi et al, 2005). Thus this difference in localization within neurons 
could account for variations in symptom type dominance. 
Endocrine symptoms that are present prior to and alongside neurological symptoms 
include androgen resistance, gynacomastia and decreased fertility, as well as elevated 
levels of testosterone and progesterone in the bloodstream. Such symptoms however, 
are variable and do not occur in all cases of KD (Li et al, 2007). In a study of 22 KD 
patients for example (Dejager, 2002), it was found that 80% of subjects presented with 
gynacomastia that occurred post-puberty but prior to the presentation of muscle 
weakness, whilst just over half of the patients monitored experienced alterations in 
testicular function (Dejager, 2002). The majority of patients (86%) developed androgen 
resistance at later disease stages, whilst 68% of patients possessed elevated blood 
levels of testosterone. Thus there is variation in the presentation of endocrine 
symptoms between patients. As is the case with neurological symptoms, a correlation 
between CAG-repeat length and endocrine symptoms has also been observed. It 
appears that the longer the length of the CAG repeat, the weaker the transactivation of 
the AR, which is consistent with the presentation of more severe symptoms (Dejager, 
2002). 
 
1.1.5.2 Symptom manifestation in female carriers 
Females carrying the mutant AR gene do not usually show clinical signs of KD 
(Schmidt et al, 2002). On the rare occasion that they do, symptoms are very mild 
relative to those of male carriers (Karaer et al, 2005). The presentation of  symptoms in 
females is thought to occur as a result of skewed inactivation of one the X 
chromosomes according to the Lyon Hypothesis (Paradas et al, 2008), so that one of 
the two X chromosomes is randomly inactivated resulting in the mutant AR gene being 
expressed in the absence of a dominant wild-type AR gene. Symptoms reported in 
female carriers include minimal distal muscle weakness, cramps and fasciculations 
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(Soraru et al, 2008). Electrophysiological data and muscle biopsies from female 
carriers also revealed very mild neurogenic and myopathic alterations such as a 
reduction of sensory action potentials and calf hypertrophy (Soraru et al, 2008), whilst 
electrophysiological studies revealed that signs of mild, chronic denervation of muscle 
groups including the Tibialis Anterior muscle and the Orbicularis Oris muscle appear to 
be the most common symptoms apparent in heterozygous females (Mariotti et al, 
2000). Motor and sensory conduction velocities however, usually appear to be within 
the normal range in heterozygous females, indicative of an absence of neuropathy 
(Mariotti et al, 2000). 
 
1.1.6 Diagnosis of Kennedy’s Disease  
There are various ways in which Kennedy’s Disease is diagnosed and distinguished 
from other MNDs and myopathies such as Amyotrophic Lateral Sclerosis (ALS) and 
Inclusion Body Myositis (IBM), respectively. The diagnosis of KD is partially based on 
family history of the patient, i.e. whether or not other family members have suffered 
from the disease. However this approach alone is not sufficient to make a reliable 
diagnosis (Domitrz et al, 2001).  
The gold standard when diagnosing KD is genetic analysis, which is used to assess the 
AR CAG-repeat number in patients (Georgiou et al, 2001). DNA samples are taken 
from patients using non-invasive techniques such as peripheral blood extraction 
(Atsuta et al, 2006) and amplified using primers flanking the CAG-repeat. Genetic 
analysis allows a precise diagnosis of individuals to be made and is thus essential 
when diagnosing a disease such as KD, which phenotypically resembles other 
diseases. 
To compliment genetic analysis, other diagnostic tools are utilised. Neurological 
examinations such as electrophysiological recordings are used to identify the presence 
of the symptoms discussed above (Section 1.1.5.1). Compound muscle action 
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potentials for example, are measured in potential KD patients. It has been found 
previously that the magnitude of muscle action potentials decreases in KD, which is 
indicative of axonal degeneration (Suzuki et al, 2008). This decrease in compound 
action potential is often more noticeable in upper limbs than lower limbs (Suzuki et al, 
2008). Evoked action potentials tend to have more prolonged peak latencies in KD 
patients than in healthy individuals. Transcranial Magnetic Stimulation (TMS) also 
reveals that the motor threshold for evoked potentials, that is, the TMS voltage needed 
to stimulate action potentials and evoke movement, is higher in KD patients (Lai et al, 
2007). 
Biopsies from both muscle and scrotal tissue are also used to assist in the diagnosis of 
KD. In muscle tissue, neuropathic and myopathic alterations are present (as discussed 
above), particularly in severely affected muscle, whilst in scrotal tissue nuclear 
accumulation of the mutant AR is observed (Soraru et al, 2008, Adachi et al, 2007). 
In addition, plasma levels of Creatine Kinase (CK) can be measured. CK has been 
previously shown to increase in the plasma of male carriers of the mutant AR gene 
(Sorenson et al, 2008). However, the identification of elevated plasma CK levels alone 
is not enough to confirm a case of KD, as CK levels are elevated in other neurological 
disorders, such as Alzheimer’s Disease (Fassbender, 2001). 
 
1.2. Models of KD 
Since the identification of the CAG-repeat expansion in KD, several animal models 
have been developed in an attempt to establish and understand the pathogenic 
mechanisms underlying the disease further.  
The challenges that are faced when developing animals models of KD include: slow 
disease progression, limited life-span of animals,  maintaining disease specificity, 
developing a disease time course that is amenable with drug testing and accounting for 
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the fact that KD is predominantly a lower motoneuron and gender-specific disease 
(Merry, 2005, Sobue et al, 1989). Early attempts at developing a model of KD included 
the use of several cell lines expressing an AR protein with 44 CAG-repeats (Bingham 
et al, 1995). An interferon-inducible antiviral Mx promoter and a neuron-specific 
enolase (NSE) promoter were used to introduce a human cDNA AR fragment with 44 
CAG-repeats into neuronal cell lines. However, in such cell lines, there was no 
detectable neuronal phenotype or repeat instability (Bingham et al, 1995), making 
these models unsuitable for the investigation of KD pathogenesis. 
A transgenic mouse model was later developed by La Spada (La Spada, 1998), in 
which a mouse line containing 45 CAG-repeats in the AR protein was developed using 
a Yeast Artifical Chromosome (YAC). The methodology for the generation of a YAC 
transgenic model is described in more detail below. This model was again relatively 
unsuccessful at modelling KD, as no neuronal phenotype was detected in AR45 mice, 
even at 18 months of age. Furthermore, the expression of the AR45 transgene was not 
detectable in all tissues of interest, suggesting that the genetic manipulation alters the 
expression pattern of the gene. Other models of KD that failed to recapitulate the KD 
phenotype were also developed using 65 CAG-repeats (Merry et al, 1996).  
Some models have been developed that do produce a neurological phenotype, but not 
one that accurately recapitulates KD. In 2001 for example, a truncated construct of the 
AR was used to develop of transgenic KD mouse (Abel, 2001). The phenotype of this 
mouse varied with the promoter used to generate the model. For instance, when a 
prion promoter was used, severe neurological symptoms were present as early as 2 
months of age followed by an early death. However when a neurofilament (NF-L) 
promoter was used instead, motor-specific symptoms appeared at approximately 8 
months of age (Abel et al, 2001). However, neither of these models had lower 
motoneuron-dominant pathology, a key characteristic of KD. 
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The features of the above models, in combination with the apparent inverse correlation 
between CAG-repeat size and time of symptom onset, lead to the idea that expanding 
the length of the CAG-repeat and using the most suitable promoter would improve the 
animal model and thus the transgenic mouse that was developed will now be 
discussed. 
The AR100 mouse model of KD that was examined in the experiments described in 
this Thesis was developed by Albert La Spada in the US and has been obtained 
through collaboration with his lab. The AR100 transgenic mouse was created using a 
Yeast Artifical chromosome (YAC) as a transgene. A human AR gene, containing 100 
CAG repeats in exon 1, was introduced to a YAC using the ‘pop-in, pop-out’ method 
(La Spada et al, 1998). Resultant YAC-bearing yeast cells were then fused with 
embryonic stem (ES) cells. Real-Time (RT) PCR was used to confirm the presence of 
the human AR transcript and human AR-positive ES cells were injected into C57BL/6J  
mouse blastocysts to create chimeric mice, whose identity was confirmed using 
Western blot analysis (Sopher et al, 2004).  
AR100 mice have been extensively characterized by both Professor La Spada’s group 
and our own and have been found to exhibit a progressive motor deficit. The first 
symptom to manifest in AR100 mice is growth retardation, which occurs at 
approximately 8 months of age (Sopher et al, 2004). By 10 months of age, AR100 mice 
appear to be smaller than Wild-Type (WT) littermates and have a lower body mass. 
This decrease in body mass in AR100 mice is shortly followed by proximal muscle 
weakness, which gives rise to curvature of the spine, giving the mice a kyphotic 
appearance. By 11 months of age, there is a difference in stride length between AR100 
mice and WT controls and by 14 months of age mobility is impaired in the diseased 
mice. At this time point, AR100 mice also start to have difficulty in walking and hindlimb 
atrophy is observable, which eventually leads to hindlimb paralysis. Between the ages 
of 15-24 months, mortality is higher in AR100 mice and is usually the result of an 
unknown cause that requires euthanasia. Importantly, by 18 months AR100 mice have 
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lost a significant number of motoneurons, and only an average of 60% of motoneurons 
survive (Malik et al, 2011). Thus the symptoms, which manifest in AR100 mice, 
resemble KD patient symptom manifestation. Furthermore, female AR100 mice fail to 
express the full KD phenotype – in keeping with the fact that KD manifests solely in 
male patients. 
 
1.3. Androgens and the Androgen receptor 
In order to determine how a mutation in the androgen receptor could give rise to KD, it 
is important to understand both the normal functions of androgens, which will give an 
indication of which processes are most likely to be affected, and the locations at which 
androgen receptors are highly expressed, which will give an indication of where 
disease pathology is likely to occur. 
The majority of androgens are secreted into the bloodstream in the form of 
testosterone (Lin et al, 1997). Testosterone is cell permeable and is metabolized in the 
cytosol by 5-reductase into dihydrotestosterone (DHT). It is generally accepted that 
Testosterone and DHT both activate the same AR, although their downstream effects 
are thought to vary to some extent, with testosterone appearing to regulate the 
anabolic effects of androgens, whilst DHT appears to regulate androgenic effects 
(Sundaram et al, 1995). 
1.3.1 Androgen receptor structure and expression 
The AR is a ligand-activated transcription factor that belongs to group 1 of the nuclear 
receptor super family (Centenera et al, 2008). The AR is a modular protein that 
contains functionally separate domains; the amino-terminal domain (NTD), which 
contains the CAG repeat that is expanded in Kennedy’s Disease, the DNA-binding 
domain (DBD), a hinge region and the ligand (androgen)-binding domain (LBD). A 
schematic representation of the structural domains in shown in Figure 1.2. Post-
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translational modification of the receptor in the form of phosphorylation – both basal 
and ligand-activated (Gioeli et al 2002), acetylation, ubiquitilation and sumoylation can 
have varying effects on receptor activity (reviewed by Faus & Haendler 2006). The 
effects of modification of each of the AR protein domains will be considered in more 
detail below. 
 
1.3.1.1 The amino terminal domain (NTD) 
The NTD, otherwise known as activation function -1 (AF-1) in the case of the AR, is not 
well conserved amongst nuclear receptors. Indeed, within group 1, there is only 15% 
homology in the NTD sequence (McEwan et al, 2007). A major role of the NTD is 
receptor activation. Within AF-1, two transcription activation units, (Tau-1 and -5), have 
been identified (Jenster et al, 1995). Both units appear to be necessary and sufficient 
for the full activity of the AR, with mutations in either unit resulting in the AR protein 
becoming completely inactive (Callewaert et al, 2006). 
The NTD contains a polymorphic glutamine (CAG) repeat and changes in length of the 
repeat have been associated not only with KD, but also with prostate cancer (Sinclair et 
al, 2007). The CAG repeat appears to mediate various aspects of androgen receptor 
activity such as the magnitude of response. AR proteins containing fewer CAG repeats, 
for example, appear to be more potent transcription factors (Callewaert et al, 2003a). 
As well as a poly-glutamine repeat, the NTD also contains a poly-glycine repeat. 
Changes in the length of this glycine expansion have also been associated with 
prostate cancer (Ding et al, 2005). 
Post-translational modification of the NTD has various effects on AR activity (Faus & 
Haendler 2006). Dephosphorylation of the domain by Protein Phosphatase 2A for 
example, has been found to result in a decrease in activity (Yang et al 2005). Likewise, 
binding of the E3 ligase; C-terminus of Hsc70-interacting protein (CHIP) to the NTD 
also results in repression of AR activity (He et al 2004). However, the monoubiquitilated 
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form of the AR is suggested to have enhanced transcriptional activity (Burgdorf et al 
2004). 
1.3.1.2 The DNA-binding domain (DBD) 
The DBD is involved in receptor dimerization that occurs following ligand activation of 
the receptor. In all nuclear receptors the DBD is a highly conserved region consisting of 
three -helices that contain cysteine-rich zinc fingers, and a C-terminal extension 
(CTE) of at least 12 residues in length (Schoenmakers et al, 1999).  The zinc fingers, 
which interact with DNA, are essential for the function of the receptor and its structural 
integrity (Glass, 1994), whilst the CTE is involved in dimerization of the receptor. It is 
not well conserved and varies with different nuclear receptors, resulting in receptor 
specificity. 
 
1.3.1.3 The Hinge domain 
The hinge domain of the AR is thought to have various functions. It is a poorly 
conserved, flexible domain that separates the DBD and LBD that is involved in DNA 
binding, nuclear translocation and transcriptional activity of the receptor (Verrijdt et al, 
2003, Zhou et al, 1994). For example, deletion of residues specific to the region, result 
in prolonged androgen responses, suggesting that the hinge domain mediates the 
duration of androgen-induced transcription (Tanner et al, 2004). 
The Hinge domain has been found to be subject to post-translational acetylation (Fu et 
al 2000). Acetylation of the domain is modulated by enzymes such as P300/CBP-
associated factor (P/CAF) and appears to be essential for normal AR function. Indeed, 
mutations of the modulation site have been found to result in functional impairment of 
the receptor (Fu et al 2000). 
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1.3.1.4 The Ligand-Binding Domain (LBD) 
The LBD regulates the activity of the AR. Its basic structure is a twelve -helical 
‘sandwich’ with a central ligand-binding region (Matias et al, 2000). Androgen activation 
of the receptor involves the closure of the ligand-binding pocket by movement of the 
twelfth helix of the LBD (Moras & Gronemeyer, 1998). The re-structured LBD is then 
thought to behave as a docking site for co-activators of the AR (Claessens et al, 2008). 
As well as interacting with AR ligands i.e. testosterone and DHT, the LBD also interacts 
with agonists and antagonists of the AR, such as mibolerone and Flutemide, 
respectively (Kemppainen et al, 1999, Gao & Dalton, 2007). 
1.3.1.5 Androgen Receptor expression 
The AR is expressed predominantly in ‘androgen target’ tissues including skeletal 
muscle, the prostate, liver, skin, and the central nervous system (CNS). RT-PCR has 
revealed that expression is at its highest in the adrenal gland, epididymis and prostate 
(Keller et al, 1996). Thus androgen effects are wide spread and involved in a vast 
number of essential processes.  
In the context of this study, the most interesting location of the AR protein is in the 
CNS, specifically in motoneurons. The expression of ARs in motoneurons has been 
suggested to be regulated downstream of BDNF signalling (Hussein et al, 1997, Yang 
et al, 2000). When BDNF availability was prevented by axotomy in bulbar 
motoneurons, androgen receptor number appeared to decrease. This decrease was 
then rescued by BDNF application (Yang et al, 2000). 
Although the precise role of androgen-mediated pathways in motoneurons has yet to 
be fully established, the most likely function of androgens in motoneurons is to provide 
essential trophic support to aid synaptic organization during development (Cary & La 
Spada, 2008, Fargo et al, 2009). For example, testosterone has been shown to 
mediate the survival of sexually dimorphic motoneuron populations such as the 
dorsolateral nucleus (DLN). 
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Figure 1.2 
 
 
 
 
This Figure depicts a schematic representation of the AR protein, compose of 4 
domains. The amino-terminal domain (encoded by exon 1), contains the poly-CAG 
tract mutated in KD. The  DNA-binding domain (encoded by exons 2 and 3), is formed 
by two zinc fingers, and the hinge region, which contains the PEST sequence and the 
nuclear localization signal (NLS). The ligand-binding domain is encoded by exons 4-8. 
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Indeed, when female rats were treated with testosterone prenatally, there was reduced 
DLN motoneuron death compared to untreated female controls (Breedlove et al, 1981). 
Conversely, males possessing a loss-of-function mutation in the androgen receptor 
gene possess a ‘female’ number of DLN motoneurons in adulthood (Breedlove et al, 
1981). Androgens also exert trophic effects on motoneurons indirectly. For instance, 
they have been suggested to regulate the survival of bulbar motoneurons indirectly via 
their actions on target muscle, which include the enhancement of myogenic cell 
commitment and satellite cell proliferation (for review see Maclean & Handlesman, 
2009) Androgen treatment in rats during late prenatal development appears to reduce 
bulbar motoneuron death despite bulbar motoneurons not expressing ARs until the 
second postnatal week (Jordan et al, 1997). 
Androgens have also been suggested to maintain the morphology of motoneurons 
during adulthood, with manipulation of androgens affecting motoneuron soma size in 
adult rats. For example, the castration of male rats and the consequential decrease in 
androgen availability results in shrinkage of bulbar motoneurons, which is prevented by 
testosterone treatment (Kurz et al, 1991). In a recent study, it has also been suggested 
that androgens may play a crucial role in mediating axonal transport in motoneurons 
(Kemp et al, 2011). When live cell imaging was used to monitor endosomal trafficking 
in sciatic nerve axons from both a knock-in model and a myogenic transgenic model of 
KD, a deficit in both the flux and run length of retrogradely-transported endosomes was 
impaired (Kemp et al, 2011). However, using the AR100 mouse model examined in this 
Thesis, our group did not detect any axonal transport deficits in either embryonic or 
adult AR100 motoneurons (Malik et al, 2011). The role of axonal transport deficits in 
KD pathogenesis is discussed in more detail on Section 1.4.2. 
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1.3.2 Genomic actions of Androgens 
The genomic actions of androgens, which result in the transcription of various 
downstream target genes, occur within minutes to hours of androgen receptor 
activation. Upon binding of Testosterone or DHT to the androgen receptor, the receptor 
dissociates from a cytoplasmic chaperone complex and the AR-ligand complex 
dimerizes at a consensus sequences of 5’-TGTTCT-3’ (Glass, 1994). The homodimer 
then translocates to the nucleus.  Once the AR dimer enters the nucleus it binds to 
sequences of DNA known as Androgen Response Elements (AREs) and recruits 
cofactors that are required for the execution of target gene transcription. Such 
cofactors include histone acetyltransferase proteins such as CREB-binding protein 
(CBP), which is involved in modulating oestrogen signalling,  and methyltransferase 
proteins such as Co-activator-associated arginine methyltransferase 1 (CARM1), which 
is required for the anabolic effects of androgens that occur during development (Baek 
et al, 2006). Figure 1.3 summarizes AR activation. 
Genes that are transcribed downstream of androgen receptor activation include 
cystatin-related protein genes (crps). Crps are involved in various sexual functions 
such as spermatogenesis. Rhox genes, which are transcription factors involved in 
embryogenesis and gametogenesis, are also transcribed downstream of AR activation 
(MacLean & Wilkinson, 2010). Thus genomic androgen effects are vital for sexual 
development, which is the process most commonly associated with androgens (Ho et 
al, 2011). 
Other genes that are transcribed downstream of AR activation have other functions that 
are not immediately associated with androgens. One such function is the maintenance 
of normal cellular Ca2+ handling.   
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Figure 1.3: Androgen receptor activation and genomic actions 
Genomic actions of androgens are elicited by a well characterized chain of events, 
which are depicted in this Figure. Initially, Testosterone diffuses into the cytosol where 
it is reduced to dihydrotestosterone (DHT) by 5-reductase (1). Upon binding of DHT to 
the androgen receptor (AR), the AR-DHT complex dissociates from the heat shock 
protein complex that normally stabilizes the AR (2). The receptor-ligand complex then 
diffuses into the nucleus where it dimerizes (3) and binds to sequences of DNA 
referred to as androgen response elements (ARE). Genes containing this sequence of 
DNA are transcribed downstream of AR activation. When the AR-DHT complex binds 
to the ARE, cofactors are recruited along with RNA polymerase II, allowing mRNA to 
be transcribed (4). This chain of events occurs over a period of minutes to hours. 
T = Testosterone 
DHT = Dihydrotestosterone 
5-R = 5-Reductase 
AR = Androgen receptor 
Hsp 70/90 = Heat Shock Protein 70/90 
ARE = Androgen Response Element 
ARA 70= Androgen receptor co-activator 70-Kd (Miyamoto 1998) 
SRC-1= Steroid Receptor Coactivator -1 (Ye 2005) 
CBP= CREB Binding Protein (Frᴓnsdal 1998) 
SP-1= Specificity Protein 1- an ubiquitous transcription factor (Dame 1997) 
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Figure 1. 3 
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For example, following AR activation, the Sarco/Endoplasmic Reticulum ATPase 2 
(SERCA2) pump gene is one of the target genes transcribed (Foradori et al, 2008). The 
SERCA2 pump, which is the SERCA pump isoform that is expressed specifically in 
neurons, is located in the ER membrane. It sequesters Ca2+ from the cytosol and 
actively pumps it into the ER lumen against its concentration gradient. This decreases 
cytosolic Ca2+ and facilitates refilling of ER calcium, both of which are protective to cells 
(see Chapter 3 for more detail). Real Time (RT) PCR has been used to show that 
activation of the androgen receptor in hippocampal neurons results in an increase in 
the level of SERCA2 mRNA, causing an increase in ER Ca2+, which is required  for 
normal cellular function (Foradori et al, 2008). 
As well as cellular Ca2+ handling, genes transcribed downstream of AR activation also 
include essential cytoskeletal genes that are involved in cell division and intracellular 
transport. For instance, the expression of -actin and -tubulin mRNA in male rat 
motoneurons was found to decrease following castration, which effectively decreases 
androgen availability (Matsumoto et al, 1994). Furthermore, this apparent decrease in 
transcription was counteracted by the administration of testosterone, indicating that 
transcription of these genes is a direct result of AR activation (Matsumoto et al, 1994). 
1.3.3 Non-genomic actions of androgens 
It has only been in recent years that the rapid, ‘non-genomic’ actions of androgens 
have received more attention.  These androgen-mediated actions have a relatively 
short latency and occur within seconds to minutes of AR activation. Interestingly, such 
responses have been shown to be evoked by non-permeable forms of Testosterone 
and DHT (for example, BSA-bound DHT), which suggests that, as well as intracellular 
receptors, plasma membrane-associated ARs with extracellular ligand-binding domains 
also exist (for review see Li & Al-Azzawi, 2009). 
Although the precise mechanism by which rapid androgen-mediated actions are 
elicited has yet to be fully established, it is accepted that the responses occur either at 
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the plasma membrane or within the cytosol, but not in the nucleus or rough ER as they 
are insensitive to inhibitors of transcription and translation (Heinlein et al, 2002). 
One of the most frequently observed consequences of Androgen-mediated, non-
genomic actions in various cell types, including neurons, is a rapid increase in cytosolic 
calcium.  There are several possible mechanisms by which the increase in calcium 
could be elicited so rapidly following AR activation.  One suggestion is that the plasma 
membrane-associated androgen receptor is a G-protein coupled receptor that is linked 
to Phospholipase C (PLC) and thus Inositol trisphosphate (IP3)-mediated Ca
2+ release 
form the ER is induced downstream of AR activation. Ca2+ influx via voltage-gated and 
ligand-activated Ca2+ channels, as an indirect effect of AR activation, is also thought to 
accompany this (Foradori et al, 2009, Michels & Hoppe, 2008). Alternatively it has been 
suggested that rapid increases in intracellular Ca2+ following AR activation occur as a 
direct inhibitory effect on plasma membrane Ca2+ ATPases (PMCAs), which expel Ca2+ 
from the cytosol (Zylinska et al, 2009). 
As well as the generation of rapid Ca2+ signals, rapid androgen-mediated effects are 
also thought to include the activation of the MAP Kinase pathway as well as Protein 
Kinases A and C, both of which are enhanced by the elevation of intracellular Ca2+ and 
thus could occur downstream of the Ca2+ signalling discussed above (Kousteni et al, 
2001, Ricote et al, 2006). The activation of Protein Kinases A and C and MAP Kinase 
is upstream of various cellular processes such as Glucose metabolism, actomyosin 
assembly contraction and the activation of transcription factors such as NF-B. Thus 
rapid androgen effects potentially mediate a wide variety of essential processes. 
 
1.4. Kennedy’s Disease pathogenesis 
The precise mechanism underlying KD pathogenesis has yet to be established and as 
with many other neurodegenerative diseases, it is notoriously multifactorial and is likely 
to occur as the result of a combination of pathogenic mechanisms.  Furthermore, 
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because of the progressive nature of the disease, it is difficult to determine which 
phenomena are causative in disease pathology, and which occur as a secondary 
effect. Some of the pathogenic mechanisms that have been suggested to play a role in 
KD pathology and other similar MNDs and CAG-repeat diseases will be discussed 
here. 
1.4.1 Alterations in transcription 
Considering the majority of AR-mediated actions result in alterations in gene 
transcription, it is not surprising that the N-terminal CAG repeat expansion mutation in 
the AR has been found to result in alterations in transcription that could contribute to 
KD pathogenesis. For example, the transcription of Nicotinamide Adenine Dinucleotide 
(NADH) dehydrogenases 1 and 5 is found to decrease as a consequence of mutant AR 
expression (Ranganathan et al, 2009). NADH dehydrogenases 1 and 5 are vital 
subunits of complex I of the electron transport chain. Their decrease in expression 
appeared to occur in both cell lines transfected with a mutant androgen receptor and in 
a transgenic mouse model of KD (Ranganathan et al, 2009). As a result, the 
mitochondrial membrane is depolarised and thus one consequence of mutation-
mediated changes in transcription is mitochondrial function impairment, which will be 
examined in more detail in Chapter 5. Because there are so many transcriptional 
changes that occur as a result of the AR mutation (Mo et al, 2010, Slagsvold et al, 
2000, Koochekpour, 2010), it is important to identify the largest and most consistent 
changes, i.e. those that are likely to have the greatest impact on cellular processes. 
One of the most effective ways to assess the most prominent changes in transcription 
is to perform microarray analysis. This has recently been carried out in both skeletal 
muscle (Mo et al, 2010) and embryonic motoneurons (Malik et al, personal 
communication) from transgenic mouse models of Kennedy’s Disease. In skeletal 
muscle, the largest and most consistent changes in transcription, which occurred in all 
animal models tested, included genes that are involved in cell adhesion, energy 
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balance, myogenesis and muscle atrophy (Mo et al, 2010). VEGF and Integrin beta 1 
binding protein 3 (Itgb1bp3), which is also known as MIBP, and is involved in the 
inhibition of myocyte adhesion to laminin, were also reduced. Increases in the 
expression of some genes were also found to occur in the skeletal muscle of all mouse 
models tested, including, Ankyrin repeat domain 1 (Ankrd 1), which is involved in  many 
aspects of muscle development such as structural fixation of the contractile machinery 
(Tee, 2010). 
Microarray analysis of primary motoneurons from the AR100 mouse model of 
Kennedy’s disease has also revealed changes in transcription of over 400 genes (Malik 
et al, personal communication). Although there appears to be a larger number of genes 
that decrease in AR100 motoneurons, the largest magnitude of change is found in 
genes whose expression increases. Thus microarray analysis does not reveal a single, 
underlying trigger, but confirms the likely multifactorial nature of KD pathology. 
 
1.4.2 Axonal transport 
Although the role of axonal transport changes in Kennedy’s Disease remains 
controversial (Kemp et al, 2011, Malik et al, 2011), the involvement of this cellular 
malfunction in both MNDs and CAG-repeat disorders has been clearly established.  
Axonal transport dysfunction has been found to occur in MNDs such as Amyotrophic 
lateral Sclerosis (ALS) prior to symptom onset in vitro (Keiran et al, 2005) in embryonic 
motoneurons and in vivo in adult SOD1 mice (Bilsland et al, 2010, Williams & 
Cleveland, 1999), indicating that the disruption of axonal transport not only occurs as 
part of ALS pathology, but may be a disease trigger. Indeed in SOD1G93A mice, deficits 
in retrograde transport not only occurred prior to disease onset but also worsened with 
disease progression (Bilsland et al, 2010). When an in vivo assay was developed to 
assess the retrograde transport of endosomes and mitochondria in axons of the sciatic 
nerve of SODG93A mice it was found that deficits occurred as early as post-natal day 36 
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(Bilsland et al, 2010). Furthermore, this early axonal transport impairment appeared to 
be specific to fast motoneurons, which are vulnerable in ALS (Hegedus et al, 2008). In 
slower motoneurons, which appear to be more resistant to ALS pathology, transport 
deficits did not appear until 120 days of age (Bilsland et al, 2010). This indicates that 
defects in axonal transport can be correlated with susceptibility to disease pathology in 
the SODG93A model of ALS. 
Evidence for axonal transport deficits in CAG-repeat disorders, such as Huntington’s 
Disease (HD) has also been obtained from transfected cell lines, transgenic mouse 
models and HD patient hippocampal autopsy tissue. For example, evidence suggests 
that the mutant Huntingtin protein inhibits fast axonal transport via JNK3 activation in a 
mouse model of HD (Morfini et al, 2009). Increased JNK3 activation subsequently 
leads to the phosphorylation of Kinesin – a motor protein that plays a pivotal role in 
anterograde axonal transport. This results in decreased association of Kinesin with 
microtubules, thus impairing axonal transport. In another set of experiments, the fast 
transport of amyloid precursor protein (APP) and Brain-derived neurotrophic factor 
(BDNF) was monitored in both a mouse model of HD, in which the Huntingtin protein 
contains 150 CAG repeats, and in mutant Huntingtin - transfected retinoblastoma cells 
(Morfini et al, 2009). It was found that the transport of APP and BDNF was impaired in 
striatal neurons from pre-symptomatic HD mice. Furthermore, the transport of APP and 
BDNF appeared to be accelerated in cell lines in which the wild-type (WT) Huntingtin 
protein was over-expressed, yet disrupted in cells transfected with the mutant 
Huntingtin protein (Her & Goldstein, 208). This suggests that the loss of normal 
Huntingtin function as opposed to protein over-expression could be the cause of axonal 
transport defects.  
Since axonal transport deficits have been detected in both MND and CAG-repeat 
disorders it is possible that such deficits may also play a role in the pathogenesis of 
KD. Indeed some evidence does suggest that fast axonal transport is impaired in KD. 
For example, as is the case with HD, JNK activation appears to increase in cell lines 
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expressing the mutant androgen receptor, resulting in impaired binding of Kinesin to 
microtubules (Morfini et al, 2006).  Evidence for axonal transport impairment in KD 
pathogenesis has also been obtained from a knock-in mouse model of the disease, in 
which the mutant AR contains113 CAG repeats (Kemp et al, 2011). Live cell confocal 
imaging of CT-AF488-labelled endosomes revealed that expression of the mutant AR 
induced severe retrograde trafficking defects in axons of the sciatic nerve (Kemp et al, 
2011), Specifically, the run length of endosomes appeared to be significantly reduced 
in AR113Q mice compared to WT controls, as demonstrated by a significantly greater 
number of endosomal stalls and the transport flux was five times lower in KD mice, as 
demonstrated by a depletion of endosomal retrograde transport over time (Kempt et al, 
2011). However, such findings should be considered with caution as the model of KD 
used in this study does not recapitulate KD as accurately as other models of the 
disease, such as the YAC AR100 model used in this Thesis and importantly do not 
exhibit any motoneuron degeneration (Sopher et al, 2004). Indeed, AR113Q mice have 
a rapidly progressing phenotype, dying by approximately 20 weeks of age (Yu et al, 
2006), whereas KD a slow, progressive disease (Suzuki et al, 2008). 
Indeed, a recent study from our lab has shown that, contrary to expectations, axonal 
transport is not impaired in motoneurons of the AR100 mouse model of KD (Malik et al, 
2011). When the levels of the microtubule-associated motor protein Tau, and the motor 
protein Kinesin were measured using Western blot analysis of both the sciatic nerve 
and spinal cord of WT and KD mice at various ages, no significant difference in 
expression levels was detected between the genotypes. Furthermore, no axonal 
transport deficits were detected either in vitro in embryonic primary motoneurons or in 
vivo, in the intact sciatic nerve of anaesthetized AR100 mice when the kinetics of both 
anterograde and retrograde transport of TeNTHC   were examined (Malik et al, 2011). 
This study suggests that whilst impaired axonal transport is implicated in the pathology 
of both MNDs and CAG-repeat disorders, it does not appear to play a significant role in 
Kennedy’s Disease. 
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1.4.3 Proteasome dysfunction 
The ubiquitin proteasome system (UPS) is a major degradation pathway for damaged 
and short-lived proteins. UPS function is vital for the removal of unwanted proteins and 
thus is essential for a variety of processes such as lysosomal degradation, normal 
synaptic function and cellular plasticity (Bingol et al, 2006, Tai & Schuman, 2008). 
At present there is much debate as to whether or not proteasome dysfunction plays a 
role in KD pathogenesis. In other MNDs, such as ALS, both decreases and increases 
in proteasome function have been reported. In neuro2a cells proteasome inhibition is 
induced by the expression of the mutant SOD1 protein (Urushitani et al, 2002). 
Reduced proteasome function has also been reported in SOD1G93A mice (Kabashi et al, 
2004). However its importance in disease pathology remains controversial.  In 
SOD1G93A mice crossed with mice lacking the LMP2 proteasome subunit, motor 
function and survival is no different to that observed in SOD1G93A mice (Puttaparthi et 
al, 2007). Therefore impairment in proteasome function via the knock-out of a vital 
proteasome subunit has no effect on disease, suggesting that the pathological 
mechanism underlying ALS pathology is independent from proteasome function. 
Conversely, some reports have shown that the presence of the mutant SOD1 protein 
results in an increase in proteasome function as shown by the induction of proteasome 
subunits such as LMP2, LMP7 and MECL-1 in astroglia and microglia of SOD1G93A 
mice compared to WT controls (Puttaparthi & Elliot 2005).  Thus evidence for both 
increases and decreases in proteasome activity in ALS has been obtained. 
Similarly, the role of proteasome dysfunction in HD is also unclear, despite the initial 
assumption that the proteasome would be overwhelmed by CAG-repeat expansions 
(reviewed by Ciechanover 2003). Decreased UPS activity has been reported in cell 
lines that have been transfected with mutant Huntingtin, as demonstrated by a 
decrease in chymotrypsin-like, trypsin-like and peptidylglytamyl-like activity (Seo et al, 
2007). Decreases in proteasome function have also been implicated from experiments 
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using animal models of HD. In the R6/2 mouse model of HD, Congo red was used to 
inhibit oligomerization of the mutant Huntingtin protein at 9 weeks of age, thus 
aggregation was inhibited (Sanchez et al, 2003). In a set of parallel experiments it was 
found that Congo red also increased proteasome activity in mutant cells but not in 
control cells, suggesting that inhibition of Huntingtin aggregation rescues proteasome 
activity (Sanchez et al, 2003). 
However, increases in proteasome activity in HD have also been reported, and for 
example, enzymatic assays for the three types of proteasome activity reveal an 
increase in proteasome function in HD94 transgenic mice, (Diaz-Hernandez et al, 
2003). Furthermore, Western blot analysis of striatal neurons from these mice reveal 
an increase in expression of the proteasome subunits LMP2 and 7, which is consistent 
with an increase in function.  
Because the role of the proteasome in MND and CAG-repeat disorder pathogenesis 
remains controversial, it is difficult to predict the role of the proteasome in Kennedy’s 
Disease. Initial suggestions that proteasome dysfunction plays a role in the 
pathogenesis of KD came from the observation that AR aggregates sequester 
proteasome components, as demonstrated by electron microscopy and 
immunohistochemistry (Stenoien et al, 1999). To date, most research into the role of 
the proteasome in KD pathogenesis has been limited to cell lines such as mutant AR-
transfected HeLa and HEK cells (Stenoien et al, 1999, Mandrusiak et al, 2003). For 
example, when a mutant AR protein containing 48 CAG repeats is introduced into 
HeLa cells, it can be detected when labelled with an antibody against the P31/PA700 
proteasome cap (Stenoien et al, 1999). This suggests a direct interaction between the 
mutant AR protein and components of the proteasome. When transglutaminase was 
used to encourage AR aggregation in HEK cells, proteasome function appeared to be 
impaired in an AR ligand-dependent manner. This was demonstrated by the 
accumulation of an unstable green fluorescent protein that is normally broken down by 
the proteasome (Mandrusiak et al, 2003).  Furthermore, Cystamine-mediated inhibition 
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of Transglutaminase and thus inhibition of mutant AR protein aggregation resulted in 
an improvement in proteasome function. This could indicate that protein aggregation 
itself results in proteasome function impairment. However the improvement in 
proteasome function could also be a result of other downstream effects of Cystamine 
application, such as the prevention of apoptosis and oxidative stress (Igarashi et al, 
1998, Dedeoglu et al, 2002). Therefore the beneficial effects of Cystamine may not be 
due to the prevention of protein aggregation specifically and thus protein aggregation 
may not play a role in proteasome dysfunction.  
1.4.4. Endoplasmic Reticulum (ER) stress 
1.4.4.1 ER function and dysfunction 
The fundamental function of the endoplasmic reticulum (ER) is to process newly 
synthesized membrane and secretory proteins.  Proteins, which are not folded 
correctly, do not progress to the next stage of the secretory pathway – the Golgi 
Complex - and in this respect, the ER is often referred to as a point of protein quality 
control in the cell (Brodsky 1999). An important aspect of ER function is its dependence 
on levels of ER Ca2+ (Pachen 2000), which will be discussed and examined in detail in 
Chapter 3. ER Ca2+ depletion, as well as other events such a change in cell redox state 
and ATP depletion, result in ER impairment, which is often referred to as ER stress 
(Kuznetsov et al, 1996, Tsai et al, 1994, Ikesugi et al, 2006). ER stress results in the 
activation of the Unfolded Protein Response (UPR) and Store-operated Calcium (SOC) 
influx, which aim to restore ER homeostasis and ER Ca2+, respectively (see Chapter 3, 
Section 3.1.2). Measurements of these two responses can be used to infer levels of ER 
stress and will form the basis of some of the experimental techniques used in this 
study. ER stress in neurodegenerative disease pathogenesis will therefore be 
discussed briefly here, and in more detail in Chapter 3. 
ER stress has been implicated to play a role in both MNDs and CAG-repeat disorders 
such as ALS and HD, respectively (Saxena et al, 2009, Reijonen et al, 2008). Evidence 
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for the involvement of ER stress is ALS and HD is discussed briefly here, but is also 
described in more detail in Chapter 3.  
1.4.5 ER stress in Amyotrophic Lateral Sclerosis and Huntington’s Disease 
In the mutant SOD1G93A mouse model of ALS, markers of the ER stress-induced 
Unfolded Protein Response (UPR) have been detected as early as P5 – prior to 
symptom onset (Saxena et al, 2009). This suggests that ER stress is not a secondary 
effect of other pathological mechanisms, and is more likely to play a causal role in ALS 
pathogenesis. Furthermore, inhibiting ER stress pharmacologically, with Salubrinal, 
results in an improvement in motor function and an increase in survival of SOD1G93A 
mice (Saxena et al, 2009). Markers of ER stress have also been found to be present in 
ALS patient tissue, and markers such as Binding Immunoglobulin Protein (BiP) are 
elevated in ALS patient spinal cord (Ilieva et al, 2007). 
There is also strong evidence to suggest that ER stress plays a major role in HD 
pathogenesis. In cell lines transfected with a mutant Huntingtin protein for example, 
there is an increase in cell death compared to control cells (Duennwald et al, 2008), 
which is prevented by treatment with Salubrinal (Duennwald et al, 2008). Furthermore, 
the level of ER stress appears to increase with the length of the CAG repeat, which is 
reflected in more severe symptoms (Reijonen et al, 2008). Thus, the severity of ER 
stress, as determined by expression levels of BiP, has been shown to correlate with 
symptom severity (Reijonen et al, 2008). 
1.4.6. Mitochondrial dysfunction  
Mitochondrial abnormalities are known to play a major role in the pathogenesis of 
several neurodegenerative diseases including Parkinson’s Disease (Murphy, 2009) as 
well as  MNDs and CAG-repeat disorders including ALS and HD, respectively (Shi et 
al, 2010, Mochel & Haller, 2011). The role of mitochondrial dysfunction in MNDs and 
HD will be discussed briefly here and in more detail in Chapter 5, where the role of 
mitochondrial dysfunction in KD is examined. 
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In the case of ALS, various mitochondrial abnormalities have been found in various 
cell-line and animal models of the disease as well as in anterior horn motoneurons from 
ALS patients (for review see Shi et al, 2010). Initial indications of mitochondrial 
dysfunction in ALS came from observations of abnormal mitochondrial morphology 
(Saski and Iwata 1992). In sporadic ALS patient spinal cord for example, dense 
conglomerates of mitochondria have been observed (Saski and Iwata 1992), whilst 
degenerating mitochondrial vacuoles are present in axons and dendrites of 
motoneurons from pre-symptomatic SOD1 mutant mice (Del Canto and Gurney 1995). 
Further investigations have confirmed that mitochondrial dysfunction accompanies the 
observed morphological abnormalities. In motoneurons from pre-symptomatic 
SOD1G93A for example, the Ca2+ loading-capacity of mitochondria was found to increase 
compared to WT controls (Damiano et al, 2006). The consequential increase in 
mitochondrial Ca2+ is accompanied by potentially pathological events such as reactive 
oxygen species generation and oxidative stress (Kruman et al, 1999). As well as 
functional impairment, mitochondrial-mediated processes also appear to be affected by 
alterations in mitochondrial transport. Unlike other organelles and cell cargo, 
mitochondria do not have a defined destination and instead, are transported according 
to the energy requirements of the cell (Goldstein et al, 2000), which is particularly vital 
in synapses that require tightly regulated supplies of Ca2+ and ATP (Rowland et al, 
2000). In primary motoneurons from the SOD1G93A mouse model of ALS, anterograde 
transport of mitochondria was found to be impaired, implicating that the mitochondrial 
supply to synapses is jeopardized both in vitro and in vivo (De Vos et al, 2007, Bilsland 
et al, 2010). Furthermore, in NSC34 cells, which over-express mutant SOD1, both 
anterograde and retrograde transport of mitochondria was found to be altered 
(Magrane & Manfredi, 2009). These results suggest that mitochondrial and thus energy 
supply is impaired in motoneurons in ALS. 
Evidence also strongly suggests that mitochondrial dysfunction also plays an important 
role in the pathogenesis of HD. Indeed the Ca2+ loading capacity of mitochondria was 
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found to be altered in three different mouse models of HD (Oliveira et al, 2007). In the 
R6/2 and YAC 128 models, Ca2+ loading capacity was found to increase under basal 
conditions compared to control littermates, whilst the striatal neurons from Hdh-150 
knock-in model appeared to be vulnerable to NMDA receptor challenges and failed to 
restore Ca2+ homeostasis (Oliveira et al, 2009). In lymphocytes from HD patients 
however, the Ca2+ loading capacity was found to decrease (Panov et al, 2002). 
Nonetheless, regardless of the direction of change, mitochondrial Ca2+ loading capacity 
is consistently altered in HD.  
As well as changes in Ca2+ loading capacity, impaired energy production has also been 
found to be involved in HD pathogenesis (for review see Chen 2011). For example, 
reduced cAMP and an ATP/ADP ratio have been observed in the Htt mouse model of 
HD and lymphoblastoid cells of HD patients (Gines et al, 2003). 
Abnormalities in the opening of the mitochondrial permeability transition pore (mPTP) 
have also been observed in HD (Panov et al, 2002). Electron microscopy has revealed 
that the mutant Huntingtin protein accumulates on the mitochondrial membrane, 
directly interacting with the mPTP and leading to mitochondrial depolarization (Panov 
et al, 2002). Furthermore, neurons from a knock-in model of HD containing a Huntingtin 
protein with 150 CAG repeats exhibited increased sensitivity to Ca2+-induced mPTP 
opening and subsequent mitochondrial swelling (Choo et al, 2004). 
Consistent with findings in other MNDs and CAG-repeat disorders, mitochondrial 
abnormalities have also been implicated in the pathogenesis of KD. Expression of the 
mutant AR protein in the motoneuron-like cell line, MN-1, resulted in a decreased 
mitochondrial membrane potential, which is indicative of mitochondrial dysfunction 
(Ranganathan et al, 2009). Furthermore, the expression of Peroxisome Proliferator-
activated receptor Co-activator-1 (PGC-1), which is an inducer of mitochondrial 
biogenesis, also decreased in these cells (Ranganathan et al, 2009). This suggests 
that mitochondrial biogenesis is decreased in these cells, resulting in a deficit in 
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mitochondria number. Indeed, both mitochondrial mass and number were found to be 
lower mutant AR-expressing cells compared to controls (Ranganathan et al, 2009). 
Evidence for mitochondrial abnormalities has also been obtained from KD patients. For 
example, the mitochondrial DNA copy number is lower in KD patients compared to 
healthy controls and the magnitude of the decrease in number is inversely correlated 
with the CAG-repeat length (Liu et al, 2003). Furthermore, both asymptomatic mutant 
AR carriers and symptomatic patients displayed higher levels of the oxidative 
biomarker, mtDNA4977, which indicates increased mitochondrial DNA damage, 
compared to healthy controls (Lui et al, 2003).  
 
1.5 Current treatment strategies for KD 
Despite the identification of the genetic cause of KD, there is currently no effective 
disease-modifying treatment for KD. Instead, only symptomatic relief is offered to 
patients in the form of B vitamins, vitamin E and physiotherapy. 
Initial attempts at developing disease-modifying therapies have used animal models of 
KD and have been designed on the basis that the disease involves a toxic gain-of-
function of the androgen receptor. Attempts at modifying KD have therefore aimed to 
lower AR activation in the hope that this will decrease its toxic effects. One study has 
observed the effects of Leuprorelin treatment in the AR97Q mouse model of KD 
(Katsuno et al, 2003). Leuprorelin is a Leutenizing Hormone-Releasing Hormone 
(LHRH) agonist that decreases testosterone levels and therefore lowers AR activation 
and subsequent translocation of the activated receptor into the nucleus (Katsuno et al, 
2004).  Following the administration of Leuprorelin to AR97Q mice, decreases in 
nuclear accumulation of the mutant androgen receptor, as demonstrated by 
immunohistochemistry and western blot analysis, were observed (Katsuno et al, 2003). 
Furthermore, treated mice have a longer life-span, larger body size and a more 
improved motor performance compared to control mice that had been treated with a 
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control vehicle alone. Based on these findings, the effectiveness of treatment in 
patients has been investigated. Initial findings suggest that within 2-3 weeks of initiating 
Leuprorelin treatment, testosterone levels decrease to those seen following castration. 
However the disease phenotype is not rescued (Katsuno 2003).  
The androgen receptor inhibitor Flutemide has also been considered as a possible 
therapeutic agent for KD. However, results suggest that Flutemide is not as effective as 
Leuprorelin. When AR97Q mice are treated with Flutemide at 13 weeks of age, 
symptoms are not alleviated and pathological features does not appear to improve 
(Katsuno et al, 2006). This has been suggested to be due to the fact that Flutemide 
may actually facilitate translocation of the mutant androgen receptor into the nucleus 
rather than lower AR activation. 
One problem when investigating possible KD treatments is the fact that suitable and 
specific markers for KD severity and progression have yet to be established so that 
even if candidate agents are identified, there is no good outcome measure to 
determine efficacy within the time frame of a viable clinical trial. Although it has been 
suggested that muscle strength, muscle volume and bulbar function could be used as 
reasonable markers for Kennedy’s disease when investigating therapies (Katsuno et al, 
2004), they may not be the ideal markers for assessing treatment effectiveness and 
more rhobust indicators of disease severity and progression at a cellular level are 
needed. Therefore the purpose of identifying KD-specific pathogenic mechanisms is 
two-fold; to establish treatment targets and to identify the ideal disease marker to 
assess the effectiveness of new therapies. 
1.6 Thesis aims 
The aims of this thesis are: 
1. To establish if ER stress plays a role in the pathogenesis of KD. 
2. To examine whether markers of ER stress are present in the spinal cord of KD 
mice and change during disease progression. 
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3. To determine if ER stress is related to motoneuron degeneration in KD. 
4. To investigate whether mitochondrial dysfunction is an early pathological 
feature of KD. 
The experiments described in this Thesis will determine whether ER stress and 
mitochondrial dysfunction are early pathological features of KD.  The results may 
therefore identify new targets for the development of novel therapeutic approaches for 
KD. 
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2.1 Transgenic mouse colonies 
In this study the AR100 mouse model of Kennedy’s Disease (KD) will be used, which 
has been used previously by the Greensmith lab to investigate the pathogenesis of KD. 
2.1.1 AR100 colony 
The generation and characterization of the AR6 YAC CAG100 (AR100) transgenic 
mice model is described in detail by Sopher et al, 2004 and is discussed in Chapter 1 
(Section 1.2). This mouse model was developed using a yeast artificial chromosome 
(YAC) containing the 450 kb Androgen Receptor (AR) gene with 100 CAG repeats in 
the N-terminal (as opposed to the normal range of 8-31). The YAC containing the 
mutant AR gene was then transfected into mouse embryonic stem cells. This type of 
cell is able to differentiate as normal in the germline hence the AR100 protein is 
incorporated in the same way that the Wild-Type AR protein would be (Sopher et al, 
2004). Mice containing this mutation develop late onset and progressive 
neuromuscular symptoms that recapitulated the symptoms of KD, for example, 
proximal muscle weakness, hind limb atrophy and difficulty in walking, developing from 
about 8 -12 months of age (Sopher et al, 2004) in addition to progressive motoneuron 
degeneration in the spinal cord (Malik et al, 2011). Male AR100 transgenic mice were 
obtained from Prof. La Spada’s laboratory in Seattle and a colony was established and 
maintained at UCL by mating male AR100 mice with C57 black 6 wild-type (WT) 
females (Harlan Laboratories, England). The genotype of each embryo was determined 
as described in Chapter 2, Section 2.5. All experiments were carried out under the 
Animals (Scientific Procedures) act of 1986 and following ethical approval from the 
Ethical Review Panel of UCL, IoN. 
2.1.2 SOD1G93A and SODH colonies 
Transgenic mice over-expressing the G93A mutant SOD-1 gene 
[(TgN(SOD1G93A)1Gur] (SOD1G93A) were maintained by breeding heterozygous males 
with female F1 hybrids. The genotype of embryos used was determined using the 
52 
 
protocol described in Chapter 2, Section 2.5.5 (Gurney et al, 1994). In addition a colony 
in which the human Wild-Type SOD-1 protein (SODH) was over-expressed was also 
used as a control for protein over-expression (Li et al, 2004). 
2.2 Experimental groups 
The following experimental groups were examined in this Thesis: 
A) WT motoneurons – derived from WT mice 
a. – DHT:- model normal female motoneurons 
b. + DHT:- model normal male motoneurons 
 
B) KD motoneurons – derived from AR100 mice 
a. – DHT:- model unaffected  female carriers with the expanded CAG 
repeat 
b. + DHT:- model affected males with the expanded CAG repeat i.e. 
diseased motoneurons 
 
2.3 Primary ventral horn motoneuron culture 
2.3.1 Preparation 
Circular glass coverslips were autoclaved and then coated with Poly-Ornithine (diluted 
1 in 1000 in sterile water) and left at 37oC and 5% CO2 overnight in sterile multi-well 
plates (FALCON). This results in the coverslips being coated with a negative charge. 
The Poly-Ornithine solution was then aspirated and coverslips were coated with 
Laminin (diluted at 1 in 200 in L-15 medium) and incubated at 37oC for a minimum of 
2.5 hours. The diameter of the coverslip required and hence the size of the multi-well 
plate used varied according to the experiment; For confocal experiments, 22 mm 
coverslips placed in 6-well plates were used; For Western blot analysis, 16 mm 
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coverslips in 12-well plates were used and for Immunofluorescence experiments, either 
16 mm coverslips in 12 well plates or 13mm coverslips in 24 well plates were used. 
Complete Neurobasal (CNB) medium was made up the day before culturing (see 
Appendix) and was kept at 4oC for no longer than 2 weeks. All other solutions were 
made up fresh for each culture. 
2.3.2 Embryonic ventral spinal cord dissection  
Female C57/B6 Harlan mice at gestation day 12-14 were sacrificed by a Schedule 1 
method and a hysterectomy performed. Each embryo-containing yolk sack was 
removed and the top of the yolk sack was carefully pierced and peeled away, revealing 
the embryo intact. Initially the tail and hind limb paws were removed and stored at 4oC 
for subsequent genotyping. The embryo was decapitated and the liver, intestines and 
stomach were removed so that the embryo could be laid flat, with the spinal column 
exposed and facing upwards. At this point the spinal column is already visible as an 
opaque white line down the centre of the back. Forceps were used to gently score 
along either side of the spinal cord and the skin was carefully peeled off. The tip of the 
forceps was then run under the dorsal meninges, and then used to score along the 
cord in a rostral-to-caudal direction, thus releasing the meninges and exposing the 
cord. The spinal cord was then released from underlying tissue and prised away from 
the body, with the ventral surface facing up. The meninges were then peeled away and 
the dorsal column of the cord removed using a scalpel. The meninges and dorsal 
column were then discarded leaving the ventral column. The ventral column was then 
stored in approximately 300-400 L 1 % Penstrep in HBSS at 4oC for a maximum of 6 
hours. 
2.3.3 Dissociation of ventral motoneurons 
In some cases, genotyping was carried out prior to dissociation and in this case up to 
five ventral columns of the same genotype were pooled and dissociated together as 
one sample. When genotyping was carried out post-dissociation however, ventral 
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columns were dissociated individually and plated in separate wells. When ventral 
columns were dissociated separately, all volumes used during the protocol described 
were halved. 
Each ventral column was cut into small fragments of approximately 1 mm or smaller in 
length. The fragments were then transferred into a new 15 ml falcon tube using a 1 ml 
pipette and were left to settle and form a loose pellet for approximately 2-3 minutes 
before excess HBSS was carefully removed. 1 ml of fresh HBSS (+ 1% Pen/Strep) was 
then added to the ventral column fragments along with 10 l of 2.5% Trypsin. The 
resulting solution was then incubated at 37oC for 10 minutes and was gently agitated 
after the first 5 minutes.  
During the Trypsin incubation period the following solution was prepared (for each 
falcon tube in incubation): 
 800 l L-15 medium 
 100 l 4% BSA (in L15) 
 100 l DNAse (1 mg/ml) 
Immediately after incubation, the resulting clump of ventral column tissue was 
transferred to this solution and was gently triturated twice and left to stand for 
approximately 2 minutes or until the tissue had settled and formed a loose pellet at the 
bottom of the flacon tube. The supernatant (containing motoneurons) was then 
transferred to a new 15 ml falcon tube. To the remaining pellet the following was 
added: 
 900 l CNB 
 100 l 4% BSA (in L15) 
 20 l DNAse (1 mg/ml) 
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The suspension was then triturated more vigorously 8 times and was left to stand for 
approximately 3 minutes. The supernatant was then transferred to the tube containing 
the first supernatant. To the remaining pellet the same combination of CNB, BSA and 
DNAse was added again. 
The suspension was then triturated vigorously 10 times and allowed to settle for 3 
minutes. The new supernatant was then added to the supernatants that had been 
collected previously and the pellet was discarded. 
1 ml of 4% BSA in L15 was then carefully added to the bottom of the supernatant tube 
to form a cushion and the pooled supernatants were spun at 1500 rpm at room 
temperature for 5 minutes.  
The resultant supernatant was then removed and the pellet was re-suspended in 1 ml 
of CNB and 20 l of DNAse in L15 and was triturated 6 times before being plated at the 
required density (see Section 2.3.5). In this final step, the volumes of CNB and DNAse 
were kept constant, regardless of whether spinal cords were pooled or dissociated 
separately. This technique results in mixed ventral horn cultures that are comprised of 
approximately 40% primary motoneurons. 
2.3.4 Purification of dissociated ventral horn motoneurons 
In some experiments, additional steps were undertaken to purify the cultures further, so 
that they contained a higher proportion of motoneurons. Instead of plating the re-
suspended pellet as described in the protocol above, 1 ml of clear L15 was added to 
the cell suspension and the solution was mixed gently. 3ml of 10.4% Optiprep (a 
density gradient solution) was gently added to this suspension to form a cushion at the 
bottom, producing a clear, sharp interface (see Figure 2.1).  The mixture was then 
centrifuged at room temperature at 760 rotations per minute (rpm) for 15 minutes. The 
break of the centrifuge was set to zero to minimize the deceleration of the centrifuge 
and thus eliminate vibration. Following centrifugation, a thin white interface (Figure 2.2) 
containing motoneurons was transferred into a new 15 ml falcon tube and re-
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suspended in 2 ml of CNB. Approximately 8 ml of clear L15 was then added to make 
the volume of solution up to 10 ml. 2 ml of BSA was then carefully applied to the 
bottom of the suspension to form a cushion though which the cells could spin through, 
and the resulting suspension was spun at room temperature for 5 minutes at 1500 rpm. 
The pellet was then re-suspended in 1 ml of CNB and plated at the required density. 
This technique resulted in primary motoneuron cultures that were consistently over 
90% pure. 
2.3.5 Cell counts & culture plating density 
In order to determine the number of cells in 1 ml of cell suspension and hence the 
required plating volume, a 10 l sample of the suspension was added to 10 l of 
tryphan blue (Sigma). The resultant solution was then pipetted onto a haemocytometer 
and the number of cells in 5 random squares of the grid was counted using a light 
microscope. An average of both sides of the haemocytometer was calculated and then 
multiplied by 50,000 to calculate the number of cells in 1 ml of the suspension. The 
volume needed for the required density was then calculated.  In the case of imaging 
experiments for example, a density of 50,000 cells per cm2 was sufficient, whilst 
approximately 300,000 cells per cm2 and greater was used for cultures that were to be 
analysed using western blot 
2.3.6 Culture Maintenance 
Cultures were kept for 7 days at 37oC and 5% CO2 in sterile conditions. They were 
examined on a daily basis to check for motoneuron development and signs of infection. 
The medium was changed as required, which was usually once during the 7 day in 
vitro (DIV) period. Cultures were treated with 5 M DHT diluted in PBS at 4 DIV. The 
appropriate volume of DHT was added to make a final concentration of 50 nM DHT. 
Cultures were imaged, fixed or homogenized on 7 DIV. 
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Figure 2.1: Purification of ventral horn motoneurons using Optiprep 
The image shows a schematic representation of the different layers obtained following 
centrifugation of a ventral horn cell/Optiprep suspension. After being spun at 760 
rotations per minute for 15 minutes, motoneurons were separated into a layer that was 
visible as an off-white interface between the supernatant and pellet. This interface was 
then carefully transferred into a new falcon tube. 
 
  
 
 
 
Supernatant containing glia
Interface containing 
motoneurons
Pellet
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2.3.7 Culture Homogenization 
When cultures were required for Western blot analysis, approximately 750 l of 
homogenization buffer at room temperature was added to each well and cells were 
agitated at 110 rpm in a shaker at 37oC for approximately 30 minutes.  The contents of 
each well was then transferred to a new 1.5 ml eppendorf tube and stored at -20oC until 
processed. Protein content was analysed as described in Section 2.7.2. 
2.4 Preparation of spinal cord tissue 
Spinal cords from WT and KD mice at 3, 12 and 18 months of age were perfused with 
fixative (4% paraformaldehyde) by Dr B. Malik. Spinal cords from P5 mice were 
prepared by me. The mice were culled by decapitation, the tails were removed for 
genotyping and the spinal columns were dissected free of the body. Lumbar spinal 
cords (between L2-L6) were carefully removed and snap frozen in liquid nitrogen and 
stored at -80oC until they were processed for Western blot analysis and 
Immunohistochemistry. 
2.5 Genotyping 
2.5.1 Rapid digestion of embryonic tissue 
The tail and/or foot were removed from E12-E14 embryos and placed in a 1.5 ml 
eppendorf tube. 48 l of rapid digestion buffer was added to the samples followed by 2 
l of Proteinase K and the samples were vortexed for about five seconds. Samples 
were then incubated at 55oC for approximately 15 minutes, vortexed for approximately 
five seconds, and subsequently incubated at 95oC for a further 10 minutes.  The 
samples were vortexed again and then spun at 14,000 rpm for 2 minutes at room 
temperature. 2.5 l of each supernatant was used in a 25 l PCR reaction (see Section 
2.5.3). 
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2.5.2 Digestion of P5 tail biopsies 
To 0.5cm of fresh or thawed tail from each P5 pup, 120 l of 0.5M EDTA (pH 8) and 
500 l of Nuclei Lysis Solution were added. 17.5 l of Proteinase K (20mg/ml stock) 
was then added and the resulting mixture was vortexed. The tails were then incubated 
at 55oC overnight or for 4 hours, in which case they were vortexed every 30-45 
minutes. Once the samples had been allowed to cool down to room temperature, 200 
l of protein precipitation solution was added and the resulting mixture was vortexed for 
approximately 20 seconds. Samples were then incubated for 10 minutes at -20oC and 
subsequently centrifuged for 6 minutes at 14000g at room temperature, with the 
precipitated protein forming a white pellet. The DNA-containing supernatant was then 
carefully transferred to a clean 1.5 ml eppendorf tube and 600 l of Isopropanol at 
room temperature was added. The solution was gently mixed by inversion until white 
thread-like strands of DNA could be seen. The solution was then centrifuged at 14000g 
at room temperature, for 3 minutes. The DNA-containing pellet was collected and the 
supernatant was discarded. The DNA was then washed in 600 l of ethanol (EtOH) at 
room temperature and centrifuged again at 14000g for 3 minutes. The EtOH was then 
aspirated and the pellet was left to air dry for approximately 5 minutes. Samples were 
then stored in 200 l distilled H2O at - 20
oC and were vortexed prior to use. 
 
2.5.3 AR100 tissue PCR 
The primers used for the PCR reaction (Invitrogen) were as follows: 
Forward Primer:  5’- CAT CTG AGT CCA GGG GAA CAG C -3’ 
Reverse Primer:  5’- GCC CAG GCG CTG CCG TAG TCC -3’ 
These primers amplified both the mutant human fragment and the inherent mouse 
gene, which are both approximately 450 base pairs (bp) in length. 
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The PCR conditions and PCR mix were as follows: 
PCR condition PCR reaction 
 
-Lid temperature: 105 
o
C 
-95
o
C for 10 minutes 
-Cycle: 
 95
o
C for 30 secs 
 68
o
C for 30 seconds 
 72 
o
C for 30 seconds 
- repeated 34 times 
- 72
o
C for 5 minutes 
- Hold at 4 
o
C 
Total time = 1 hour and 34 minutes 
 Per  
Sterile water 18.15 
PCR buffer 2.5 
MgCl2 0.75 
dNTP 0.5 
Forward Primer 0.25 
Reverse Primer 0.25 
Taq polymerase 0.1 
 
Total Volume 22.5 
DNA 2.5 
 
2.5.4 AR100 Restriction enzyme digestion 
 glucosidase 1 (Bgl 1) was used to digest the human fragment of the AR gene whilst 
leaving the inherent mouse fragment intact allowing identification of AR100 Vs. WT 
samples. To 12.5 l of each PCR product, 1 l of Bgl1 (New England Biolabs) and 1.5 
ml of PCR buffer (Invitrogen) was added and the resulting mixture was incubated at 
37oC for 1.5-2.5 hours.  The resulting positive transgene products produced bands at 
450 bp, 350 bp and 100 bp when run on a 3% agarose gel at 90 volts for 25 minutes. 
Transgene negative products i.e. WT, produced only the 450 bp band (Figure 2.2).  
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Figure 2.2: AR100 PCR products 
Samples were run on a 3% agarose gel at 90 volts for 25 minutes. AR100 samples 
produced bands at 450 base pairs (bp), 350 bp and 100 bp. Transgene-negative 
products i.e. WT, produced only the 450 bp band 
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2.5.5 SOD1G93A Genotyping 
The primers used for SOD1G93A PCR were as follows: 
IMR0042 5’- CTA GGC CAC AGA ATT GAA AGA TCT -3’ 
IMR0043 5’- GTA GGT GGA AAT TCT AGC ATC ATC -3’ 
IMR0113 5’- CAT CAG CCC TAA TCC ATC TGA -3’ 
IMR0114 5’- CGC GAC TAA CAA TCA AAG TGA -3’ 
The PCR conditions and PCR mix were as follows: 
PCR condition PCR reaction 
 
-Lid temperature: 105 
o
C 
-95
o
C for 3 minutes 
-Cycle: 
 95
o
C for 30 secs 
 60
o
C for 30 seconds 
 72 
o
C for 30 seconds 
- repeated 35 times 
- 72
o
C for 2 minutes 
- Hold at 4 
o
C 
 
  
Sterile water 17.65 
PCR buffer 2.5 
MgCl2 0.75 
dNTP 0.5 
All primers (x 4) 0.25 
Taq polymerase 0.1 
 
Total Volume 22.5 
DNA 2.5 
 
15 l of each sample along with 3 l of bromophenol blue was then loaded into a 2% 
gel and run at 50 V for 30 minutes. SOD1G93A positive products produced bands at 324 
bp and 236 bp, whilst WT products produced one band at 324 bp (Figure 2.3). 
2.5.6 SODH PCR 
The PCR conditions and mix were identical to those used for SOD1G93A PCR. SODH-
positive samples produced a band at 236 bp. WT products produced a band at 324 bp. 
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Figure 2.3: PCR products for SOD1G93A genotyping 
PCR products were run on a 2% gel at 50 V for 30 minutes. Wild type products 
produced only one band that was 324 base pairs (bp) in length. Mutant SOD1G93A 
(mSOD1) -positive products however produced a smaller band as well, which was 236 
bp in length. 
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2.5.7 Identification of embryo sex by genotyping 
In the same experiments, motoneuron cultures of each sex were prepared. Therefore 
for these experiments the genotyping of individual embryos was established by PCR 
according to the method described by McClive and Sinclair, 2001, see Figure 2.4) 
The primers used for PCR-sexing were as follows: 
SrY (Y chromosome): 5’ TCA TGA GAC TGC CAA CCA CAG 3’ 
5’ CAT GAC CAC CAC CAC CAC CAA 3’ 
Myogenin (control): 5’ TTA CGT CCA TCG TGG  ACA GC 3’ 
5’ TGG GCT GGG TGT TAG TCT TA 3’ 
The SrY gene is a male sex-determining gene found exclusively on the Y chromosome 
whilst the Myogenin (Myog) gene acts as a control, being present on both the X and Y 
chromosomes. The PCR conditions and PCR mix were as follows: 
PCR condition PCR reaction 
 
-Lid temperature: 105 
o
C 
-94
o
C for 5 minutes 
-Cycle: 
 94
o
C for 5 secs 
 67
o
C for 40 seconds 
- repeated 30 times 
- 72
o
C for 1 minutes 
- Hold at 4 
o
C 
 
  
Sterile water 16.095 
PCR buffer 2.0 
MgCl2 0.57 
dNTP 0.095 
All primers (x 4) 0.04 
Taq polymerase 0.08 
 
Total Volume 19.0 
DNA 1.0 
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Figure 2.4: Sex-determination PCR using the Y chromosome-specific SrY gene 
 
PCR products were run on a 0.75% gel at 120 V for 15 minutes. Male samples 
produced bands at 441 and 245 bp, representing SrY and MyoG, respectively, whilst 
female sample produced only the MyoG band, which is 245 bp. 
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2.5.8 Minigel preparation 
10ml of 10 X TBE was diluted in 90 ml of double distilled water. 50 ml of the resulting 
solution was then used to make the agarose gel, the percentage of which varied with 
the PCR being carried out (AR100 requires a 3% gel, SOD1 requires a 2% gel, and 
SrY requires a 1.5% gel). The agarose was boiled for 2 minutes and 5 l of ethidium 
bromide was added once the gel had cooled to approximately 70oC. The agarose was 
then poured into the minigel apparatus and left to set for a minimum of 20 minutes. The 
combs and frames were then removed and the remaining 50 ml of TBE was poured 
over the set gel. 8 l of a DNA ladder (Invitrogen) was loaded into the first well followed 
by 15 l of each sample along with 3 l of Bromophenol Blue into subsequent wells. 
The gel was then run as required. 
2.6 Confocal Experiments 
ER Ca2+ can be measured in cells in vitro indirectly by measuring the increase in 
cytosolic Ca2+ that occurs following the application of drugs that deplete the ER of Ca2+, 
in a Ca2+-free external environment. A Ca2+-free environment ensures that the ER is 
the only source of the observed cytosolic Ca2+ elevation following drug application. The 
magnitude of this elevation can therefore be assumed to reflect ER Ca2+ levels (see 
Chapter 3). 
One way in which a read out of cytosolic Ca2+ can be obtained is by using confocal 
microscopy in combination with drugs that alter cellular Ca2+ handling. 
2.6.2 Ratiometric Vs. non-ratiometric Ca2+ indicators 
Fluo 4-AM is a commonly used non-ratiometric, or single wave (SW) dye that 
measures free cytosolic Ca2+. In choosing Fluo 4-AM for this study, it is important to be 
aware of its limitations and disadvantages and control for them by conducting the same 
experiments using Fura 2- a ratiometric dye. One disadvantage of using a SW dye 
such as Fluo 4-AM is the fact that the intensity of the emission and excitation spectra 
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varies with levels of free cytosolic Ca2+. This makes measurements sensitive to 
confounding variables other than Ca2+ concentration. Such factors include leakage of 
the dye out of cells, uneven dye loading and photobleaching (destruction of the dye 
upon exposure to light). Ratiometric dyes such as Fura 2 however, overcome this 
problem. Because they are excited at two different wavelengths depending on whether 
the dye is Ca2+-bound or Ca2+-free, a ratio between the two maxima can be calculated, 
which minimizes the effects of the confounding variables that create problems when 
using SW dyes (Barreto-Chang and Dolmetsch 2009). Table 1 summarizes the key 
features of the two types of dye. The problem with ratiometric dyes such as Fura 2 
however is the fact that they are excited by UV light. This is not ideal because 
exposure to UV excitation for prolonged periods can lead to cell death, with the 
phototoxic effects of UV rays causing depletion of the cellular NAD(P)H pool. 
Furthermore, Fura 2 is more prone to compartmentalization than Fluo 4-AM. Fluo 4-AM 
also has a greater Kd value then Fura 2, meaning that it is more suitable for monitoring 
larger changes in ER Ca2+. Based on this characteristic, Fluo 4-AM appears to be more 
suitable for this study, although, precautions need to be made when analysing data, 
and carrying out control experiments using Fura 2 are essential. 
2.6.2 Fluo 4-AM as a Ca2+ indicator 
Confocal images were obtained using a Zeiss 510 confocal laser scanning microscope 
(Oberkocken, Germany) using a 40 x oil-objective lens. Cells were kept at 37oC using a 
heated stage. 22 mm coverslips were loaded with 500 l of 5 M Fluo 4-AM (Molecular 
Probes, Invitrogen) and 0.005% pluronic acid diluted in confocal recording medium 
(see Appendix). Coverslips were incubated in the dark for approximately 30 minutes at 
37oC. Fluo 4-AM was excited at 488 nm and the emission fluorescence was measured 
at 518 nm. A ‘z stack’ scan was taken once a second for 800 seconds (to avoid the 
bias of sampling from a single plane) and background fluorescence was subtracted 
from the selected motoneurons. Motoneurons were selected using specific criteria as 
discussed below (Section 2.6.8).  
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The fluorescence values that were obtained were then calibrated into a Ca2+ 
concentration in nM using the following equation (Maravall et al, 2000): 
 
[Ca2+] = Kd x (F/Fmax – 1/Rf) 
(1 - F/Fmax) 
 
For Fluo 4-AM: Kd = 350nM, Fmax = maximum fluorescence post – Ionomycin 
application, Rf = 100  
2.6.3 Fura 2 as a Ca2+ indicator 
In the case of Fura 2 experiments, the ORCA system (Hamamatsu) was used, 
although the cells were still viewed using a 40 x oil objective at 37oC. Coverslips were 
incubated with 500 l of 5 M Fura 2 (Molecular probes, Invitrogen) and 0.005% 
pluronic acid diluted in confocal recording medium. Again, coverslips were incubated 
for approximately 30 minutes at 37oC and 5% CO2 in the dark. Fura 2 was excited at 
340 nm and 380 nm and the emission fluorescence was measured at 505 nm. A ratio 
between to two maxima at the different wavelengths was calculated by dividing the 340 
nm fluorescence value at a given time point by the 380 nm fluorescence value. 
Because of the mechanics of scanning via two channels, one image could only be 
taken approximately every 4 seconds.  
2.6.4.1 Pharmacological induction of ER calcium depletion: Thapsigargin 
There are various pharmacological agents that can be employed to manipulate and 
measure cellular Ca2+. One such agent is Thapsigargin (TG), which non-competitively 
inhibits the SERCA pump in the ER membrane. In doing so, it prevents the ER from 
replenishing lost calcium, which results in a net loss of ER Ca2+. One problem when 
using TG however is that it may not completely deplete the ER of Ca2+ and hence the 
69 
 
consequential rise in cytosolic Ca2+ may be an underestimation of ER Ca2+ levels. 
Indeed there is evidence to suggest that the application of TG results in depletion of a 
subset of TG-sensitive ER Ca2+ pools exclusively, which account for approximately 
85% of total ER Ca2+ (Poulsen et al, 1995, Verma et al, 1990). However, in this study it 
is the difference between WT and KD motoneurons with respect to ER Ca2+ that is 
important, as opposed to absolute levels. 
Another problem when using TG is the fact that there is some evidence to suggest that 
TG can directly lead to the influx of Ca2+ through the plasma membrane. For example, 
calcium influx was found to occur following the application of TG to human platelets, as 
indicated by a rise in free Ca2+. This occurred in the presence of intracellular BAPTA – 
suggesting the calcium source was external, hence influx had occurred (Voster & 
Shafer 1996). This ‘artefact’ means that the observed level of SOC influx may be an 
overestimation of the actual level of SOC influx if calcium is present in the external 
medium at the time of TG application. Therefore, when using TG, it is vital to exclude 
Ca2+ from the external medium and to only introduce it at the time at which SOC influx 
is measured. 
 
2.6.4.2 Fluorescence calibration: Ionomycin 
Ionomycin is a common pharmacological tool used to investigate cellular Ca2+. It is a 
neutral ionophore derived from the bacterium Streptomyces conglobatus. It is used to 
completely deplete all intracellular stores of Ca2+ and thereby achieve a maximum level 
of cytosolic Ca2+. This is required for the calibration of confocal fluorescence.  
 
2.6.5 Determination of ER Ca2+ levels: Measurement of cytosolic Ca2+ 
Figure 2.5 shows an example of the protocol used to determine ER Ca2+ levels. 
Immediately prior to the start of the protocol, the Ca2+-containing imaging media was 
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replaced with a Ca2+-free medium. A basal of level of cytosolic fluorescence (Figure 2.7 
A) was obtained and 1 M Thapsigargin (TG) was then introduced approximately 45 
seconds later (Figure 2.5 B); any increase in cytosolic Ca2+ measured would reflect ER 
Ca2+ as there is no external Ca2+ which could act as a source of increased cytosolic 
Ca2+. The actions of TG are complete within 300 seconds and so the cells were left 
untouched for this time. Following ER Ca2+ depletion, Ca2+ was reintroduced into the 
external medium (Figure 2.5 C), allowing SOC influx to occur. Therefore, SOC influx 
was considered to be the subsequent increase in cytosolic Ca2+ following the 
reintroduction of Ca2+ to the external medium. 5 M Ionomycin was then added 
approximately 60 seconds later (Figure 2.5 D) so that the maximum cytosolic Ca2+ 
fluorescence could be obtained, which was necessary for the calibration of 
fluorescence into Ca2+ concentration in nM (see Section 2.6.2 for the calibration 
procedure). 
In experiments using Fluo 4-AM, cytosolic Ca2+ was analysed using LSM software (Carl 
Zeiss GmbH in association with EMBL, Heidelberg, Germany). In experiments using 
Fura 2, the concentration was analysed using AQM software (Tech Direct). In all 
experiments background fluorescence was deducted prior to calibration. 
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Figure 2.5: ER Ca2+ levels: Measurement of cytosolic Ca2+ concentration 
Untreated and DHT-treated WT and KD primary motoneurons were imaged using 
confocal microscopy at 7 DIV. Cultures were incubated for approximately 30 minutes at 
37 oC with 500 l of 5 M Fluo 4-AM and 0.005% pluronic acid diluted in confocal 
recording medium. Throughout the experimental period cultures were maintained at 
37oC using a heated stage. The image shows an example trace of cytosolic 
fluorescence. 
 
 
 
 
 
 
 
 
72 
 
2.6.6 Measurement of cytosolic Ca2+: Protocol inclusion criteria  
Many confounding variables affect the measurements obtained from confocal imaging 
experiments, such as temperature, age of drug solutions, drug concentration and 
length of exposure to drugs. These confounding variables are therefore kept as 
constant as possible. If a condition is altered, the experiment is rejected. 
Even if all conditions are kept constant however, the measurements obtained still need 
to fit certain criteria in order to be included in the analysis. Traces are rejected for 
example, if a stable basal cytosolic Ca2+ concentration is not apparent. If the level of 
Ca2+ is fluctuating even in the absence of drug application, the effects of the drugs 
cannot be determined. Traces are also rejected if there is no increase in cytosolic Ca2+ 
in response to the application of Ionomycin. Ionomycin acts by depleting all internal 
stores of Ca2+, as described above, resulting in a maximum cytosolic Ca2+ 
concentration. This maximum level of Ca2+ is required for calibration of the Fluo 4-AM 
fluorescence signal and thus if it is not obtained, fluorescence cannot be converted into 
a concentration and a comparison between different cells cannot be made. Finally, 
traces are rejected if the background noise is so large that it could conceal effects of 
drug application.  
2.6.7 Tetramethylrhodamine methylester (TMRM) 
Confocal images were obtained using a Zeiss 510 confocal laser scanning microscope 
(Oberkocken, Germany) using a 40 x oil-objective lens. 22 mm coverslips were loaded 
with 50 nM TMRM (Invitrogen) in confocal recording medium (see Appendix). 
Coverslips were incubated in the dark for approximately 30 minutes at room 
temperature. TMRM was excited at 543 nm and the emission fluorescence was 
measured above 560 nm. A ‘z stack’ scan was once every 4 seconds for 800 seconds 
and background fluorescence was subtracted. Motoneurons were selected using 
specific criteria (Section 2.6.8). Carbonyl cyanide p-trifluoromethoxyphenyl hydrazone 
73 
 
(FCCP, 1 M) treatment was used as a control for mitochondrial membrane 
depolarization.  
2.6.8 Motoneuron selection criteria  
Most of the in vitro experiments described in this Thesis involved the use of primary 
mixed ventral horn cells, so it was important to use a consistent set of criteria to identify 
primary motoneurons. Motoneurons were identified on the basis of strict visual criteria 
that allowed them to be differentiated from interneurons; namely, a cell body diameter 
of greater than 15mm, and possessing more than 2 neuritic processes. Motoneurons 
also tend to grow in the upper focal plane of the culture (Bilsland et al, 2008). 
2.7 Western Blot 
2.7.1 Selection of time points for Western blot analysis 
Markers of ER stress were examined in tissues at various key stages of disease by 
Western blot analysis at E13, P5, and 3, 12 and 18 months of age. Embryonic 
motoneurons were investigated in order to establish whether or not ER stress occurs at 
the earliest time point possible and thus is likely to be an early pathological feature of 
disease as opposed to a secondary effect. 
2.7.2 Protein content determination assay for Western blot analysis 
For primary ventral horn cultures, at 7 DIV, the medium was removed from the wells 
and was replaced with 750 l of homogenizing buffer (see Section 2.1.5).  Cells were 
incubated with homogenizing buffer as described above and a homogenate was 
obtained. 10 l of each mixture was then pipetted into a new 96 well plate, and the top 
row was left free for the BSA controls (see Appendix).  
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Figure 2.6: Motoneurons imaged using a confocal microscope 
 
The image in this figure was obtained using a Zeiss Confocal microscope and analysed 
using LSM software. It shows an example of a cell that is considered to be a 
motoneuron (A) and one that is not (B) according to the criteria described previously 
(Bilsland et al, 2008). Although both cells were in the same focal plane and have very 
similar sized cell bodies, cell A) possessed 3 processes whereas cell B possessed only 
2 and is therefore discounted when regions of interest were selected. 
 
 
 
 
 
 
A
B
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25 l of Reagent ‘A’ followed by 200 l of Reagent ‘B’ (BIO-RAD, Dc Protein assay 
reagents) was then added to each well and the plate was left to incubate at room 
temperature in the dark for 15-30 minutes. The concentration was then determined 
using the spectrophotometer at 750 nm. The value obtained for each sample was then 
calibrated using the values obtained for the BSA controls. In the case of spinal column 
tissue, homogenizing buffer was added to a sample of the cord in a 2:1 ratio. 
 
2.7.3 Western Blot Protocol 
Plates were assembled according to manufacturer’s instructions and the resolving gel 
mixture was pipetted into the chambers, leaving approximately 2 cm at the top for 
stacking gel. A layer of water saturated-butanol was pipetted on top of the resolving gel 
to ensure that the gel would not evaporate before setting. It was then left to set at room 
temperature for 1 hour. During this period, transfer buffer, running buffer and the first 
part of the stacking gel were prepared. Samples were prepared by adding sample 
buffer in a 1:1 ratio. The sample volume varied so that the same amount of protein was 
present in each sample. The volume needed was determined using the protein content 
assay described above. On average, 40 g of protein was loaded per well, although 
this varied between experiments (but not within the same experiment). The samples 
were then boiled at 95 oC for 5-10 minutes and left at room temperature until needed. 
Once the resolving gel had set, the water-saturated butanol was decanted. The 
stacking gel was then completed and pipetted on top of the resolving gel. Combs were 
inserted immediately and the stacking gel was left to set. The plates were then loaded 
into the tank and the space between the plates was filled with running buffer. The 
combs were removed and 5 l of Western Standard Marker (Bio-RAD) was loaded into 
a well.  20-30 l of each sample was then loaded into each consecutive well and the 
remainder of the running buffer was poured into the tank. The gel was then run at 160 
V for 1 hour, or until the samples had run to the bottom of the gel.  Filter paper and 
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nitrocellulose blotting membrane were then soaked in ice cold transfer buffer and the 
blotter was set up. 
The blotter was then placed in the tank, which was filled with ice cold transfer buffer 
and was run at 90 V for approximately 70 minutes. It was stirred continuously. The 
membrane was then removed and soaked in Ponceau solution for 2 minutes to test 
whether or not the transfer was successful. The membrane was washed in PBS and 
stored at 4oC in PBS for up to 48 hours. 
The blotting membrane was blocked at room temperature for 1 hour, and was gently 
agitated throughout this period. 10 ml of the required primary antibodies diluted in 
blocking solution was then applied and the blot was incubated overnight at 4oC. The 
blot was then washed six times in PBS-Tween and was incubated at room temperature 
for 2 hours with suitable HRP-conjugated secondary antibodies, along with streptactin 
(a secondary antibody for the marker), both diluted in blocking solution. The blot was 
kept in the dark and gently agitated throughout this period. The blot was again washed 
six times before being incubated for 5 minutes at room temperature with approximately 
1 ml each of solutions A and B (Supersignal West Pico, Thermo Scientific). The blot 
was imaged using a chemiluminescence camera and FluorChem software (Cell 
Biosciences, California). 
2.8 Immunocytochemistry 
2.8.1 Protocol 
For cell cultures, at 7 DIV, the medium was removed from wells and cells were fixed in 
4% PFA for 15-20 minutes at room temperature. The PFA was then carefully removed 
and coverslips were washed three times in PBS (Oxoid BR14) for 5 minutes each time. 
For the analysis of spinal cord tissue, fresh spinal cords were removed from terminally 
anaesthetized WT and AR100 mice at P5, 3, 12 and 18 months, placed in an 
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eppendorf tube and stored at -80oC until processed.  Transverse spinal cord sections 
were cut serially at 10 m on a cryostat onto glass slides. 
Coverslips or spinal cord sections were incubated at room temperature for one hour in 
blocking solution, which consisted of 5% milk and 3% serum in PBS-0.1% Triton X-100 
(Sigma T8787). The type of serum used varied with the secondary antibody host, for 
example, for goat secondary antibodies sections were blocked in goat serum. The 
blocking solution was aspirated and the slides were incubated at 4oC overnight in the 
primary antibody diluted in blocking solution. The primary antibody was removed and 
the slides were washed three times in PBS for 10 minutes each time. The appropriate 
secondary antibody diluted in blocking solution to the required concentration, was then 
applied and the slides were incubated at room temperature, in the dark for 2 hours. The 
slides were then washed three times and then if required (i.e. if the secondary antibody 
used was a biotinylated antibody as opposed to a fluorescently conjugated antibody), 
an Avadin tertiary antibody (diluted in PBS) was applied and again, the slides were 
incubated in the dark at room temperature for 2 hours. Following a further 3 washes, 
the slides were then incubated with DAPI (1 in 2000 in PBS) in the dark at room 
temperature for 10 minutes. The slides were washed in PBS before being mounted 
using fluorescent mounting medium (DakoCytomation Fluorescent mounting medium 
S3023). 
In all experiments a negative control (incubated overnight in blocking solution only, with 
no primary antibody) was included to test the specificity of the secondary antibody. 
2.8.2 Microscopy 
Spinal cord sections and motoneuron cultures were imaged using the Leica (DFC420 
C) fluorescent microscope using a 40 X and 20 X objective lens. 
 
 
78 
 
2.8.3 Primary motoneuron counts 
All counts were undertaken blind by concealing the identity of the slides using labels 
placed on the slide by a fellow lab member. Fields were selected systematically so that 
the whole coverslip was represented. The number of motoneurons in a field was 
measured by counting the number of nuclei (positive DAPI staining), which were -III 
tubulin positive cells and which also fitted the criteria for identifying motoneurons (see 
Section 2.6.5). The number of motoneurons in each culture was established and 
expressed as a percentage of the DAPI-positive cells.  
2.9 Statistical Analysis 
Statistical analysis was performed using SPSS v15. To test for significance, non-
parametric data analysis was performed using the KruskalWallis test and for parametric 
data, one-way ANOVA with Tukey’s HSD and Bonferoni post-hoc tests carried out for 
pairwise comparison between all groups within the experiment. A p value of < 0.05 was 
considered statistically significant. 
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CHAPTER 3: RESULTS 1 – ER CALCIUM DEPLETION AND 
ER STRESS IN KD MOTONEURONS 
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3.1. Introduction 
ER stress has been implicated in the pathogenesis of Motor Neuron Diseases (MNDs) 
and CAG-repeat disorders such as Amyotrophic Lateral sclerosis (ALS) and 
Huntington’s Disease (HD), respectively (Saxena et al, 2009, Reijonen et al, 2008). 
Kennedy’s Disease is classified as both an MND and CAG-repeat disorder and so this 
Chapter will investigate the role of ER stress in its underlying pathogenesis. The 
function of the ER is Ca2+-dependent, with the depletion of ER calcium (Ca2+) resulting 
in ER stress. This Chapter will therefore establish whether ER Ca2+ depletion occurs in 
KD ventral motoneurons and results in ER stress as early as E13, making it an early 
disease trigger. The presence of ER stress will also be monitored at various disease 
stages in order to further understand its role in KD pathogenesis. 
3.1.1 Endoplasmic Reticulum (ER) function and Ca2+ dependence 
3.1.1.1 Endoplasmic reticulum structure and function 
The Endoplasmic Reticulum (ER) is a eukaryotic organelle that is composed of an 
interconnected network of tubules, cisternae and vesicles. The ER exists as two forms 
– rough and smooth. The rough ER is studded with ribosomes on its surface, giving the 
ER a rough appearance and hence its name. Ribosomes are the site at which proteins 
that are destined for the secretory pathway are synthesized. Indeed, the rough ER is 
the first cellular compartment that is involved in the secretory pathway. In general 
terms, its function is to process nascent membrane and secretory proteins, ensuring 
that they are folded correctly. The smooth ER however, which lacks ribosomes, is the 
site of synthesis of steroids, cholesterol and other lipids.  
The ER is often considered to be the point of protein ‘quality control’ in cells – proteins 
that are not folded correctly do not progress to the next stage of the secretory pathway 
– the Golgi complex. Protein folding is relatively easy to disrupt, and it is often impaired 
in diseases. In order to understand why protein folding is so easily disrupted, an 
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appreciation for the thermodynamics and kinetics of protein folding in the ER is 
needed. 
Different protein conformations have a different amount of free energy. The ‘native’ 
conformation of a protein is the conformation, which possesses the lowest amount of 
free energy (Dobson et al, 1998). This conformation is determined by the amino acid 
sequence of the protein. Therefore, disease-related mutations that result in changes in 
amino acid sequences will alter the native conformation of the protein.  
Another reason why protein folding can be easily disrupted is because it occurs at a 
relatively fast pace. Small proteins are folded in less than 50 set al, whilst mRNA 
translation is much slower, at 4-6 amino acids per second (Mayor et al, 2003). This 
means that for relatively long periods of time, preceding amino acid residues in the ER 
are kept in a folding-competent state until more residues can be translated and added. 
This makes the process of protein folding vulnerable to disturbances. 
There are also many ways in which the folding capacity of the ER can be 
compromised. These include ATP depletion, changes in the cell’s redox state and 
glucose deprivation (Kuznetsov et al, 1996, Tsai et al, 1994, Ikesugi et al, 2006). 
However, the focus of this study will be the way in which depletion of Ca2+ from the ER 
lumen disrupts ER function and results in what is known as ‘ER stress’. 
3.1.1.2 ER Ca2+ homeostasis 
A key feature of ER function is that it is Ca2+-dependent (for review see Pachen, 2000). 
Unlike the cytosol, which, under normal conditions, has a Ca2+ concentration of 0.1 M, 
the ER has a relatively high level of Ca2+, at approximately 0.3-1 mM (Jafri et al, 1992). 
Ca2+ is essential for protein folding as it participates in poly-peptide electrostatic 
interactions and is also necessary for the function of various ER chaperone proteins 
(Ostwald & MacLennan 1974, Roy et al, 1996). ER chaperone proteins are imperative 
to the protein folding capacity (for review see Ma & Hendershot 2004). As well as 
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actively promoting protein folding, they bind to unfolded proteins in order to prevent 
aggregation. The majority of ER chaperones are either members of the Glucose-
Regulated Proteins (GRP) family, such as GRP78, otherwise known as Binding 
immunoglobulin Protein (BiP), or lectin-like proteins such as Calreticulin and Calnexin 
(Demaurex et al, 2000). These chaperones have a high binding capacity for luminal 
Ca2+ (Milner et al, 1992). Their expression and activity levels are partly determined by 
ER Ca2+ concentration – with decreases in ER Ca2+ resulting in increased expression 
but decreased activity (Vassilakos et al, 1998, Ivessa et al, 1995). 
Under normal circumstances the ER tightly regulates luminal levels of Ca2+. It achieves 
this through receptor channels and pumps in the ER membrane that control the 
movement of Ca2+ into and out of the ER lumen (Verkhratsky 2004). The release of 
Ca2+ from the ER is mediated through two channel receptors; the Inositol trisphosphate 
(IP3) receptor and the Ryanodine receptor, whilst the uptake of Ca
2+ from the cytosol 
into the ER is mediated by the Sarco/Endoplasmic Reticulum ATPase (SERCA) pump 
(Verkhratsky 2004). These ER membrane proteins form a dynamic equilibrium that 
regulates the amplitude and duration of Ca2+ signals in the cytosol. 
3.1.1.3 ER Ca2+ release 
Ca2+ release from the ER plays a vital role in a variety of signal transduction pathways. 
The IP3 receptor is activated by plasma membrane receptors that are coupled to 
Phospholipase C (PLC), such as Adrenergic, Serotonergic and Cholinergic receptors 
(Shi et al, 2006, Feng et al, 2001, de Sevilla et al, 2008). PLC stimulation results in the 
production of the second messenger Inositol Trisphosphate (IP3), which is required, 
along with Ca2+, for the activation of IP3 receptors (Yuan et al, 2005). Ca
2+ release that 
occurs as a consequence of IP3 receptor activation is involved in various processes 
such as synaptic plasticity and cell proliferation and is therefore essential for normal 
cellular function (for review see Berridge et al, 2008). Ca2+ release from the ER also 
occurs via the Ryanodine receptor, which is one of the major mediators of Ca2+-
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induced Ca2+ release (CICR). CICR is the process by which Ca2+ triggers the release of 
further Ca2+ from the ER and is essential for excitation of contractile machinery in 
cardiac and skeletal muscle cells (Collier et al, 2000, Endo 2009).  
As well as being a necessary component of signal transduction and normal cell 
function, the release of Ca2+ from the ER can be detrimental to cells and has been 
suggested to play a role in triggering apoptosis (Nakano et al, 2006). Release of Ca2+ 
via IP3 receptors for example, has been suggested to result in the release of the pro-
apoptotic protein Cytochrome C, from mitochondria, which triggers the apoptotic 
pathway (Wozniak et al, 2006). This process will be discussed in more detail in Chapter 
5. 
3.1.1.4 ER Ca2+ uptake 
Since elevated cytosolic Ca2+ can be toxic to cells, a mechanism by which Ca2+ is 
sequestered from the cytosol and into the ER needs to be in place and tightly regulated 
in order for normal cellular function to be maintained. 
The SERCA pump is a 110 KDa ATPase that is present in the ER membrane that 
actively transports Ca2+ ions against a steep concentration gradient into the ER. It 
exists as various isoforms: SERCA1a and b, SERCA2a-c and SERCA3a-f. These 
isoforms are tissue specific, with motoneurons expressing the SERCA2b isoform 
exclusively (Van den Bosch et al, 1999).  The SERCA pump lowers cytosolic Ca2+ 
whilst increasing ER Ca2+. Because ER Ca2+ levels are a major determinant of cellular 
Ca2+ signals and plasma membrane channel activity (see below), the SERCA pump is 
a direct modulator of cellular Ca2+ signalling.  
Under normal circumstances, SERCA2b expression is elevated in response to 
increased cytosolic Ca2+ concentration (Wu et al, 2000), presumably as a defence 
mechanism by which excess Ca2+ is sequestered from the cytosol into the ER. As well 
as elevated cytosolic Ca2+, SERCA2b pump expression is also elevated downstream of 
Androgen Receptor (AR) activation (Foradori et al, 2008). For instance, following 
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treatment of primary hippocampal neurons with the AR ligand, dihydrotestosterone 
(DHT), SERCA2 expression is up-regulated and consequentially, ER Ca2+ levels 
increase (Foradori et al, 2008).  
The SERCA pump can therefore be considered as a modulator of cellular Ca2+ signals 
that sequesters Ca2+ from the cytosol resulting in lower cytosolic Ca2+ levels and 
elevated ER Ca2+, both of which are considered to serve a protective function to cells. 
3.1.2 Consequences of ER Ca2+ depletion 
In response to Ca2+ depletion – induced ER stress, the ER attempts to tackle both the 
source of ER stress (Ca2+ depletion) and the consequence of ER stress (functional 
impairment). 
3.1.2.1 Store-operated Ca2+ influx – ER Ca2+ replenishment 
Store-operated Ca2+ (SOC) influx is a phenomenon that is triggered as a result of ER 
Ca2+ depletion (Parekh et al, 2005). As discussed briefly in Chapter 1 (Section 1.3.5.1), 
SOC influx can be used to confirm the occurrence of ER Ca2+ depletion. Investigating 
SOC influx in greater detail can reveal more information about the mechanism by which 
the ER attempts to tightly regulate levels of Ca2+. 
The concept of SOC influx is relatively new and the precise mechanism by which it 
occurs has yet to be widely accepted. The proposed mechanism is shown in Figure 
3.1. Despite the concept being relatively new, the key proteins that are involved in the 
process have been identified (as discussed briefly in Chapter 1). The key ER-
associated protein that has been identified is Stromal Interacting Molecule 1 (STIM1), 
which is responsible for sensing the depletion of luminal Ca2+ (Williams et al, 2001). 
STIM1 is anchored to the ER via a single transmembrane domain and possesses key 
regions that have vital functions in the execution of SOC influx. The EF hand for 
example, which refers to a Ca2+-binding motif composed of two helices – E and F, 
faces the ER lumen, is responsible for sensing the depletion of Ca2+ (Zhang et al, 
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2005), whilst the alpha-motif domain, which is referred to as SAM (Sterile Alpha Motif), 
appears to have a role in the oligomerization of STIM1 monomers – a key event in 
SOC influx (Cai 2007).  Upon oligomerization, STIM1 has been shown to translocate to 
punctuate areas of the plasma membrane (Rao et al 2010). This is made possible by 
the fact that STIM1 contains microtubule plus ends, which associate with the 
microtubule end–binding protein, EB1 (Grigoriev et al, 2008). Translocation of STIM1 
then leads to the dimerization of proteins in the plasma membrane, which 
consequentially form functional Ca2+ channels through which Ca2+ influx can occur 
(Kiviluoto et al, 2011). The suggested plasma membrane protein component of this 
pathway, which has been identified using RNAi screening, is Orai1 (Feske et al, 2006). 
Orai1 channels do not appear to bear any structural similarity to other Ca2+ channels. 
For example, there is evidence, which suggests that, unusually, both the N and C 
terminal are cytoplasmic. Many findings indicate that Orai1 is still the strongest SOC 
channel candidate (for review see Authi 2009). For example, co-expression of Orai1 
and STIM1 in HEK293 cells produced a SOC entry current that was 10-100 times 
greater than the current observed in non-transfected cells (Peinelt et al, 2006). 
Furthermore, Orai1 is able to act as a Ca2+ channel despite its unusual structure. For 
instance, a point mutation (glutamate to alanine) near the extracellular emergence of 
the first transmembrane region of the protein, gives rise to non-functional channels 
(Yeromin et al, 2006). Furthermore, channel activity was selectively altered when the 
mutation made was more conservative – indicating that Orai1 forms a pore that permits 
Ca2+ entry (Prakriya et al, 2006). 
As well as Orai1, Transient Receptor Potential (TRP) channels have also been 
identified as a possible candidate for the plasma membrane component of SOC influx 
(Perez et al, 2003), since they possess features that resemble those of the SOC influx 
channel, such as current, amplitude and latency (Perez et al, 2003).   
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Figure 3.1: Proposed mechanism for Store-Operated Ca2+ (SOC) influx 
Although the mechanism by which SOC influx occurs has yet to be established, the 
most accepted mechanism at present is summarized in the diagram below. Depletion 
of Ca2+ from the ER lumen is sensed by the luminal EF hands of STIM1 (1). This 
results in the oligomerization of STIM1 monomers (2). This then leads to the 
translocation of the STIM1 oligomer to punctate areas of the membrane that are 
associated with the protein Orai1 (3). Orai 1 monomers can then dimerize and in doing 
so form functional Ca2+ channels that permit Ca2+ entry in the cell (4). As a result, 
cytosolic Ca2+ levels increase, which facilitates refilling of the ER (5). 
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Indeed, the inhibition of TRPC (the C isoform of the TRP channel) channel transcription 
by the introduction of antisense TRP sequences results in a dramatic decrease in SOC 
influx (Zhu et al, 1996). Inhibition of TRPC4 (isoform 4 of TRPC) transcription produces 
the same results, suggesting that TRPC4 is the main TRPC homologue that 
contributes to SOC influx (Phillip, et al, 2000). However, the fact that SOC influx is not 
completely inhibited suggests that other channels may also be involved. Furthermore, 
Orai1 silencing appears to completely inhibit SOC influx, at least in vascular smooth 
muscle cells, although TRPC4 silencing has no observable effect (Potier et al, 2009). 
These findings make Orai1 a stronger candidate for the predominant plasma 
membrane component of SOC influx. 
3.1.2.2 The Unfolded Protein Response  
In conditions of ER stress the Unfolded Protein Response (UPR) is activated (for 
review see Lai et al, 2007). The UPR is a well conserved homeostatic mechanism that 
consists of three converging pathways, all of which attempt to restore ER function. The 
three pathways are activated sequentially (Figure 3.2), beginning with the dissociation 
of Binding immunoglobulin Protein (BiP), from the ER membrane protein Pancreatic ER 
Kinase–like Kinase (PERK), which is the first of three core stress transducers of the 
UPR. Dissociation of BiP from PERK results in the phosphorylation of eukaryotic 
Initiating Factor 2 (eIF2). This results in the arrest of global protein translation, which 
alleviates the protein load of the ER. UPR proteins however, are exempt from this 
translation arrest and the translation and translocation of Activating Transcription 
Factor 4 (ATF4) into the nucleus follows. Upon translocation of ATF4 to the nucleus, 
the transcription of genes encoding both pro-survival and pro-apoptotic proteins occurs.  
The second UPR pathway to be activated begins with the dissociation of BiP from 
another UPR transducer in the ER membrane – Activating Transcription Factor 6 
(ATF6). Upon dissociation of BiP, ATF6 is cleaved in the Golgi complex, resulting in 
liberation of the transcriptionally active domain of the protein (Lai et al, 2007). 
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Figure 3.2: The Unfolded Protein Response (UPR) 
The diagram below summarizes the UPR pathway. Following the aggregation of 
unfolded proteins, BiP dissociates from three different ER stress receptors and in doing 
so triggers three different, yet converging pathways. Following dissociation of BiP from 
Pancreatic ER Kinase (PERK) (1), eIF2is phosphorylated (2) and global translation is 
inhibited. ATF4 is exempt from this translational block and is therefore translated. ATF4 
translocates to the nucleus and activates the transcription of pro-survival genes, 
required to restore ER homeostasis, as well as pro-apoptotic genes. (3)The second ER 
stress receptor from which BiP dissociates is activating transcription factor 6 (ATF6). 
This dissociation leads to the cleavage of ATF6 (4) and its subsequent translocation to 
the nucleus, where it also activates the transcription of both pro-survival and pro-
apoptotic genes. (5) The final ER stress receptor to be activated is Inositol-requiring 
enzyme 1 (IRE1). This leads to splicing of X box-binding protein 1 (XBP1), which then 
translocates to the nucleus leading to the transcription of more proteins required to 
restore ER function and degrade misfolded proteins (6). P58IPK is also transcribed 
downstream of IRE1 activation and provides negative feedback for the PERK pathway 
of the UPR by preventing eIF2 phosphorylation (7).  
Thus all three sequentially activated pathways converge to restore the function of the 
ER by decreasing the load of the ER and by enhancing the capacity of the cell to 
restore ER function and degrade misfolded proteins. 
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Figure 3.2  
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Cleaved ATF6 then translocates to the nucleus, which leads to the transcription of a 
variety of proteins that aid ER function restoration such as Chaperone proteins and X-
box binding protein 1 (XBP1). XBP1 is spliced as part of the third pathway of the UPR 
(Lai et al, 2007). This third pathway involves the ER membrane protein Inositol-
Requiring enzyme 1 (IRE1). Upon dissociation of BiP from IRE1, it mediates the 
splicing of XBP1. Spliced XBP1 then translocates to the nucleus and activates the 
transcription of chaperone proteins and proteins involved in protein degradation. P58IPK 
is also transcribed and down-regulates eIF2activity (Huizen et al, 2003). The third 
UPR pathway therefore provides negative feedback that regulates activity of the PERK 
pathway of the UPR. 
As well as increasing the expression of chaperone proteins, the UPR also controls ER-
associated degradation (ERAD), which degrades misfolded polypeptides that cannot 
be processed by the ER (Lai et al, 2007). In general terms, ERAD involves dislocation 
of the misfolded poly-peptide from the ER to the cytosol, where it undergoes 
proteolysis as part of the ubiquitin-proteasome system (Meusser et al, 2005).  
Thus the three pathways activated as part of the UPR have the convergent effects of 
reducing the rate of protein synthesis and increasing the transcription of genes that 
encode proteins involved in the UPR, protein handling and protein degradation (Lai et 
al, 2007, Szegezdi et al, 2006). 
Although the UPR has a protective function, prolonged activation and continuous 
exposure to conditions that cause ER stress can be detrimental to cell survival, 
because the UPR also results in the expression of pro-apoptotic proteins. One such 
protein is CCAAT/enhancer-binding Protein Homologous Protein (CHOP), which is 
activated downstream of both the PERK and IRE1 pathways of the UPR (Lai et al, 
2007). In general terms, CHOP inhibits anti-apoptotic mediators. This process is 
discussed in more detail below (Section 3.1.4.4). CHOP also acts as a feedback 
inhibitor of the phosphorylation of eIF2 as it activates expression of GADD34, which 
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directs the protein phosphatase PP1 to eIF2 thus dephosphorylating it (Novoa et al, 
2001). 
Another example of a pro-apoptotic protein that is upregulated as a result of the UPR is 
the Proapoptotic BH3-only protein, PUMA (Reimertz et al, 2003). Expression of PUMA 
results in the release of Cytochrome C from the mitochondria as well as activation of 
Caspase-3 and Caspase-9 (Reimertz et al, 2003). Thus if ER stress is prolonged and 
the UPR is not arrested, ER stress-induced apoptosis will ensue. This process is 
discussed in more detail in Chapter 4. 
3.1.3 ER stress in neurodegenerative disease 
ER stress has been implicated in the pathology of both MNDs and CAG-repeat 
disorders (Saxena et al, 2009, Reijonen et al, 2008). It has been found to occur pre-
symptomatically and is present at symptom onset and progression. Because 
Kennedy’s Disease is both a MND and CAG-repeat disorder, it is therefore likely that 
ER stress plays a role in the underlying pathology of this neurodegenerative disorder. 
3.1.3.1 ER stress and Motor Neuron Disease (MND) 
Amyotrophic Lateral Sclerosis (ALS) is the most common form of adult MND (Eisen et 
al, 1998). It is characterized by the progressive degeneration of spinal and cranial 
motoneurons. ER stress has been implicated in the pathology of ALS and has been 
found to occur in mouse models of the disease (Saxena et al, 2009) as well as ALS 
patient tissue (Atkin et al, 2008), both pre-symptomatically and after symptom 
manifestation (Saxena et al, 2009). 
Several markers of ER stress have been found to increase in motoneurons in a number 
of mouse models of ALS including BiP, eIF2, ATF4 and CHOP (Saxena et al, 2009). 
ER stress has been observed in spinal motoneurons of the G93A mutant SOD1 mouse 
(SOD1G93A) as early as P5, well before symptom onset and motoneuron degeneration 
(Saxena et al, 2009). These markers are up-regulated in the SOD1G93A mouse spinal 
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cord in a subset of motoneurons that appear to be more vulnerable to the disease 
(Saxena et al, 2009). In addition evidence suggests that there is the same correlation 
between the presence of ER stress and disease progression. For instance, an increase 
in BiP expression is detected at an early age (P5) in the SOD1G93A mouse, which has a 
relatively early symptom onset and rapid disease progression, compared to the less 
aggressive SOD1G85R mouse (Bruijn et al, 1998), in which an abrupt increase in BiP 
expression is observed in spinal motoneurons just prior to muscle denervation (Saxena 
et al, 2009). 
Markers of ER stress are also found in spinal cord biopsies from ALS patients and 
correlate well with the findings from mouse models. CHOP expression for example, 
was found to be higher in ALS patient spinal cord tissue than in control samples, which 
typically expressed low levels of CHOP (Ito et al, 2009). 
In SOD1G93A mice, the presence of the SOD1G93A protein not only results in ER stress 
but also appears to prevent one of the mechanisms that is protective against ER 
stress, ER associated degradation (ERAD). The SOD1G93A protein has been found to 
interact with Derlin-1 and as a result, retro-translocation of the misfolded protein is 
impaired, thereby preventing ERAD. This leads to ER stress-activation of Apoptosis 
Signal-regulating Kinase 1 (ASK1), which results in apoptosis (Nishitoh et al, 2008). 
To summarize, ER stress appears to play an important and early role in the pathology 
of ALS. In the SOD1G93A mouse model of ALS ER stress appears to be present as early 
as P5 and remains throughout disease progression until end-stage, suggesting that ER 
stress could play a causal role in disease pathology. Furthermore, sharp increases in 
ER stress marker levels appear to correlate with symptom onset. 
3.1.3.2 ER stress and CAG-repeat disorders  
As well as ALS, ER stress has also been suggested to play a role in the underlying 
pathology of CAG-repeat disorders such as Huntington’s Disease (HD). In cell lines 
transfected with mutant N-terminal Huntingtin proteins of varying CAG-repeat lengths, 
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RT-PCR revealed that levels of BiP, eIF2 and CHOP were greater in cells transfected 
with the mutant Huntingtin proteins compared to EGFP-transfected controls (Reijonen 
et al, 2008). Furthermore, the level of BiP appeared to increase with an increasing 
number of CAG repeats, suggesting a correlation between CAG-repeat number and 
ER stress. In the same cells, death and protein aggregation were also found to occur. 
This was counteracted however by the administration of Salubrinal, which inhibits ER 
stress, suggesting that ER stress has a major role in cell death in this disease model 
(Reijonen et al, 2008). 
As is the case in ALS, expression of the mutant Huntingtin protein also appears to 
impair ERAD. This has been shown in vitro in both PC12 and striatal cells that were 
transfected with a mutant Huntingtin protein containing 103 CAG repeats. In these 
transfected cells, the toxic CAG-expansion mutation appeared to entrap proteins that 
are vital for ERAD, such as Ufd1 and p97 (Duennwald et al, 2008). Furthermore, 
application of low levels of Tunicamycin (an ER stressor) affected these cells more 
than cells containing a control protein with just 25 CAG repeats, suggesting that the 
presence of the CAG repeat expansion sensitizes the cells to ER stressors (Reijonen 
et al, 2008). 
As well as entrapping proteins involved in ERAD, another way in which the mutant 
Huntingtin protein has been suggested to inhibit ERAD is by preventing the interaction 
of ER chaperone proteins with ERAD-associated proteins. For example, the mutant 
Huntingtin protein was found to interact with BiP and in doing so it is thought to 
sterically block the interaction between BiP and p97, which is essential for the initiation 
of ERAD (Yang et al, 2010). 
3.1.4 Examination of ER stress markers 
A number of markers can be used to investigate ER stress. The experiments in this 
Chapter will focus on the ‘PERK branch’ of the UPR and will measure the expression of 
the markers BiP, phospho-eIF2, ATF4 and CHOP (Figure 3.3). These markers have 
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been selected for examination in this study as they have been previously shown to be 
elevated in both motoneuron diseases and CAG-repeat disorders (as discussed in 
Section 3.1.3), and represent various UPR events. 
3.1.4.1 BiP 
Since BiP senses misfolded proteins, it represents the first event involved in signal 
transduction in response to ER stress.  BiP consists of an N-terminal ATPase and a C-
terminal substrate binding domain (Chevalier et al, 1998). The ADP-bound form of BiP 
has a high affinity for protein substrates. Upon binding of proteins to BiP, the proteins 
become locked in their current conformation and the ATPase activity of BiP is 
activated. When ADP is exchanged with ATP, the protein is released from BiP. ATP 
hydrolysis occurs subsequently and BiP again exists in its ADP-bound, high protein 
affinity form. Thus BiP undergoes a constant protein binding-unbinding cycle in which it 
is very sensitive to changes in protein conformation (Chevalier et al, 1998). 
BiP resides in the ER as both monomeric and oligomeric forms (Freiden et al, 1992). 
The monomeric form is suggested to interact with unfolded proteins in the ER, whilst 
the oligomeric form, is suggested to be subject to posttranslational modification, such 
as phosphorylation (Freiden et al, 1992). Oligomeric BiP is suggested to form a BiP 
‘storage pool’ in the ER from which monomeric BiP is recruited (Zu et al, 2005). 
3.1.4.2 Phosphorylated eIF2
 eIF2 is a 65 kDa translation initiation factor protein that is present in the cytosol 
(Kimball 1999). It functions by forming a ternary complex with both initiator tRNA and 
GTP (Fels & Koumeris 2006). This complex binds to the 40s ribosome subunit followed 
by the binding of mRNA. As a result, a 43S pre-initiation complex is formed, which 
moves along mRNA towards to 3’ end in order to find the start codon and commence 
translation.   
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Figure 3.3: The PERK branch of the UPR 
The PERK branch of the UPR has been shown to be elevated in other MNDs and 
CAG-repeat disorders. The diagram illustrates this pathway and highlights the markers 
that are examined in the experiments described in this thesis (red boxes). They 
include: 1) BiP, a misfolded protein sensor that is transcribed downstream of the PERK 
branch of the UPR; 2) phospho-eIF2, a marker of translational arrest; 3) ATF4, a 
transcription factor that is exempt from global arrest; and 4) CHOP, a pro-apoptotic 
marker that is transcribed downstream of ATF4. 
 
 
 
 
96 
 
Conversion of the 43S complex into the 80S complex, which is required for completion 
of translation, requires hydrolysis of GTP that is bound to eIF2(Fels & Koumeris 
2006). This GDP/GTP exchange allows eIF2 to be recycled between different rounds 
of translation. What prevents this recycling, and hence inhibits translation, is the 
phosphorylation of eIF2at its serine 51 residue by various kinases such as PERK 
(Fels & Koumeris 2006). By measuring the levels of phospho-eIF2 specifically, the 
occurrence of PERK activation and subsequent translation inhibition in response to ER 
stress can be inferred. 
3.1.4.3 ATF4  
Although global translation is inhibited by the phosphorylation of eIF2, the translation 
of ER stress response genes is elevated. One of these genes is Activating 
Transcription Factor 4 (ATF4). ATF4 is a member of the cAMP responsive element 
binding protein (CREB) family and is a transcription factor that translocates into the 
nucleus following translation (Steiger et al, 2004). Upon entering the nucleus ATF4 
forms a complex with its nuclear co-activator, phosphorylated CREB1, and binds to the 
promoter sequences of a variety of pro-survival and pro-apoptotic genes including BiP 
and CHOP, respectively. Measuring levels of ATF4 therefore represents the 
transduction of ER stress into changes in gene transcription.  
3.1.4.4 CHOP 
CHOP, also known as GADD53, is a transcription factor that is activated downstream 
of various events of ER stress such as ATF4 translation. The elevated expression of 
CHOP can be indicative of the initial ER stress-induced apoptosis and therefore is the 
connection between prolonged activation of the UPR and apoptosis. Indeed, deletion of 
the CHOP protein is enough to protect cells against Tunicamycin treatment, which 
normally results in ER stress-induced apoptosis (Marciniak et al, 2004). 
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One way in which CHOP results in cell death is via the down-regulation of the anti-
apoptotic protein, B-cell lymphoma 2, or Bcl2 (Yamaguchi and Wang 2004). CHOP 
transcription also leads to the induction of the tribbles ortholog 3 (TRB3) protein, which 
is thought to bind to a serine/threonine-specific protein kinase referred to as Akt. This 
prevents the phosphorylation of Akt, which in turn prevents its anti-apoptotic actions 
(Ohoka et al, 2005). 
Measuring CHOP is useful because in combination with the above ER stress markers, 
it gives an indication of the balance between the expression of pro-survival and pro-
apoptotic proteins that are transcribed downstream of the UPR. 
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3.2 Results 
3.2.1 Summary 
In this Chapter Wild-Type (WT) and KD primary E13 motoneuron cultures were 
prepared and changes in cytosolic Ca2+ in response to pharmacological agents were 
determined using confocal microscopy in order to establish if ER Ca2+ depletion was 
present in KD motoneurons. In addition, markers of ER stress were examined in vitro 
and in spinal cords from WT and KD mice at various stages of disease. These stages 
include postnatal day 5 (P5), 3, 12 and 18 months of age. These ages represent, 
respectively, the earliest time point at which ER stress has been detected in the 
SOD1G93A model of ALS (Saxena et al, 2009); a pre-symptomatic stage; the time of 
symptom onset; and disease end stage. 
Throughout this thesis four experimental groups are examined: 
1) Untreated WT motoneurons 
2) 72 hour DHT-treated WT motoneurons 
3) Untreated KD motoneurons 
4) 72hour DHT-treated KD motoneurons 
These four groups are used to model affected males (DHT-treated KD motoneurons) 
and unaffected females (untreated KD motoneurons) as well as non-disease controls 
(untreated and treated WT motoneurons). 
3.2.2 Fluo 4-AM fluorescence remains stable during the recording period 
Prior to carrying out any experiments it was important to establish whether or not the 
fluorescence intensity of Fluo 4-AM changes during the recording period independently 
of pharmacological manipulation e.g. due to dye leakage or photobleaching, which 
would produce confounding results. 
99 
 
In order to control for this, the fluorescence of Fluo 4-AM was measured over a period 
of 10 minutes – twice the length of time of the recording period used in the protocol in 
this study. As shown in Figure 3.4 over the course of 10 minutes there is no significant 
change in fluorescence. This observation is reproducible (n = 30, from 3 different 
cultures). 
3.2.3 50 nM DHT does not affect normal Ca2+ handling in motoneurons 
The basal cytosolic Ca2+ level in WT motoneurons was assessed following treatment of 
cultures for 72 hours with a range of DHT concentrations (Figure 3.5). 
The results indicate that there is a negative correlation between the concentration of 
DHT applied and basal cytosolic Ca2+ concentration. When cells are treated with 0.1 
nM DHT, the average basal cytosolic Ca2+ concentration is approximately 580 nM (+/- 
26.8 nM SEM, n=7). This then decreases to 500 nM (+/- 29.4 nM SEM, n=6) after 72 
hour treatment with 1 nM. The average basal Ca2+ levels decrease further to 
approximately 420 nM (+/- 29.0 nM SEM, n=8) when cultures are treated with 10 nM 
DHT and the basal concentration then levels off at approximately 250 nM (+/- 22.3 nM 
SEM, n=5) following treatment with  50 nM DHT. 
3.2.4 Motoneuron Ca2+ handling 
3.2.4.1 Basal cytosolic Ca2+ in primary KD motoneurons 
3.2.4.1.1 Cytosolic Ca2+ in a Ca2+-free recording medium  
As shown in Figure 3.6A, when cultures are imaged in a Ca2+-free medium there is very 
little difference in cytosolic Ca2+ levels between the WT and KD motoneurons. The 
highest basal cytosolic Ca2+ is found in DHT-treated KD motoneurons, which have a 
mean concentration of 110 nM (+/- 5.59 nM SEM, n=35). 
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Figure 3.4: Fluo 4-AM fluorescence does not change during the protocol 
At 7 days in vitro (DIV) primary motoneurons were incubated with Fluo 4-AM for 30 
minutes at 37oC. Cultures were then imaged for at least 10 minutes in the absence of 
any pharmacological manipulation. The fluorescence of selected motoneurons was 
measured and background fluorescence deducted. A representative trace of recordings 
during the 10 minute period is shown here.  There is no change in Fluo 4-AM 
fluorescence over time. This finding is reproducible (n = 30 motoneurons from 3 
different cultures). 
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Figure 3.5: DHT reduces basal cytosolic [Ca2+] in WT motoneurons 
Primary WT motoneuron cultures were treated at 4 DIV with a range of concentrations 
of DHT between 0.1 nM – 50 nM. Cultures were incubated with Fluo 4-AM at 7 DIV and 
baseline fluorescence in selected motoneurons was obtained. Ionomycin was then 
applied to obtain a maximum fluorescence value for calibration purposes. Background 
fluorescence was deducted and the resulting fluorescence values were converted into 
basal cytosolic Ca2+ concentrations. The average basal Ca2+ concentration was 
calculated by taking the average of all values prior to Ionomycin application. The 
schematic diagram (A) illustrates this procedure. 
There is a negative correlation between basal Ca2+ concentration and DHT 
concentration as shown in the graph (B) so that as the concentration of DHT is 
increased, the level of cytosolic Ca2+ decreases.  
(Error Bars = standard error of mean) 
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Figure 3.5 
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The lowest level of basal cytosolic Ca2+ however is found in DHT-treated WT 
motoneurons, which have a Ca2+ concentration of 97 nM (+/- 4.67 nM SEM, n=31). 
There is only a negligible difference of 3 nM in the average basal cytosolic Ca2+ 
concentration between untreated WT and untreated KD motoneurons, which have a 
Ca2+ concentration of 100 nM (+/- 2.12 nM SEM, n=32) and 103 nM (+/- 6.43 nM SEM, 
n=28), respectively. 
3.2.4.1.2 Cytosolic Ca2+ in a 1 M Ca2+ recording medium  
As shown in Figure 3.6B, when cultures are imaged in a recording medium containing 
1 mM Ca2+, the highest cytosolic Ca2+ level is present in DHT-treated KD motoneurons, 
which have an average concentration of 275 nM (+/- 7.60 nM SEM, n=35).   The lowest 
level of cytosolic Ca2+ is present in DHT-treated WT motoneurons, which have an 
average concentration of 110 nM (+/- 7.18 nM SEM, n=31). The difference between 
DHT-treated WT and DHT-treated KD motoneurons is significant (p= 0.002). There is 
also a significant difference (p=0.02) between untreated WT and untreated KD 
motoneurons, which have an average basal cytosolic Ca2+ concentration of 130 nM (+/- 
3.71 nM SEM, n=32) and 240 nM (+/- 6.43 nM SEM, n=28), respectively. 
3.2.4.2 Inferred ER Ca2+ in KD motoneurons 
ER Ca2+ levels are inferred by treating the cultures with Thapsigargin (TG), which 
causes the release of Ca2+ from the ER lumen into the cytosol, where changes in 
cytosolic Ca2+ can be determined. 
3.2.4.2.1 Average ER Ca2+ values in motoneurons 
The lowest level of inferred ER Ca2+, as indicated by the lowest rise in cytosolic Ca2+ 
following TG application, is observed in DHT-treated KD motoneurons, which have an 
TG-induced increase in cytosolic Ca2+ of 10 nM (+/- 5.07nM SEM, n=35). 
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Figure 3.6: Basal cytosolic Ca2+ concentration in WT and KD primary 
motoneurons  
Primary WT and KD motoneuron cultures were imaged at 7 DIV. Cultures were either 
left untreated or were treated with 50 nM DHT at 4 DIV. Cultures were incubated at 
37oC with Fluo 4-AM, diluted in a 1 mM Ca2+ recording medium, prior to imaging. After 
30 mins of incubation cultures were washed with, and subsequently imaged in, 
recording medium. In some cases however, cultures were imaged in a Ca2+-free 
recording medium to ensure that there was no extracellular source of Ca2+. In all cases 
cultures were kept at 37oC throughout the protocol. The Bar Charts summarize basal 
cytosolic Ca2+ in untreated and DHT- treated WT and KD motoneuron cultures in the 
absence of external Ca2+ (A) and in medium containing 1 M Ca2+ (B). 
 (Error Bars = standard error of mean) 
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Figure 3.6 
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This is significantly lower (p=0.002) than the response observed in DHT-treated WT 
motoneurons, which have the highest level of TG-induced increase in cytosolic Ca2+ at 
140 nM (+/- 3.41 nM SEM, n=31). Thus steady state ER Ca2+ appears at least an order 
of magnitude lower in DHT-treated KD motoneurons than in DHT-treated WT controls 
(Figure 3.7). In the absence of DHT, there is only a 2.5 nM difference in TG induced 
increase in the cytosolic Ca2+ concentration between WT and KD motoneurons, (60nM 
(+/- 5.30 nM SEM, n=32) and 57.5 nM (+/- 4.82 nM SEM, n=28), respectively). 
3.2.4.2.2 Effects of DHT treatment on ER Ca2+ levels 
In WT motoneurons, DHT treatment causes an increase in inferred ER Ca2+ of 60 nM 
and in KD motoneurons DHT causes a decrease of approximately 40 nM (Figure 3.7). 
3.2.4.2.3 The kinetics of changes in cytosolic Ca2+ in response to TG treatment  
Examination of the TG-induced cytosolic Ca2+ response reveals a difference in the 
response kinetics between WT and KD motoneurons (Figure 3.7Ai & Aii). The Ca2+ 
response to TG appears to be of similar onset latency in WT and KD motoneurons, 
regardless of whether or not they have been treated with DHT. In all cases, the 
response to TG application is immediate and reaches a peak within 40-50 seconds. 
However, in WT motoneurons (both untreated and DHT-treated), the response to TG is 
more prolonged than the response in KD motoneurons and cytosolic Ca2+ only falls to a 
negligibly lower concentration than the peak TG-induced response during the protocol. 
In KD motoneurons, the response to TG appears to have more of a transient nature 
and the level of Ca2+ falls by 10 nM in the case of untreated KD motoneurons, and back 
to basal levels in the case of DHT-treated KD motoneurons, within 130 seconds. 
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Figure 3.7: Inferred ER Ca2+ levels in WT and KD motoneurons 
ER Ca2+ can be inferred by the rise in cytosolic Ca2+ that occurs following drug-induced 
ER Ca2+ depletion in a Ca2+-free recording medium. Removal of external Ca2+ ensures 
that any elevation in cytosolic Ca2+ can only be the result of Ca2+ release from the ER. 
Following determination of basal Ca2+ in a Ca2+-free medium, ER Ca2+ depletion was 
induced by treatment with Thapsigargin and the resultant increase in cytosolic Ca2+ 
was measured. A value for inferred ER Ca2+ was calculated by taking an average of the 
Ca2+ concentration values at ten time points around the peak of the response. The 
traces shown in A & B show the typical response to TG treatment in untreated (Ai) and 
DHT-treated (Aii) cultures. These traces illustrate the kinetics of this response and 
show that although the onset of the TG-induced response is similar in WT and KD 
motoneurons, the response is relatively prolonged in WT motoneurons and of a more 
transient nature in KD motoneurons. The Bar Chart (B) summarizes the mean elevation 
in cytosolic Ca2+ in response to TG (inferred ER Ca2+) in untreated and DHT-treated 
WT and KD motoneurons. 
(Error Bars = standard error of mean) 
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Figure 3.7  
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3.2.4.3 Inferred Store-operated Ca2+ influx in WT and KD motoneurons 
3.2.4.3.1 Average values of inferred SOC influx in WT and KD motoneurons 
Traces illustrating the typical store-operated Ca2+ (SOC) influx in WT and KD 
motoneurons (+/-DHT) are shown in Figures 3.8Ai (WT) and 3.8Aii (KD). SOC influx 
can be inferred from the increase in cytosolic Ca2+ that occurs following introduction of 
Ca2+ into the recording medium following treatment with TG. As shown in Figure 3.8C, 
the highest level of SOC influx is observed in DHT-treated KD motoneurons at 1.3 M 
(+/- 34.63 nM SEM, n=35). This is significantly higher (p=0.027) than the level 
observed in DHT-treated WT motoneurons, which have the lowest inferred level of 
SOC influx at approximately 300 nM (+/- 34.11 nM SEM, n=31). 
3.2.4.3.2 Effects of DHT treatment on SOC influx 
DHT treatment appears to have opposing effects on WT and KD motoneurons (Figure 
3.8B). In KD motoneurons, DHT treatment results in a significant increase in SOC 
influx of approximately 350 nM (p=0.0012). In WT motoneurons however, DHT 
treatment results in a significant decrease in SOC influx of 400 nM (p=0.05). 
3.2.4.3.3 The kinetics of cytosolic Ca2+ changes in response to Ca2+ introduction  
The traces showing the responses to Ca2+ introduction into the recording medium 
reveal that both DHT treatment and genotype affect the response kinetics (Figure 8A & 
B). In both genotypes DHT treatment increases the rate at which the peak Ca2+ 
response is achieved. In untreated cultures, the peak Ca2+ concentration is reached 20-
40 seconds following Ca2+ introduction. However, following DHT treatment, the peak 
concentration is reached within 15 seconds of Ca2+ introduction. 
The nature of SOC influx is more transient in WT motoneurons than in KD 
motoneurons. Cytosolic Ca2+ does not decrease back to the level it was prior to Ca2+ 
introduction in the time frame of the experiment for either genotype, although it 
decreases more substantially in WT motoneurons than KD motoneurons. 
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Figure 3.8: Inferred Store-Operated Ca2+ (SOC) influx in WT and KD 
motoneurons. 
SOC influx can be inferred by the increase in cytosolic Ca2+ following TG application 
and subsequent Ca2+ introduction into the recording medium. By controlling the time 
point at which external Ca2+ is available, the occurrence of SOC influx can be isolated 
and measured. Typical traces of the inferred SOC influx (changes in cytosolic Ca2+ in 
response to Ca2+ introduction to the medium) are shown in Ai) and Aii), in the absence 
and presence of DHT, respectively. A value for inferred SOC influx was calculated by 
taking an average of the Ca2+ concentration values at ten time points around the peak 
of the response. The Bar Chart (B) summarizes differences between untreated and 
DHT-treated WT and KD motoneurons with respect to SOC influx.  
(Error Bars = standard error of mean) 
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Figure 3.8  
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3.2.5 Examination of Ca2+ handling in motoneurons of male and female embryos. 
Because KD symptoms manifest exclusively in males, it is important to determine 
whether or not the differences in Ca2+ handling observed in motoneurons are due to 
androgen availability or inherent differences in AR expression in motoneurons. The 
same protocol was therefore carried out in DHT-treated motoneurons that had been 
cultured from spinal cords of identified male and female embryos (Figure 3.9). 
Measurement of basal Ca2+, inferred ER Ca2+ and inferred SOC influx showed that 
there is only a negligible difference in Ca2+ handling between motoneurons of different 
sex but the same genotype. 
In the case of basal cytosolic Ca2+, both male and female WT motoneurons have an 
average concentration ranging between 200-210 nM (n=25 and 29, respectively). Both 
male and female KD motoneurons however, have an average concentration in the 
range of 450-490 nM (n=22 and 26, respectively).  
The same trend is apparent when measuring inferred ER Ca2+ (Figure 3.9B) and SOC 
influx (Figure 3.9C). Again, there is only a negligible difference between motoneurons 
of different sexes and the same genotype.  
Finally, the same trend is apparent for inferred SOC influx (Figure 3.9C). In this case 
there appears to be a slightly greater difference between male and female KD 
motoneurons, although this difference is not significant. 
3.2.6 Fura 2 control experiments 
In order to ensure that measurements of Ca2+ handling determined using Fluo 4-AM as 
the Ca2+ indicator were reliable, a short series of control experiments were undertaken 
using Fura 2 as an alternative Ca2+ indicator (see Figure 3.10). When the experiment 
performed in Section 3.3.4 is carried out using Fura 2 as the cytosolic Ca2+ indicator 
instead of Fluo 4-AM, the same pattern of results is apparent (Figure 3.10). 
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Figure 3.9: Ca2+ handling in male and female motoneurons 
Measurements of basal cytosolic Ca2+, inferred ER Ca2+ and SOC influx were obtained 
in DHT-treated WT and DHT-treated KD motoneurons that had been cultured from 
specific male and female embryos. By comparing male and female motoneurons in the 
presence of DHT, any inherent differences in the AR due to the CAG repeat expansion 
would be revealed. Because KD symptoms manifest exclusively in males, it is 
important to establish whether or not this is due to an inherent difference in the AR, or 
due to the difference in androgen availability. The results shown in the Bar Charts 
reveal that there is only a negligible difference between male and female WT, and male 
and female KD motoneurons with respect to basal cytosolic Ca2+ (A), inferred ER Ca2+ 
(B) and SOC influx (C). 
(Error Bars = standard error of mean) 
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Figure 3.9 
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Fura-2 signals were quantified as the ratio between 340/380nm. It is important to note 
that these values are proportional to Ca2+, but the function is not linear, which is why 
calibration is required. However, in the presence of EGTA, which is required for 
calibration purposes, motoneurons lose their integrity, giving rise to significant 
artefacts. Calibration could therefore not be performed in these experiments and so the 
results obtained using Fluo 4-AM and Fura-2 could not be directly compared. Instead, 
the trend in results was compared. 
3.2.6.1 Basal cytosolic Ca2+ (Figure 3.10A) 
The lowest level of basal cytosolic Ca2+ is still observed in DHT-treated WT 
motoneurons as indicated by the lowest 340/380 nm ratio of 0.5 (+/- 0.02 SEM, n=26). 
The highest ratio of 0.8 (+/- 0.01 SEM, n=28) is found in DHT-treated KD motoneurons 
indicating that cytosolic Ca2+ is 60% higher in KD motoneurons than in WT 
motoneurons. This is a greater difference than that observed using Fluo 4-AM, where 
the results showed that basal cytosolic Ca2+ in DHT-treated KD motoneurons is 20% 
higher than in DHT-treated WT motoneurons.  
The effect of DHT treatment on cytosolic Ca2+ is also more pronounced when using 
Fura 2 as a Ca2+ indicator compared to Fluo 4-AM. For example, treated WT 
motoneurons have a basal Ca2+ ratio that is 20% lower than untreated WT 
motoneurons using Fura 2, but only 1% higher using Fluo 4-AM. Likewise, the basal 
level of Ca2+ is 42% higher in DHT- treated KD motoneurons than untreated KD 
motoneurons when using Fura 2, but only 17% higher when using Fluo 4-AM. These 
results suggest that Fura 2 is more sensitive to changes in cytosolic Ca2+. 
3.2.6.2 Inferred ER Ca2+ (Figure 3.10B) 
The trend observed using Fura 2 to measure inferred ER Ca2+ is consistent with that 
obtained using Fluo 4-AM. The lowest level of inferred ER Ca2+ is observed in DHT-
treated KD motoneurons, which respond to TG application with an increase in cytosolic 
Ca2+ with a 340/380 nm ratio of 0.03 (+/- 0.01 SEM n=28). This is significantly lower (p 
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< 0.001) than the increase observed in DHT-treated WT motoneurons, which was 0.18 
(+/- 0.01 SEM, n=26). Thus the level of inferred ER Ca2+ is approximately six times 
lower in KD motoneurons than WT controls. This is a similar magnitude of difference to 
that observed using Fluo 4-AM, where the results show that DHT-treated KD 
motoneurons have an ER Ca2+ concentration that is seven times lower than that 
observed in DHT-treated WT motoneurons. In keeping with the Fluo 4-AM 
measurements, Fura 2 measurements also suggest that DHT causes a negligible 
increase in ER Ca2+ in WT motoneurons. However, Fura 2 measurements also suggest 
that there is a 150% decrease in ER Ca2+ in KD motoneurons following DHT treatment 
whilst a 240% increase is observed when using Fluo 4-AM. This could be because 
Fura 2 is more prone to compartmentalization (Thomas et al, 200), which will be 
discussed in more detail in the discussion (3.12.4). 
3.2.6.3 Store-operated Ca2+ influx (Figure 3.10C) 
Using Fura 2 to measure SOC influx confirmed the trend in SOC influx observed using 
Fluo 4-AM. The highest level of SOC influx is observed in DHT-treated KD 
motoneurons, which respond to external Ca2+ introduction with an increase in the 
340/380 nm ratio of 0.045 (+/- 0.002 SEM, n=28). This ratiometric change is 22.5 times 
greater than that observed in DHT-treated WT motoneurons, which respond to Ca2+ 
introduction with an increase in 340/380 nm ratio of 0.002 (+/- 0.0015 SEM, n=26). This 
is a much greater difference than that observed using Fluo 4-AM. 
3.2.7 Ca2+ handling in motoneurons from a mouse model of ALS 
ER stress is known to play a role in the degeneration of motoneurons that occurs in the 
SOD1G93A mouse model of ALS (Saxena et al, 2009, Nishitoh et al, 2008). In this 
model, ER stress has been examined using biochemical approaches. In order to 
assess whether the changes observed in Ca2+ handling in KD motoneurons may be 
indicative of ER stress, in the next set of experiments, Ca2+ handling in primary 
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motoneurons derived from  SOD1G93A mice were examined using the protocols 
described above. 
Figure 3.10 Fura-2 control experiments 
Some of the experiments undertaken using Fluo 4-AM as the Ca2+ indicator were 
repeated using Fura-2 in order to control for confounding factors that are known to 
affect single wave dyes such as Fluo 4-AM but not ratiometric dyes such as Fura 2. All 
variables were kept constant and primary motoneuron cultures were treated with DHT 
at 4 DIV and imaged at 7 DIV. 
Fura 2 fluorescence ratios were obtained by dividing the fluorescence value at 340 nm 
(Ca2+-bound) by the fluorescence value at 380 nm (Ca2+-free). The ratio is proportional 
the level of cytosolic Ca2+, although it is not linear. 
The Bar Charts summarize ratios that represent basal cytosolic Ca2+ (A), inferred ER 
Ca2+ (B) and inferred SOC influx (C) in untreated and DHT-treated WT and KD 
motoneurons. With respect to all three parameters, the trends observed when using 
Fluo 4-AM are still apparent when using Fura 2.  
(Error Bars = standard error of mean) 
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Figure 3.10 
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3.2.7.1 Basal cytosolic Ca2+ in SOD1G93A motoneurons (Figure 3.11A) 
The concentration of basal cytosolic Ca2+ is significantly higher in SOD1G93A 
motoneurons compared to WT littermate controls (p=0.02). SOD1G93A motoneurons 
have a basal Ca2+ concentration of 1100 nM (+/- 12.89 nM SEM, n=33), whilst 
motoneurons cultured from WT littermates of the SOD1G93A embryos have a basal Ca2+ 
concentration of 800 nM (+/- 17.99 nM SEM, n=29). Motoneurons from embryos that 
overexpress WT human SOD1 (SODH, which controls for overexpression of the SOD1 
protein) have a basal cytosolic Ca2+ concentration of approximately 920 nM (+/- 16.55 
nM SEM, n=27), which is approximately 120nM higher than WT basal cytosolic Ca2+ 
and 180 nM lower than the basal Ca2+ level observed in SOD1G93A motoneurons. 
3.2.7.2 Inferred ER Ca2+ (Figure 3.11B)  
Inferred ER Ca2+ is lowest in the SOD1G93A motoneurons at 52 nM (+/- 4.88 nM SEM 
n=33). The highest level of ER Ca2+ is observed in WT control motoneurons, which 
have a luminal Ca2+ concentration of 348 nM (+/- 47.54 nM SEM, n=29), which is seven 
times higher than that observed in SOD1G93A motoneurons. This difference is significant 
(p=0.029).  An intermediate level of ER Ca2+ is observed in SODH motoneurons, which 
have an inferred ER Ca2+ concentration of 130nM (+/- 8.85 nM SEM, n=27). This is 
significantly lower than the level of inferred ER Ca2+ observed in WT motoneurons 
(p=0.047).  
3.2.7.3 Store-operated Ca2+ influx (Figure 3.11C) 
Inferred SOC influx is highest in SOD1G93A motoneurons, at 1400 nM (+/- 64.80 nM 
SEM, n=33), which is significantly higher (p=0.000) than the SOC influx observed in 
WT motoneurons (300nM +/- 55.71 nM SEM, n=29). SODH motoneurons respond to 
Ca2+ introduction with an increase in Ca2+ of 385 nM (+/- 60.62 nM SEM, n=27), which 
is intermediate between WT and mSOD1 motoneurons. 
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Figure 3.11: Cellular Ca2+ handling motoneurons of the SOD1G93A model of ALS. 
Primary motoneurons were cultured from the ventral spinal cord of SOD1G93A, WT and 
SODH embryos. At 7 DIV, Fluo4-AM fluorescence was measured at basal levels (A), 
following Thapsigargin application (thus inferring ER Ca2+) (B) and following 
reintroduction of Ca2+ into the external medium (thus inferring Store-operated Ca2+ 
influx) (C).  Fluorescence values were then calibrated into a Ca2+ concentration in nM, 
using the Ionomycin-induced maximum concentration as a reference point. Background 
fluorescence was subtracted from values throughout.  
The Bar Chart (A) shows that basal cytosolic Ca2+ is lowest in WT motoneurons (n=29 
from 3 different cultures) and highest in SOD1G93A motoneurons (n=33 from 3 different 
cultures). This increase in cytosolic Ca2+ is significant (p < 0.005). The Bar Chart (B) 
shows that relative to WT motoneurons there appears to be significant ER Ca2+ 
depletion in both SOD1G93A motoneurons and SODH motoneurons (n=27 from 3 
different cultures, p < 0.005).  In (C), the Bar Chart shows that the greatest level of 
SOC influx is observed in SOD1G93A motoneurons; whilst the level of SOC influx in WT 
motoneurons is significantly lower (p < 0.005). 
(Error Bars = standard error of mean) 
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3.2.8 Analysis of markers of ER stress in KD motoneurons 
In the next set of experiments, the expression of markers of ER stress in KD 
motoneurons was assessed and compared to that observed in WT motoneurons.  
In order to reliably conclude that the level of ER stress marker expression is 
representative of motoneurons only, as opposed to other cell types found in mixed 
ventral horn cultures, the primary cultures were purified using Optiprep (Chapter 2) so 
that the percentage of motoneurons is as close to 100% as possible.  
In both WT and KD purified motoneuron cultures, the percentage of motoneurons is 
consistently greater than 85% (Figure 3.12A). The average percentage of motoneurons 
in WT cultures is 96% (+/- 0.67% SEM, n=34 fields from 3 different cultures), and the 
average percentage of motoneurons in KD cultures is 92% (+/- 1.09% SEM, n=41 
fields from 3 different cultures). In both WT and KD cultures, purification significantly 
increases in the percentage of motoneurons (p<0.000). In unpurified WT ventral horn 
cultures the average percentage of motoneurons is 42% (+/- 2.01% SEM, n = 42 fields 
from 3 different cultures), whilst in KD cultures the average percentage of motoneurons 
is approximately 30% (+/- 3.4 % SEM, n=36 fields from 3 different cultures).  
However purifying motoneuron cultures drastically decreases motoneuron survival 
despite increasing motoneuron purity (Figure 3.12B). In unpurified WT ventral horn 
cultures, the average total number of cells present per field is 251 (+/- 23 SEM, n=42 
fields from 3 different cultures), whilst in purified WT cultures, the total number of cells 
decreases to approximately 108 (+/- 11.4 SEM, n=36 fields from at least 3 different 
cultures). In unpurified KD ventral horn cultures, the average total cell number is 
approximately 221 (+/- 18.7 SEM, n=36 fields from 3 different cultures) whilst in purified 
KD motoneuron cultures the total number of cells decreases to just 45 (+/- 5.2 SEM, 
n=36 fields from 3 different cultures). Therefore, the purification process decreases cell 
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survival in both WT and KD cultures by approximately 57 % and 80 %, respectively. In 
both cases this decrease is significant (p=0.001 and 0.0003, respectively). 
Figure 3.12: Purification of ventral horn cultures improves the proportion of 
primary motoneurons 
Ventral horn cultures were purified using Optiprep – a density gradient medium that 
allows motoneurons to be separated from other cell types. The Bar chart (A) 
summarizes the percentage of motoneurons in unpurified and purified WT (n=42 and 
34, respectively) and KD cultures (n=36 and 44, respectively). In unpurified ventral 
horn cultures the percentage of motoneurons ranges between 30 and 42%. In purified 
motoneuron cultures, the population of motoneurons increases to over 90%. Bar chart 
B) demonstrates the effects of purification on motoneuron survival. Following 
purification the number of motoneurons present at 7 DIV decreases significantly in both 
WT and KD cultures (p < 0.001). 
(Error Bars = standard error of mean) 
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3.2.9 Sarco/Endoplasmic Reticulum ATPase (SERCA) expression – the link 
between motoneuron genotype and ER Ca2+ (Figure 3.13) 
As shown in Figure 3.13B, Western blot analysis of purified ventral horn motoneurons 
from embryonic WT and KD mice reveals that the expression level of the SERCA2b 
protein is significantly higher in WT motoneurons than in KD motoneurons (p=0.04). 
Indeed, the level of SERCA2b protein expression relative to actin (the loading control - 
1.0) is 1.28 (+/- 0.2, n=6) in the case of WT motoneurons and 0.78 (+/- 0.22, n=6) in 
the case of KD motoneurons (Figure 3.13C).  
3.2.10 Does ER Ca2+ depletion result in ER stress in embryonic KD 
motoneurons? 
To assess whether or not ER stress is present in embryonic KD motoneurons, Western 
blot analysis and Immunohistochemistry were used to determine levels of ER stress 
markers in DHT-treated primary motoneuron cultures from E13 KD and WT mice. 
3.2.10.1 Binding immunoglobulin Protein (BiP) 
3.2.10.1.1 BiP Immunoreactivity  
Primary WT and KD motoneurons were immunostained for BiP. As shown in Figure 
3.14A, there is a clear increase in BiP immunoreactivity (red) in KD motoneurons 
particularly within the cytosol, compared to WT motoneurons (Figure 3.14A) 
3.2.10.1.2 Western blot analysis of BiP  
Levels of BiP were also examined by Western blot analysis. A typical blot is shown in 
Figure 3.14C. Assessment of the optical density of the Western blot (Figure 3.14D) 
reveals that the level of BiP is 39% higher in KD primary motoneurons than in WT 
primary motoneuron controls. In WT motoneurons, the BiP expression level relative to 
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Actin (1.0) is 1.13 (+/- 0.06 SEM, n=3), whereas in KD motoneurons it is 1.41 (+/- 0.12 
SEM, n=3).  This increase in BiP levels in KD motoneurons is significant (p= 0.05). 
Figure 3.13: SERCA pump expression decreases in KD motoneurons 
The SERCA2b pump sequesters Ca2+ from the cytosol into the ER; increasing luminal 
Ca2+ levels in motoneurons, as shown in (A). Western blot analysis of purified primary 
motoneurons from KD embryos and their WT littermates at 7 DIV was used to assess 
levels of SERCA2b expression. (B) Shows a representative Western blot.  The Bar 
Chart (C) summarizes the optical density of each Western blot. The expression level of 
SERCA2b (relative to the loading control actin, which has been given a value of 1.0) is 
21% lower in KD motoneurons than in WT controls (n = 6 in both cases). This decrease 
in expression is significant (p < 0.05). 
(Error Bars = standard error of mean) 
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Figure 3.14: BiP expression is elevated in embryonic KD motoneurons 
WT and KD motoneuron cultures were immunostained for BiP (red) and co-stained for 
-III tubulin (green, a neuronal marker) and DAPI (blue, a nuclear marker). Images 
showing the typical patterns of BiP immunoreactivity in WT and KD motoneuron 
cultures are shown in Ai) and Aii), respectively. Levels of BiP in WT and KD 
motoneuron cultures were also analysed by Western blot. A representative Western 
blot is shown in (B). Optical density analysis was performed and protein levels were 
expressed relative to the house-keeping protein, Actin, which was used as a loading 
control and given a value of 1.0. As shown in the bar chart (C), BiP expression is 
significantly elevated in embryonic KD motoneurons compared to WT controls (p < 
0.05).  
(Error Bars = standard error of mean, scale bars = 50 M) 
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3.2.10.1.2 Eukaryotic translation initiation factor 2 (eIF2) 
As is the case with BiP, phospho-eIF2 expression appears to be slightly elevated in 
KD motoneurons compared to WT motoneurons (Figure 3.15). Western blot analysis 
reveals that the level of phospho-eIF2 in KD motoneurons, normalized to Actin is 1.25 
(+/- 0.29 SEM, n=3), which is 11.2 % higher than WT motoneurons, in which the 
relative level of eIF2 expression is 1.11 (+/- 0.24 SEM, n=3). This difference however 
is not significant (p=0.07). (eIF2 immunohistochemistry was not possible as no 
suitable antibody is currently available). 
3.2.10.1.3 Activating Transcription Factor 4 (ATF4)  
The expression of ATF4, an upstream ER stress marker, was also examined in WT 
and KD cultures by immunohistochemistry and Western blot analysis. 
3.2.10.1.3.1 ATF4 Immunoreactivity (Figure 3.16A & B) 
Immunostaining of primary motoneuron cultures for ATF4 shows that ATF4 
immunoreactivity is much higher in KD motoneurons (Figure 3.16A) than in WT 
motoneurons (Figure 3.16A) and that ATF4 immunoreactivity is largely located to 
motoneuron nuclei. No extra-nuclear staining for ATF4 was detected and non-
motoneuron cells have a considerably lower ATF4 immunoreactivity than motoneurons. 
3.2.10.1.3.2 Western blot analysis  
ATF4 expression in WT and KD motoneuron cultures was also examined by Western 
blot analysis (Figure 3.16C). The Western blot and the data presented in the bar chart 
(Figure 3.16D) show that ATF4 levels are higher in KD primary motoneurons than in 
WT controls. Analysis of the mean optical density of ATF4 Western blots reveals that 
ATF4 expression is 69 % higher in KD motoneurons than WT motoneurons, which 
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have ATF4 expression levels of 1.55 (+/- 0.19 SEM, n = 3) and 1.01 (+/- 0.26 SEM, n = 
3), respectively. This difference is significant (p=0.047). 
Figure 3.15: eIF2 expression is elevated in embryonic KD motoneurons 
The expression level of phospho-eIF2, which is a marker of ER stress-induced 
translation arrest, in E13 WT and KD primary motoneuron homogenates was assessed 
by Western blot. A) shows a representative blot. The bar chart (B) summarizes the 
mean optical density of such blots, where results are expressed relative to the house 
keeping protein Actin, which was given a value of 1.0. The level of phospho-eIF2 is 
higher in embryonic KD motoneurons than in WT controls. This difference approaches 
significance (p = 0.066). 
(Error Bars = standard error of mean) 
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Figure 3.16: ATF4 expression is elevated in embryonic KD motoneurons 
In order to assess expression levels of the ER stress marker ATF4 in embryonic WT 
and KD motoneurons the cultures were immunostained with a specific antibody for 
ATF4. Typical staining patterns observed in E13 WT and KD motoneuron cultures at 7 
DIV are shown in Ai) and Aii), respectively. ATF4 immunoreactivity is shown in red. The 
cultures were also co-stained with -III tubulin (green) and DAPI (blue). The images 
show that ATF4 immunoreactivity (red) is higher in KD motoneuron cultures than in WT 
controls, although WT controls still express low levels of ATF4. This increased ATF4 
immunoreactivity is specific to motoneuron nuclei. Homogenates from E13 WT and KD 
motoneuron cultures were also processed for Western blot analysis of ATF4 
expression levels. A typical Western blot is shown in B). The bar chart (C) summarizes 
quantification of the blot. The optical density of the blot was obtained and protein levels 
were normalized to the house keeping protein Actin, which was used as a loading 
control and given a value of 1.0. The expression of ATF4 is significantly higher in 
embryonic KD motoneurons than in WT controls (p < 0.05).  
(Error Bars = standard error of mean, scale bar = 50 M) 
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3.2.10.1.4 CCAAT/enhancer-binding protein homologous protein (CHOP) 
Levels of expression of CHOP in E13 WT and KD motoneurons were examined by 
immunohistochemistry and Western blot analysis. 
3.2.10.1.4.1 Immunoreactivity  
Immunostaining of primary ventral motoneuron cultures shows that CHOP 
immunoreactivity is considerably higher in KD motoneurons than in WT controls, and 
that CHOP expression in KD cultures is specific to motoneuron nuclei (Figure 3.17B). 
In WT cultures there is no detectable CHOP immunoreactivity in motoneuron nuclei, 
and only low intensity staining is detected in non-neuronal cells. In KD cultures the 
staining intensity in the non-neuronal cells is similar to that in WT cultures. 
3.2.10.1.4.2 Western Blot analysis  
The level of expression of CHOP in E13 WT and KD motoneuron cultures at 7 DIV was 
also examined by Western blot. A typical Western blot is shown in Figure 3.17C, and 
the mean optical density measurements of such blots are summarized in the bar chart 
(Figure 3.17D). CHOP levels, like all previous ER stress markers, are elevated in KD 
ventral motoneurons compared to WT controls. The Western blot data shows that the 
level of CHOP expression is approximately 39% higher in KD motoneurons than WT 
motoneurons. Indeed, the relative level of CHOP in KD motoneurons is 1.48 (+/- 0.12 
SEM, n=3), compared to 1.12 (+/- 0.10 SEM, n=3) in WT controls. This difference is 
significant (p= 0.008).  
In order to assess whether or not ER stress is present in vivo in KD mice spinal cord, 
Western blot analysis and immunocytochemistry were used to assess the levels of ER 
stress markers in spinal cord homogenates and sections from both KD and WT mice at 
P5, 3 months, 12 months (symptom onset) and 18 months (end stage).  
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Figure 3.17: CHOP expression is elevated in embryonic KD motoneurons 
The expression level of the ER stress-induced, pro-apoptotic protein CHOP in 
embryonic WT and KD motoneurons was assessed by immunohistochemistry and 
Western blot analysis. The pattern of CHOP immunoreactivity in E13 WT and KD 
motoneuron cultures at 7 DIV is shown in Ai) and Aii), respectively. Cultures were 
immunostained for CHOP (red) and MAP2 (green), a neuronal-specific marker, and 
stained with DAPI (blue), a nuclear marker. The images show that CHOP 
immunoreactivity is higher in KD motoneuron cultures than in WT controls and that this 
increase in CHOP immunoreactivity is specific to motoneuron nuclei. Although there is 
some CHOP-positive staining in non-neuronal cells in WT cultures there is no 
difference in the pattern of intensity of CHOP immunoreactivity between WT and KD 
cultures.  
Homogenates of E13 WT and KD motoneuron cultures at 7 DIV were also analysed by 
Western blot. A typical CHOP Western blot is shown in B). Quantitative analysis of 
these blots was undertaken and the results are summarized in the bar chart (C). CHOP 
protein levels were expressed relative to the house keeping protein Actin, which was 
given a value of 1.0. It can be seen that CHOP expression is significantly elevated in 
embryonic KD motoneurons compared to WT controls (p<0.05).  
Although the molecular weight of CHOP is 19 kDa, the antibody used (abcam) is 
detected at 31 kDa.  
 (Error Bars = standard error of mean, scale bar = 40 M) 
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3.2.11 The presence of ER stress markers in vivo in spinal cords of KD mice 
3.2.11.1 BiP 
3.2.11.1.1 BiP Immunoreactivity  
Spinal cord sections from WT and KD mice at 3 months, 12 months and 18 months 
were immunostained for BiP. Examples of the pattern of BiP immunoreactivity is shown 
in Figure 3.18, for WT and KD mice (Figure 3.18A & B, respectively). BiP 
immunoreactivity is much higher in KD ventral motoneurons than in WT motoneurons 
at 3 months of age. However the clear difference in staining intensity between the 
genotypes observed at 3 months is not detected in 12 and 18 month old mice. At 12 
months, BiP immunoreactivity appears to be slightly more intense in the KD spinal cord 
sections than in WT; however there is no observable difference in BiP staining intensity 
between KD and WT at 18 months. 
The elevation of BiP expression that is observed in KD spinal cord sections appears to 
be specific to the cytosol of motoneurons and is not apparent in other cell types, which 
are identifiable by a positive DAPI stain but a negative -III tubulin stain. 
3.2.11.1.2 Western blot analysis  
Western blot analysis of BiP expression levels (Figure 3.18 C & D) reveals that the 
expression levels of BiP are higher in KD spinal cord tissue than in control WT spinal 
cord tissue at all of the time points tested. Optical density analysis of Western blot data 
shows that the peak difference in BiP expression between WT and KD spinal cords 
occurs at P5. At this time point, the expression levels of BiP are approximately 44% 
higher in KD spinal cord than in WT controls. At 3 months of age, the difference 
between WT and KD expression is almost unchanged at 41%. The elevation of BiP 
expression at both P5 and 3 months is significant (p = 0.002 and 0.05, respectively). 
However, this difference between WT and KD spinal cord BiP expression diminishes as 
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the disease progresses. By 12 months of age the average expression level of BiP in 
KD spinal cord is just 5% higher than in WT spinal cord and at 18 months, the level of 
BiP expression is just 2% higher in KD spinal cords compared to WT controls. 
Differences at these stages are not significant. 
3.2.11.2 phospho-eIF2expression levels 
The expression of phospho-eIF2 in WT and KD spinal cords was examined by 
Western blot analysis. Immunohistochemistry was not undertaken due to the lack of a 
suitable antibody for immunohistochemistry. As seen in Figure 3.19, Western blot 
analysis reveals that the expression level of phopsho-eIF2is greater in KD spinal cord 
than in WT spinal cord at all ages studied apart from 18 months, when expression of 
eIF2 in KD spinal cord is not significantly different from WT spinal cord tissue. 
The greatest elevation in phospho-eIF2 expression in KD spinal cord is observed at 
P5. At this age, the level of phospho-eIF2 expression is 104% greater in KD spinal 
cord than in WT. This difference is significant (p= 0.001).  At 3 months, the difference 
between KD and WT spinal cord expression declines to 42 %, which is still significantly 
greater than WT. By 12 months of age, phospho-eIF2 expression in KD spinal cord is 
only 4.6% greater than in WT spinal cord, which is not a significant difference. 
3.2.11.3 ATF4 
ATF4 expression in KD and WT spinal cords was examined by both 
immunohistochemistry and Western blot analysis. 
3.2.11.3.1 ATF4 Immunoreactivity (Figure 3.20A) 
Immunostaining of KD and WT spinal cord sections for ATF4 reveals that at 3 and 12 
months of age there is a clear increase in ATF4 immunoreactivity in KD motoneurons 
compared to WT controls.  However by 18 months ATF4 expression is not significantly 
different from the pattern or intensity of ATF4 staining in WT controls. 
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Figure 3.18: BiP expression in spinal cords of KD mice at different stages of 
disease progression 
BiP expression in the spinal cord of KD mice was examined at various stages of 
disease by immunohistochemistry and western blot analysis.  
Lumbar spinal cords were removed from KD and WT littermates at P5, 3, 12 and 18 
months of age. Examples of the pattern of BiP immunoreactivity in the ventral horn of 
WT and KD spinal cords are shown in Ai) and Aii) respectively at i) 3 months, ii) 12 
months and iii) 18 months. The sections were immunostained for BiP (red) and co-
stained for -III tubulin (green), a neuronal marker, and stained with DAPI (blue), a 
nuclear marker. A clear increase in BiP immunoreactivity is observed in the cytoplasm 
of KD motoneurons at 3 months of age, but the intensity of BiP staining decreases 
significantly during disease progression and by 18 months is no longer detectable. No 
BiP staining was observed in WT motoneurons at any age examined. Western blot 
analysis of BiP expression in spinal cord homogenates of WT and KD mice was also 
undertaken. A typical Western blot for BiP is shown in B), and the quantitative analysis 
of such blots is summarized in the bar chart (C). The results indicate that BiP 
expression is already significantly increased in the spinal cord of KD mice as early as 
P5, compared to WT levels, and continues to be raised at 3 and 12 months. However, 
by 18 months BiP expression in KD spinal cords is not significantly greater than that 
observed in WT spinal cords. 
(Error Bars = standard error of mean, scale bars = 30 M) 
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Figure 3.19: Phospho-eIF2 expression in spinal cord of KD mice at different 
stages of disease progression 
Western blot analysis was used to determine the expression levels of phosho-eIF2in 
WT and KD spinal cord homogenates from P5, 3, 12 and 18 month old mice. A typical 
blot is shown in A). For each genotype and age, 3 different mice were used and 
samples were run twice to test reproducibility. Quantitative analysis of the optical 
density of such blots is summarized in the bar chart (B) in which phospho-eIF2 levels 
are expressed relative to the loading control actin (given a value of 1.0). The largest 
increase in phospho-eIF2 expression in KD spinal cord is observed at P5, and levels 
remain significantly elevated at 3 months of age. From this stage on, phospho-
eIF2expression is not significantly greater in KD spinal cord than WT spinal cord. 
(Error Bars = standard error of mean) 
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In KD motoneurons, the expression of ATF4 appears to be exclusively nuclear in all 
spinal cord sections. Indeed, over exposure of the sections does not reveal any 
additional extra-nuclear staining. The elevated ATF4 expression in KD motoneurons is 
also detected in cell types other than motoneurons, although not all non-motoneuron 
cells display elevated ATF4 levels whereas, all motoneurons do. 
3.2.11.3.2 Western blot analysis (Figure 3.20B) 
As observed with BiP and phospho-eIF2, the expression of ATF4 is elevated in KD 
spinal cords compared to WT spinal cords although the difference between the two 
genotypes diminishes as the disease progresses, so that by 18 months levels are no 
longer significantly higher in KD spinal cords than WT spinal cords.  
The peak increase in ATF4 expression in KD spinal cord occurs at P5, when ATF4 
expression is 80% higher in KD spinal cords than in WT control tissue. This difference 
in expression is significant (p=0.015). At 3 months of age the increased ATF4 
expression in KD spinal cord is 39 % greater than in WT tissue (p = 0.002). At 12 
months ATF4 levels are still 31% higher in KD spinal cord than in WT (p= 0.0014). By 
18 months however the difference between the genotypes is no longer significant, and 
ATF4 expression is only 10% higher in KD spinal cords than in WT controls. 
3.2.11.4 CHOP expression in WT and KD spinal cords 
The expression of CHOP was examined by immunohistochemistry and Western blot 
analysis in spinal cords of WT and KD mice at various stages of disease progression. 
3.2.11.4.1 CHOP Immunoreactivity (Figure 3.21A) 
CHOP immunoreactivity appears to be predominantly motoneuron-specific and nuclear 
in spinal cord sections of both KD and WT mice. 
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Figure 3.20: ATF4 expression in KD spinal cord at various stages of disease 
progression 
Sections of WT and KD lumbar spinal cords were immunostained for ATF4 at various 
stages of disease progression. Typical examples of the pattern of ATF4 
immunoreactivity in WT and KD motoneurons are shown in Ai) and Aii), respectively at 
i) 3 months, ii) 12 months and iii) 18 months. Sections were immunostained for ATF4 
(red), the neuronal marker MAP2 (green) and the nuclear marker DAPI (blue). A clear 
increase in ATF4 immunoreactivity is detected in KD motoneurons at 3 and 12 months 
of age, although no significant increase in staining is detected at 18 months of age. 
Western blot analysis of ATF4 expression was also undertaken and a typical Western 
blot for ATF4 is shown in B). The bar chart (C) summarizes the quantification of the 
optical density of such blots and shows that ATF4 levels are significantly greater in KD 
spinal cords at P5, 3 months and 12 months of age, but are not significantly elevated 
compared to WT by 18 months of age. 
(Error Bars = standard error of mean, scale bars = 30 M ) 
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At 3 months and 12 months of age no difference in nuclear CHOP staining intensity is 
detected between WT and KD motoneurons and at 18 months only a slight increase in 
staining intensity is observed in KD motoneurons. Overall, the background staining for 
CHOP appears higher in the KD spinal cord sections, but CHOP-specific 
immunoreactivity appears to be at the same intensity in both KD and WT sections. 
3.2.11.4.2 Western blot analysis (Figure 3.21C & D) 
Western blot analysis reveals that CHOP expression is elevated in KD spinal cords 
compared to WT controls at all ages, and like all three of the previous ER stress 
markers investigated, the magnitude of the difference between KD and WT expression 
peaks at P5, and is lower at end stage. Indeed, at P5 CHOP expression levels are 70% 
higher in KD spinal cords compared to WT controls and this difference is significant (p= 
0.008). At 18 months however, CHOP expression is not significantly higher in KD 
spinal cords than in WT controls. Unlike other ER stress markers examined, the 
difference between KD and WT expression of CHOP is higher at 12 (42%, p < 0.001) 
and 18 months (15%, not significant) than at 3 months (10%, not significant).  
3.2.11.5 ER stress marker expression with disease progression (Figure 3.22) 
Figure 3.22 summarizes the changes in ER stress markers observed in KD spinal cord 
relative to the changes observed in WT controls. The results show that all ER stress 
markers examined are elevated in KD spinal cords relative to WT controls at some 
stages of the disease. Furthermore, the peak ER stress marker elevation in KD spinal 
cords relative to WT controls mainly occurs at P5 and for most markers declines by 
disease end-stage. In the case of ER stress markers that are further upstream in the 
UPR, i.e. BiP and phospho-eIF2a, there is only a negligible difference in expression 
levels between KD and WT spinal cords at disease end-stage. In the case of 
downstream ER stress markers although there is a decline in the expression difference 
between WT and KD spinal cords at end-stage, the difference is not significant. 
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Figure 3.21: CHOP expression in KD spinal cord at various stages of disease 
progression 
Sections of WT and KD lumbar spinal cords were immunostained for CHOP at various 
stages of disease progression. Typical examples of the pattern of CHOP 
immunoreactivity in WT and KD motoneurons are shown in Ai) and Aii), respectively at 
i) 3 months, ii) 12 months and iii) 18 months. Sections were immunostained for CHOP 
(red), the neuronal marker MAP2 (green) and the nuclear marker DAPI (blue). A 
modest increase in CHOP immunoreactivity is detected in KD motoneurons at 3, 12 
and 18 months of age. Western blot analysis of CHOP expression was also undertaken 
and a typical Western blot for CHOP is shown in B). The bar chart (C) summarizes the 
quantification of the optical density of such blots and shows that CHOP levels are 
significantly greater in KD spinal cords at P5, and 12 months of age, but are not 
significantly elevated compared to WT at 3 months and 18 months of age. 
(Error Bars = standard error of mean, scale bars = 25 M) 
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Figure 3.22: Summary of ER stress marker expression with disease progression 
The bar chart summarizes the increase in expression of ER stress markers (BiP, 
phospo-eIF2, ATF4 and CHOP) detected by Western blot in KD spinal cords relative 
to WT controls at all stages of disease examined. Optical density analysis was 
performed and protein levels were expressed relative to the house-keeping protein 
Actin (1.0). For each ER stress marker and time point the percentage increase in 
expression in KD spinal cord samples relative to corresponding WT controls was 
calculated.  Levels of all of the ER stress markers examined are increased in KD spinal 
cords throughout disease progression, with a peak increase in all markers detected at 
P5, followed by a slow decline to WT levels by 18 months. 
(Error Bars = standard error of mean) 
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3.3 Discussion 
3.3.1 Summary 
In this study I investigated whether ER stress was a feature of Kennedy’s Disease 
Pathogenesis using two approaches; i) Ca2+ imaging; and ii) Determination of ER 
stress marker levels using immunohistochemistry and Western blot analysis.   
I have shown that Ca2+ handling is disrupted in primary KD motoneurons resulting in 
ER Ca2+ depletion, which is suggestive of ER stress. Furthermore, ER stress markers 
are elevated in KD embryonic motoneuron cultures and in spinal cords, especially at 
early stages of the disease. This indicates that ER stress has a potential role as an 
early trigger of the disease. 
3.3.2 Ca2+ handling in KD motoneurons 
3.3.2.1 Effects of DHT on cytosolic Ca2+ under normal conditions 
Under normal circumstances, 50 nM DHT serves a protective function to motoneurons. 
This is confirmed by treating WT motoneurons with various DHT final concentrations, 
ranging from 0.1 nM to 50 nM, for 72 hours and then imaging them at 7 DIV to obtain 
readouts of Ca2+. 
As the concentration of DHT increases, the basal cytosolic Ca2+ concentration in WT 
motoneurons decreases. This decrease in cytosolic Ca2+ can be considered as being 
protective to cells (Ciutat et al, 1995) however it is important to note that decreases in 
cytosolic Ca2+ are not exclusively protective to cells (Arduino et al 2004). It is important 
to establish whether or not a final DHT concentration of 50 nM, which has been used 
previously to treat KD motoneurons (Malik et al, 2011), is detrimental to cell survival 
and thus would confound results obtained in this study. Because increases in DHT 
result in decreases in cytosolic Ca2+, it can be assumed that 50 nM DHT is not 
detrimental to motoneurons under normal circumstances. Therefore any toxic effects of 
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the AR100 mutation can be attributed to the mutation specifically and not to the 50 nM 
DHT treatment. 
Indeed, when Ca2+ handling is investigated in KD motoneurons and WT controls the 
detrimental effects of the mutation are evident. 
3.3.2.2 Basal cytosolic Ca2+ in primary KD motoneurons 
The first indication that KD motoneurons have an imbalanced Ca2+ homeostasis 
compared to WT controls is presented by their cytosolic Ca2+ concentration. My results 
show that cytosolic Ca2+ is significantly higher in DHT-treated KD motoneurons both in 
the absence and presence of external Ca2+, than in WT motoneurons. The lowest level 
of cytosolic Ca2+ is detected in DHT-treated WT motoneurons. These results suggest 
that DHT-treated KD motoneurons may be more vulnerable, for example, to excitotoxic 
insult. Indeed it has been shown previously that increases in cytosolic Ca2+ in 
motoneurons makes them more vulnerable to excitotoxicity (for review see Choi, 1996). 
High levels of cytosolic Ca2+ are known to result in various pathological processes such 
as opening of the mitochondrial permeability transition pore and the consequential 
release of Cytochrome C from mitochondria, triggering apoptosis (Brustovetsky et al, 
2002). Elevated cytosolic Ca2+ can also disturb the production of ATP thus jeopardising 
the energy supply to the cell. This would be detrimental to a vast number of essential 
cellular processes such as active transport, metabolism and DNA synthesis  (et 
al,Phebus et al, 1995, Yu et al, 2006). 
Measurement of cytosolic Ca2+ in both DHT-treated and untreated WT and KD cultures, 
reveals the toxic effect of activation of the mutant AR. In WT motoneurons, DHT 
treatment results in a decrease in basal cytosolic Ca2+ – more noticeably when Ca2+ is 
present in the recording medium. Thus DHT treatment in WT motoneurons can be 
considered to be protective. In KD motoneurons however, DHT treatment results in an 
increase in cytosolic Ca2+, indicating that activation of the mutant AR has a potentially 
toxic effect on motoneurons. 
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3.3.2.3 ER Ca2+ in primary KD motoneurons 
Unlike the cytosol, where increases in Ca2+ are likely to have deleterious effects, the 
ER has relatively high levels of Ca2+ under normal conditions, so that decreases in ER 
Ca2+ are detrimental to ER function.  
The lowest level of ER Ca2+ was detected in DHT-treated cultures and the highest level 
was found in DHT-treated WT cultures. Since a decrease in ER Ca2+ is indicative of ER 
stress (Chami et al, 2008), these results suggest that ER stress is present in DHT-
treated KD motoneurons. Under normal circumstances the concentration of Ca2+ in the 
ER is in the 0.3-1 mM range. Because DHT-treated WT cultures, despite having the 
highest level of ER Ca2+ recorded in these experiments, still have a concentration that 
is below the normal M range (Narayanan et al, 2010), it is possible that the process of 
culturing primary motoneurons results in ER Ca2+ depletion even in WT motoneurons. 
Thus the experimental protocol used can only give an indication of relative levels of ER 
Ca2+. Conclusions based on these experiments however, need to be approached with 
caution, as the values obtained for ER Ca2+ are not absolute. Indeed, following TG 
application, Ca2+ is released into the cytosol, which is a larger compartment than the 
ER and thus the Ca2+ signal is diluted. Furthermore, Ca2+ is pumped out of the cytosol 
by the plasma membrane calcium ATPase, (PMCA) so is decreasing during 
quantification of the signal. Thus, it is the relative levels of Ca2+ that are considered. 
As observed with the measurement of basal cytosolic Ca2+, DHT treatment appears to 
have opposite effects on ER Ca2+ in WT and KD motoneurons. In WT motoneurons, 72 
hour DHT treatment results in an increase in ER Ca2+, suggesting an improvement in 
ER function. In KD motoneurons however, DHT treatment results in a significant 
decrease in ER Ca2+, suggesting a significant impairment of ER function. Furthermore, 
there is only a negligible difference between untreated WT and untreated KD 
motoneurons with respect to inferred ER Ca2+, yet the response of WT and KD 
motoneurons is significantly different following DHT treatment. This finding suggests 
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that the presence of the mutant AR alone, in the absence of the ligand, does not cause 
significant ER Ca2+ depletion. However when the ligand i.e. the androgen, is present 
and the AR is activated, there is significant ER Ca2+ depletion. This observation reflects 
the clinical phenotype of KD, where the disease only manifests in males. In cases 
where females express the mutant AR, the absence of the ligand, i.e. androgens, 
means that the AR remains inactive, resulting in an asymptomatic phenotype. 
3.3.2.3 Inferred Store-operated Ca2+ (SOC) influx in primary KD motoneurons 
ER Ca2+ depletion results in store-operated Ca2+ influx (SOC influx), as discussed in 
detail in Section 3.1.2.1. Briefly, SOC influx involves the entry of Ca2+ through plasma 
membrane channels, resulting in elevated cytosolic Ca2+. This aids ER Ca2+ 
replenishment. Thus the lower the level of ER Ca2+, the higher the level of 
consequential SOC influx. Indeed, in the results presented in this Chapter, in keeping 
with the finding that DHT-treated KD motoneurons have the lowest level of inferred ER 
Ca2+, they also possess the highest level of SOC influx. Furthermore, the level of SOC 
influx is significantly higher in DHT-treated KD motoneurons than in DHT-treated WT 
motoneurons, which have a significantly higher level of inferred ER Ca2+. 
The increased level of SOC influx in DHT-treated KD motoneurons could also explain 
the increased level of basal Ca2+ observed when cultures are examined in a 1 mM Ca2+ 
recording medium. If the ER is depleted of Ca2+ and external Ca2+ is available, SOC 
influx would already be occurring in the motoneurons and thus under basal conditions, 
the concentration of cytosolic Ca2+ would be higher. 
3.3.2.3 Kinetics of the cytosolic responses of motoneurons to TG application and 
external Ca2+ introduction 
As well as measuring absolute values, observation of the kinetics of Ca2+ handling in 
motoneurons in response to both Thapsigargin (TG) application and Ca2+ introduction 
can also provide information about the mechanisms responsible for disturbances in 
cellular Ca2+ handling.  
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Following TG application to cultures, the response onset and time-to-cytosolic Ca2+ 
peak are similar for WT and KD motoneurons. TG inhibits the SERCA pump and this 
prevents Ca2+ from being pumped from the cytosol into the ER. The elevated cytosolic 
Ca2+ that occurs as a result of TG application is therefore a result of Ca2+ leaving the 
ER without being pumped back in. Because the onset and time-to-cytosolic Ca2+ peak 
are the same in WT and KD motoneurons, it can be suggested that Ca2+ exit out the 
ER is not impaired in KD motoneurons. However, the lower steady state level of ER 
Ca2+ in KD motoneurons indicates that Ca2+ exit out of the ER occurs at a slower rate 
than in WT motoneurons. Thus a greater amount of ER Ca2+ is able to exit the ER in 
WT motoneurons in the same amount of time as a lower amount of Ca2+ from the ER in 
KD motoneurons, due to higher Ca2+ concentration gradient between the ER and the 
cytosol in the WT cells. 
The duration of Ca2+ elevation in response to TG application also provides some useful 
information about cellular Ca2+ handling. In WT motoneurons the response to TG is 
relatively prolonged, but it is more transient in KD motoneurons. This could reflect the 
lower level of Ca2+ in the ER in KD motoneurons. Because the ER is depleted of Ca2+ 
in these motoneurons, the supply of ER Ca2+ runs out more rapidly in KD motoneurons 
following TG application and thus the duration of the response is shorter. These results 
could also suggest however that processes by which Ca2+ is expelled from the cytosol, 
for example activation of the Plasma Membrane Ca2+ ATPase (PMCA) pump, are 
heightened in KD motoneurons. The nature of SOC influx however does not support 
this possibility – in this case the WT response is transient whilst the KD response is 
relatively prolonged. Therefore it is more likely that the ER rapidly runs out of Ca2+ in 
KD motoneurons giving rise to a shorter TG-induced response. The prolonged SOC 
influx in KD motoneurons suggests that because the ER is depleted of Ca2+, a greater 
amount of time and a higher level of Ca2+ influx are needed for ER Ca2+ to be 
replenished in KD motoneurons. 
157 
 
3.3.3 Activation of the mutant AR by androgens is essential for the induction of 
ER stress in motoneurons 
Taken together, these results indicate that the presence of the mutant AR in 
combination with receptor activation in the presence of androgens, are detrimental to 
ER Ca2+ and thus ER function. If ER Ca2+ depletion does indeed play a role in KD 
pathogenesis, it is important to determine whether or not it would occur in KD males 
due to an inherent difference between male and female androgen receptors or due to 
differences in androgen availability. The manifestation of KD is believed to occur due to 
the availability of androgens rather than an inherent difference in the AR. This is 
because AR antagonists relieve KD symptoms, whilst the administration of androgens 
to female mice possessing the mutant receptor results in presentation of the disease 
phenotype (Katsuno et al, 2003). Therefore, in these experiments it was important to 
establish if the differences observed in ER Ca2+ in WT and KD motoneurons were the 
result of an intrinsic defect due to the presence of the mutant AR, or only manifest in 
KD motoneurons in the presence of androgens irrespective of the sex of the mouse 
from which they were derived. I showed that there were no differences in ER Ca2+ in 
motoneurons from male and female mice, in the presence of the androgen i.e. female 
KD motoneurons and male KD motoneurons showed the same deleterious changes 
following exposure to DHT. 
With respect to basal cytosolic Ca2+, there is only a negligible difference between DHT-
treated male and DHT-treated female KD motoneurons. A similar trend is observed for 
inferred ER Ca2+ and inferred SOC influx. These results show that there is no 
difference between DHT-treated KD male and DHT-treated KD female motoneurons 
with respect to cytosolic and ER Ca2+ levels. This finding suggests there is no inherent 
difference in the AR. Female motoneurons treated with DHT have elevated levels of 
cytosolic Ca2+ and depleted ER Ca2+, in the same way that female mice possessing the 
mutation present with KD symptoms when treated with androgens (Breedlove et al, 
1981). It can therefore be suggested that the pattern of occurrence of depleted ER Ca2+ 
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is consistent with symptom presentation in KD motoneurons and thus it is a candidate 
for an underlying pathological mechanism. 
3.3.4 Control experiments using Fura 2 
The results discussed above were obtained using Fluo 4-AM as a Ca2+ indicator. 
Measurements obtained when using single wavelength excitation (SW) dyes such as 
Fluo 4-AM are often difficult to interpret because the fluorescence intensity of the dye 
often changes in response to factors other than Ca2+ concentration such as 
heterogeneous loading of the dye in different cells, dye leakage or bleaching of the 
signal by continuous illumination. Ratiometric dyes overcome this problem (Rudolf 
2003). Therefore, I re-examined some of the key features of Ca2+ handling in WT and 
KD motoneurons using the ratiometric dye, Fura 2 in order to see if the trend in results 
is reproducible and reliable. The same trend was indeed observed for basal cytosolic 
Ca2+, inferred ER Ca2+ and SOC influx using Fura 2 as had been recorded using Fluo 
4-AM. DHT-treated KD motoneurons have the highest basal Ca2+ and SOC influx and 
the lowest ER Ca2+. The largest discrepancy between Fluo 4-AM and Fura 2 read-outs 
is observed when measuring inferred ER Ca2+. Fura 2 measurements suggested that 
there was a 150% decrease in ER Ca2+ in KD motoneurons following DHT treatment 
but a 240% increase is observed when using Fluo 4-AM as the calcium indicator. This 
could be because Fura 2 is more prone to compartmentalization than Fluo 4-AM 
(Thomas et al, 2000), which could produce a lower global cytosolic calcium 
concentration average. However, because the Fura 2 signal is not calibrated, the 
discrepancies in the results cannot be explained. 
3.3.5 ER stress in a model of ALS 
In order to test the reliability of ER Ca2+ depletion measurements to assess ER stress I 
undertook a similar series of recordings using a different model of MND that is known 
to involve ER stress in its underlying pathology (Saxena et al, 2009). If ER Ca2+ 
depletion is detected in motoneurons from the SOD1G93A mouse model of ALS in which 
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convincing evidence for ER stress has been published, the occurrence of ER Ca2+ 
depletion correlates with the occurrence if ER stress. 
The SOD1G93A mouse model overexpresses the SOD1 enzyme and therefore in order 
to control for the effects of overexpression of the SOD1 protein, SODH mice, which 
over express the Wild-Type SOD1 protein were used as a control as they allow the 
effects of the mutation per se to be examined as opposed to over-expression of the 
protein. 
The highest level of cytosolic Ca2+ was detected in SOD1G93A motoneurons, whilst WT 
motoneurons possess a significantly lower level of basal cytosolic Ca2+, which may 
contribute to the selective vulnerability of SOD1G93A motoneurons to excitotoxicity (Van 
Den Bosch et al, 2006). SODH motoneurons however, have a basal cytosolic Ca2+ 
concentration that is intermediate between SOD1G93A and WT. This suggests that 
protein over-expression is enough to result in elevated cytosolic Ca2+ and has toxic 
effects on motoneurons.  
The same trend was observed for ER Ca2+. Inferred ER Ca2+ is highest in WT 
motoneurons and significantly lower in SOD1G93A motoneurons. ER Ca2+ is not as low 
in SODH motoneurons as it is in SOD1G93A motoneurons, however the level of ER Ca2+ 
is still significantly lower in SODH motoneurons than in WT motoneurons. This 
suggests that over-expression of the SOD1 protein alone is enough to cause ER Ca2+ 
depletion. As is the case with basal cytosolic Ca2+ however, SOD1G93A expression and 
protein over-expression appear to have a cumulative effect on ER Ca2+.  
SOD1G93A motoneurons not only have the lowest level of ER Ca2+, but they also have 
the highest level of SOC influx. Furthermore, the lowest level of SOC influx is observed 
in WT motoneurons, which have the highest level of ER Ca2+. The level of SOC influx 
observed in SODH motoneurons lies between the levels measured in WT and 
SOD1G93A motoneurons. This suggests that although over-expression of the SOD1 
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protein is detrimental for motoneuron Ca2+ handling, the mutation per se also has 
effects on cellular Ca2+. 
3.3.6 What causes ER Ca2+ depletion in KD motoneurons? 
Although confocal microscopy reveals that the ER is depleted of Ca2+ in KD 
motoneurons, it does not reveal any information about what may be the cause of this 
ER Ca2+ depletion. Furthermore, it also only allows the presence of ER stress to be 
inferred and not confirmed. Western blot analysis of purified DHT-treated WT and DHT-
treated KD embryonic motoneurons can provide some of the information that confocal 
experiments lack. 
ER Ca2+ is controlled by the InsP3 and Ryanodine receptors, which allow movement of 
Ca2+ out of the ER, and the Sarco/Endoplasmic Reticulum ATPase 2 (SERCA2 pump), 
which pumps Ca2+ into the ER against its concentration gradient. It has been shown 
previously that one of the downstream actions of the AR is to up-regulate expression of 
SERCA2 pump mRNA, leading to an increase in ER Ca2+ (Foradori et al, 2008). 
Therefore, the SERCA2 pump could be a link between mutations in the AR and ER 
Ca2+ levels. 
Western blot analysis reveals that the level of SERCA2b pump protein expression is 
significantly lower in E13 DHT-treated KD motoneurons than in WT controls. This is 
very likely to contribute to the lower level of ER Ca2+ observed in KD motoneurons. A 
lower level of SERCA2b pump expression in the ER membrane would impair the 
capacity of the ER to sequester Ca2+ from the cytosol and thus could result in ER Ca2+ 
depletion. However in order to determine whether or not this could account for levels of 
ER Ca2+, future work would need to establish expression levels and activity of the InsP3 
and Ryanodine receptors. If expression levels and activity of these channel receptors 
are impaired, it could balance out SERCA2 pump impairment and so there would be no 
net decrease in ER Ca2+. This will be discussed in more detail in Chapter 6. 
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The fact the SERCA2b expression decreases in KD motoneurons is in keeping with the 
observed ER Ca2+ depletion. However, it is not in keeping with the finding that 
SERCA2b expression normally increases as a result of cytosolic Ca2+ increase and as 
a downstream effect of AR activation, as discussed earlier (Chapter 1, Section 1.2.2). 
This suggests that the AR mutation alters the transcriptional activity of the receptor. 
Indeed it has been suggested that the CAG-repeat expansion in the N-terminal domain 
of the AR results in truncated forms of the receptor being produced (Fischbeck et al, 
1999). Translocation of the truncated form of the AR into the nucleus has been found to 
be impaired and so the transcription of downstream targets of the receptor is also likely 
to be impaired (Butler et al, 1998). Indeed, residues 101-370 of the N-terminal domain 
of the AR are required for full ligand activated transcriptional activity (Bevan et al, 
1999). 
3.3.7 ER Ca2+ depletion results in ER stress in KD motoneurons 
Although ER Ca2+ depletion occurs in KD motoneurons, possibly as a result of reduced 
SERCA2b expression, these findings did not confirm that ER stress is a feature of KD 
motoneurons. However, examination of the expression levels of several markers of ER 
stress revealed that ER stress is significantly higher in embryonic KD motoneurons 
than in WT controls. BiP levels for example, are approximately 20 % higher in KD 
motoneurons than in WT controls, which is indicative of both ER stress and elevated 
cytosolic Ca2+ depletion, as BiP is transcribed as a result of these two events (Hong et 
al, 2005).  
The expression of phospho-eIF2 is also higher in embryonic KD cultures by 
approximately 11.2 %, which suggests that ER stress-induced protein translation is 
arrested to a greater extent in KD motoneurons than in WT controls, even as early as 
E13. This conclusion however, would be more reliable if eIF2expression was also 
measured as it is the phospho-eIF2eIF2 ratio of that quantifies ER stress (van 
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Huizen et al, 2003). This would therefore be a necessary future experiment to 
investigate ER stress further. 
Expression levels of ER stress markers that are further downstream of the UPR such 
as ATF4 and CHOP are also elevated in embryonic KD motoneurons compared to WT 
controls. Increased expression of CHOP in KD motoneurons suggests that there is a 
greater amount of pro-apoptotic protein transcription in these motoneurons than in WT 
controls. This increases the risk of ER stress-induced apoptosis occurring in KD 
motoneurons. This possibility will be examined further in Chapter 4. Because ER stress 
occurs to a greater extent in KD motoneurons even at such an early stage of 
development it can be considered as a strong candidate for an underlying disease 
trigger for KD. 
3.3.8 ER stress during disease progression in the spinal cord of KD mice 
As well as identifying the earliest time point at which ER stress occurs in motoneurons 
of KD mice it is also useful to determine whether or not ER stress persists throughout 
disease progression. As discussed previously (Section 3.1.3.1), markers of ER stress 
are elevated throughout disease progression in the SOD1G93A model of ALS (Saxena et 
al, 2009). The earliest observed increase in the ER stress marker BiP occurs at P5 in 
the SOD1G93A mice suggesting that ER stress plays an early role in ALS pathogenesis 
(Saxena et al, 2009). Sharp increases in BiP in the SOD1G93A model also coincide with 
the occurrence of denervation, indicating that the occurrence of ER stress correlates 
with symptom manifestation (Saxena et al, 2009). 
All of the markers of ER stress measured in this study appear to be elevated in KD 
spinal cords compared to WT controls as early as postnatal day 5 (P5) and evidence of 
ER stress observed throughout disease progression. However, in all cases the 
difference between WT and KD spinal cords with respect to ER stress marker levels 
diminishes with disease progression and in the case of BiP and phospho-eIF2, there 
is no difference between the genotypes at disease end-stage. It is possible that at 
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disease end stage, a large proportion of motoneurons have already degenerated so 
that KD motoneurons, which would be expressing elevated levels of ER stress 
markers, are no longer present. The read out that is obtained at end-stage is based on 
surviving motoneurons only – not all disease-affected motoneurons. Furthermore, at 
disease end-stage, the natural effects of aging, which also occur in WT motoneurons, 
have also influenced levels of ER stress markers. Indeed, up until 12 months of age, 
the level of ER stress markers appears to be modestly increasing in WT motoneurons. 
These motoneurons are not made vulnerable by an underlying pathology and do not 
degenerate, whereas KD motoneurons are progressively lost. Thus, the overall protein 
levels of ER stress markers from WT 18 month spinal cords, where there is a low level 
of age-related ER stress in a large number of motoneurons, is similar to the overall 
protein levels in KD spinal cords, where there is a high amount of ER stress in very few 
motoneurons. Indeed, data from our lab shows that by 18 months of age only 60% of 
motoneurons survive in the sciatic motor pool of KD mice (Malik et al, 2011). 
The levels of BiP observed at various stages of disease in KD mice reveal that ER 
stress may in fact be an earlier event in KD pathology than in ALS pathology. Indeed, 
the peak elevation in BiP in KD motoneurons is detected at P5 in KD motoneurons but 
at P28 SOD1G93A mice (Saxena et al, 2009). Furthermore, disease progress is much 
slower in the AR100 mouse model of KD than in the SOD1G93A model of ALS, with the 
first symptoms manifesting at approximately 440 days (Sopher et al, 2004) and 90-120 
days of age (Reyes et al, 2010), respectively. Thus an earlier peak elevation of BiP in 
the KD mouse model suggests that ER stress is more likely to be a feature of disease 
pathology in KD than in ALS pathology. 
As observed at E13, increased expression of BiP in spinal cords of KD mice of different 
ages appears to be specific to motoneurons, as demonstrated by BiP immunoreactivity 
in spinal cord sections. This correlation between the expression of ER stress markers 
and vulnerability to disease pathology further suggests that ER stress is an underlying 
pathological mechanism in KD. 
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In keeping with the results found for BiP expression levels, phospho-eIF2 expression 
also appears to be elevated in KD spinal cord tissue compared to WT tissue and the 
peak of this elevation is also at P5. This suggests that the PERK pathway of the UPR is 
active in KD spinal cord tissue at P5 and that translational block is occurring. However, 
as discussed above, conclusions regarding the expression of eIF2 need to be 
approached with caution until the ratio of phospho-eIF2:eIF2 is obtained. 
The expression of ATF4 and CHOP are also elevated in KD spinal cord tissue 
compared to WT controls and this elevation peaks at P5.  However unlike BiP and 
phospho-eIF2, ATF4 and CHOP remain elevated in KD spinal cord compared to WT 
controls at disease end-stage. Therefore, markers that are further downstream of the 
UPR appear to remain elevated for longer. This could be because of an imbalance 
between the expression of pro-survival and pro-apoptotic proteins expressed 
downstream of the UPR in KD motoneurons. The results suggest that this is indeed the 
case. Both BiP (pro-survival) and CHOP (pro-apoptotic) are transcribed downstream of 
the PERK pathway as discussed above. When the relative protein levels of BiP and 
CHOP are examined in WT and KD spinal cords at P5 – when there is peak ER stress- 
the imbalance between pro-survival and pro-apoptotic proteins is revealed. In WT 
spinal cord the relative levels of BiP and CHOP are both approximately 0.7. However in 
KD spinal cord tissue, the relative protein level of CHOP is 20% higher than the level of 
BiP. Thus there could be a skew in expression towards pro-apoptotic proteins in KD 
motoneurons at P5. 
3.3.9 Summary 
The results presented in this Chapter have shown that there is elevated basal cytosolic 
Ca2+ in embryonic motoneurons cultured from the AR100 mouse model of Kennedy’s 
Disease (KD) compared to WT littermate controls, implying that KD motoneurons could 
be more vulnerable to excitotoxic insult. Embryonic KD motoneurons also possess a 
lower concentration of ER Ca2+ than WT controls and as a direct result respond to 
165 
 
drug-induced ER Ca2+ depletion and subsequent Ca2+ introduction with a higher level of 
SOC influx.  
The decrease in ER Ca2+ that occurs in KD motoneurons is likely to be a result of a 
decreased expression of the SERCA2b pump in these motoneurons. A decrease in 
SERCA2b expression lowers the ability of the ER to sequester Ca2+ from the cytosol 
and thus Ca2+ that exits the ER is not replaced efficiently and there is a resultant net 
decrease. 
 All of the ER stress markers measured are elevated in primary embryonic KD 
motoneurons compared to embryonic WT motoneurons. The presence of ER stress at 
such an early stage of disease indicates that ER stress may be a causative event in KD 
pathology as opposed to a secondary effect. ER stress remains in motoneurons 
throughout disease progression in the AR100 model of KD although the difference 
between KD and WT motoneurons with respect to ER stress marker expression 
decreases over time, possibly because disease-affected motoneurons are suspected to 
be dying. Examination of ER stress longitudinally also reveals an imbalance between 
pro-survival and pro-apoptotic protein transcription downstream of the UPR in KD 
motoneurons, in which levels of pro-apoptotic proteins are higher. 
Because ER stress is present in embryonic KD motoneurons, and the peak difference 
in ER stress marker expression between KD and WT spinal cord tissue is at P5, it 
seems likely that the role of ER stress is at its peak pre-symptomatically. This makes 
ER stress a strong candidate for an early, underlying disease trigger. 
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APOPTOSIS IN KD MOTONEURONS 
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4.1. Introduction 
The Unfolded Protein Response (UPR) is a cellular response that is activated 
downstream of ER stress as an attempt to restore ER homeostasis. It results in the 
transcription of both pro-survival and pro-apoptotic proteins so when the source of ER 
stress cannot be resolved and the UPR is activated for a prolonged length of time, pro-
apoptotic proteins accumulate and ER stress-induced apoptosis ensues (Szegezdi et 
al, 2007). The results presented in Chapter 3 show that ER stress is an early feature of 
pathology in KD motoneurons in vitro. However, it is not necessarily the case that such 
stress results in ER stress-induced apoptosis and therefore it cannot be concluded that 
the ER stress observed in embryonic KD motoneurons contributes to the death of 
motoneurons observed in Kennedy’s Disease.  
Therefore, in this Chapter in order to determine the contribution of ER stress to 
motoneuron death in KD, markers of ER stress-induced apoptosis were examined in 
WT and KD primary motoneurons and the effects of pharmacologically inhibiting ER 
stress on motoneuron survival investigated. 
4.1.1 ER stress-induced apoptosis & the role of Caspase 12 
ER stress-induced apoptosis can be considered to involve three separate stages; 
initiation, commitment and execution (Szegedi et al, 2003). The initiation and 
commitment phases occur when the UPR is initiated and pro-apoptotic proteins, such 
as CHOP, are consequentially transcribed, (Discussed in Chapter 3, Section 3.1.2.2). 
The execution of ER stress-induced apoptosis essentially involves the activation of 
Caspases and will be the focus of this Chapter. Although mitochondrial and death 
receptor-mediated apoptosis are well characterized, Caspases involved in ER stress-
induced apoptosis have yet to be established with Caspases 12, 3, 6, 7, 8 and 9 being 
implicated in the process (Dahmer et al, 2005, Rosati et al, 2010, Szegedi et al, 2003).  
Caspase 12 has been suggested to be the key mediator of ER stress-induced 
apoptosis and was the first Caspase to be associated with the ER (Nakagawa et al, 
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2000). Caspase 12 is expressed in rodents exclusively, with Caspase 4 fulfilling the 
same role in humans (Szegedi et al, 2003) and its activation is specific to ER stress-
induced apoptosis (Yoneda et al, 2001). Indeed, Caspase-12 knock-out mice display 
an increased resistance to ER stress-induced apoptosis whilst vulnerability to triggers 
of other apoptotic mechanisms is unchanged (Nakagawa et al, 2000). 
Caspase 12 is a Group 1 Caspase (Eckhart et al, 2009). These proteins consist of a 
long Caspase-recruitment domain (CARD domain), which interacts with various 
proteins such as TNF receptor-associated factor 2 (TRAF2) and other Caspases. 
Group 1 Caspases also contain two catalytic domains referred to as P10 and P20 
(Eckhart et al, 2009). The proposed structure of Caspase 12 is depicted in Figure 4.1. 
There are several suggested mechanisms for the activation of Caspase 12 that occurs 
downstream of ER stress. One such mechanism involves the protein TRAF2, which is 
recruited by Inositol Requiring Enzyme 1 (IRE1) during the UPR (Urano et al, 2000). 
Inactive pro-Caspase 12 forms a stable complex with TRAF2 in unstressed cells 
(Yoneda et al, 2001). Following ER stress however, pro-Caspase 12 is thought to 
dissociate from TRAF2 and in doing so is able to form pro-Caspase 12 oligomers 
(Yoneda et al, 2001). Oligomerization of pro-Caspase 12 is then thought to trigger 
autoprocessing of the CARD domain and as a result, active catalytic domains are 
cleaved and Caspase 12 is activated (Yoneda et al, 2001). 
Another proposed mechanism of Caspase 12 activation, which is suggested to 
specifically occur downstream of ER Ca2+ depletion has also been suggested 
(Nakagawa et al, 2000).  Ca2+ release from the ER is proposed to activate the Ca2+-
dependent, neutral protease Calpain, which cleaves pro-Caspase 12 (Nakagawa et al, 
2000). Calpain cleavage of pro-Caspase 12 at residue D318, releases the CARD 
domain, leaving a 38 kDa Caspase fragment. 
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Figure 4.1: Proposed structure of Caspase 12 
Caspase 12 consists of a long Caspase-recruitment domain (CARD domain), which is 
also referred to as the Pro-domain and is 2-32 kDa in size. Caspase 12 also contains 
two catalytic domains referred to as P10 and P20, which are 17-20 kDa and 10-13 kDa 
in size, respectively. Aspartate residues at the borders of the catalytic domains form 
the cleavage sites involved in Caspase 12 activation.  
Prior to activation, Caspase 12 dimerizes and the most accepted configuration is 
shown in diagram B): The P20 domains are exposed to the cytosol, whilst the P10 
domains are concealed. 
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Figure 4.1 
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The P10 subunit is then cleaved, leaving a 23 kDa Caspase fragment that contains the 
P20 subunit and an intact catalytic residue; C298. Finally, autolytic cleavage is 
proposed to result in the release of the P20 fragment (Martinez et al, 2010). 
As well as Calpain-mediated cleavage of pro-Caspase 12, other Caspases, such as 
Caspase 7 are thought to cleave and thus activate Caspase 12 (Martinez et al, 2010). 
Furthermore, the cleavage of pro-Caspase 12 by Caspase 7 has been suggested to 
play a more pivotal role than Calpain-mediated cleavage in apoptosis triggered 
downstream of ER Ca2+ depletion. Indeed, decreases in both Caspase 12 activation 
and Thapsigargin-induced death in PC12 cells are larger following Caspase 7 inhibition 
than they are following Calpain inhibition (Martinez et al, 2010). 
By whatever mechanism, once Caspase 12 has been activated, apoptosis ensues. 
This occurs via the activation of Caspase 3, which is an ubiquitously expressed 
Caspase that mediates the execution of apoptosis (Kerbiriou et al, 2009). The 
mechanism of action by which Caspase 3 is activated downstream of Caspase 12 is 
summarized in Figure 4.2. The activation of Caspase 3 induces apoptosis via the 
cleavage of several essential cellular proteins. For example, the activation of Caspase 
3 has been associated with the proteolytic cleavage of Protein Kinase C (Anantharam 
et al, 2002), cytoskeletal proteins (Mashima et al, 1999) and Poly-ADP ribose 
polymerase, or PARP (Jimenez et al, 2002). 
4.1.2 ER stress-induced apoptosis in Motor Neuron Diseases 
Caspase 12 activation has been found to occur in other models of Motor Neurone 
Diseases (MNDs) such as the SOD1G93A transgenic mouse model of Amyotrophic 
Lateral Sclerosis (ALS). For example, quantitative PCR analysis has revealed that the 
level of cleaved Caspase 12 is significantly higher in the spinal cord of symptomatic 
SOD1G93A ALS mice compared to WT controls (Wootz et al, 2004). 
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Figure 4.2: Activation of Caspase 3 downstream of Caspase 12 
The schematic illustrates two mechanisms, which have been proposed for the 
activation of Caspase 12. 
Following ER stress-induced activation of the UPR, TRAF2 dissociates from Caspase 
12 and interacts with IRE1 in the ER membrane (1a). This results in Caspase 12 
dimerization (1b). Alternatively, Ca2+release from the ER results in the activation of 
Calpain, which cleaves Pro-Caspase 12 (2). Active Caspase 12 then activates 
Caspase 9 (3), which activates Caspase 3 (4).  
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Figure 4.2 
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Furthermore, the level of cleaved Caspase 12 is higher in symptomatic SOD1G93A mice 
than in pre-symptomatic SOD1G93A mice, although these asymptomatic mice express 
higher levels of active Caspase 12 than WT mice (Wootz et al, 2004). This suggests 
that the presence of the mutant SOD1 protein alone increases levels of active Caspase 
12 pre-symptomatically and that Caspase 12 activation increases further with symptom 
manifestation. Increased levels of Caspase 12 have also been detected in the 
cerebrospinal fluid (CSF) of ALS patients relative to healthy controls (Vijayalakshmi et 
al, 2010). Furthermore, rat spinal motoneurons exposed to CSF from ALS patients 
express elevated levels of Caspase 12 compared to control motoneurons that are 
exposed to non-ALS CSF (Vijayalakshmi et al, 2010). This suggests that, in the case of 
ALS, the causes of ER stress can be extrinsic to motoneurons. 
4.1.3 ER stress-induced apoptosis in CAG-repeat disorders: the effect of repeat 
size 
ER stress-induced apoptosis also occurs in other CAG-repeat disorders such 
Huntington’s Disease (HD). The presence of Poly-CAG aggregates is accompanied by 
activation of Caspase 12 via cleavage at the D318 residue (Kouroku et al, 2002). 
Immunoblotting of this cleavage site reveals that the levels of active Caspase 12 
following Tunicamycin treatment are higher in cells expressing a Huntingtin protein 
possessing 72 CAG-repeats than cells expressing a control protein with 11 CAG 
repeats (Kouroku et al, 2002). These findings therefore indicate that levels of active 
Caspase 12 increase with increasing CAG-repeat number. 
4.1.4.1 Salubrinal: Pharmacological inhibition of ER stress 
As well as measuring expression levels of markers of ER stress-induced apoptosis, the 
role of ER stress-induced apoptosis in disease pathology can also be investigated by 
examining the effects of pharmacological inhibition of ER stress. One such ER stress 
inhibitor is Salubrinal, (C21H17N4OSCl3), a cell-permeable inhibitor of phosphatases that 
normally dephosphorylate phospho-eIF2(Boyce et al, 2005). Salubrinal maintains the 
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phosphorylation state of eIF2 and therefore maintains the translational block that 
occurs when the UPR is elicited. This effectively makes the response to ER stress 
more potent. 
4.1.4.2 Salubrinal in MNDs and CAG-repeat diseases 
Salubrinal has been used previously to investigate the role of ER stress-induced 
apoptosis in both MNDs and CAG-repeat disorders. 
In models of MNDs such as ALS, the administration of Salubrinal has been found to 
decrease motoneuron death both in vitro and in vivo (Oh et al, 2008, Saxena et al, 
2009).  For instance, in vitro, 48 hour Salubrinal treatment of Neuro2a cells expressing 
the mutant SOD-1 protein (mSOD-1) prevents mSOD1-induced cell death. Salubrinal 
treatment also improves the viability of the remaining motoneurons as demonstrated by 
Propidium Iodide staining (Oh et al, 2008).  The benefits of Salubrinal are also evident 
in animal models of ALS. In SOD1G93A mice, Salubrinal attenuates symptoms of 
disease, such as denervation, and delays disease progression (Saxena et al, 2009). 
These findings suggest that ER stress can be directly implicated in disease pathology 
in MND and is associated with disease-related motoneuron death. Thus, when ER 
stress is inhibited by Salubrinal, motoneuron death decreases and disease progression 
is delayed. 
Salubrinal treatment has also been used to determine the role of ER stress in the 
pathology of CAG-repeat disorders. In a cell model of Huntington’s Disease, in which 
PC6.3 cells are transfected with a mutant Huntingtin protein containing up to 120 CAG-
repeats, Salubrinal treatment decreases neuronal death by 40 % (Reijonen et al, 
2008). Furthermore, Salubrinal treatment also results in a decrease in Caspase 12 
cleavage and thus the pharmacological prevention of ER stress correlates with both 
decreased Caspase 12 activation and decreased neuronal death. 
Since Kennedy’s Disease is both a MND and a CAG repeat disorder, and because the 
results presented in Chapter 3 showed that ER stress occurs in the AR100 mouse 
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model of the disease (see Chapter 3), it is possible that the treatment of motoneurons 
from AR100 mice with Salubrinal will reduce ER stress and thereby increase 
motoneuron survival. The experiments in this Chapter aim to determine if this is true 
and will also establish whether or not inhibition of ER stress alone is enough to 
significantly rescue KD motoneurons from death. 
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4.2. Results 
4.2.1 KD motoneurons are less viable in culture than WT motoneurons 
In these experiments, the effects of ER stress on motoneuron survival were 
investigated. In the first instance, in order to determine if the presence of the expanded 
Androgen Receptor (AR) itself increased the vulnerability of motoneurons, the level of 
motoneuron survival in basal culture conditions was established for WT and KD 
motoneurons at 7 DIV. 
At 7 DIV, DHT-treated WT and DHT-treated KD primary ventral motoneuron cultures 
were stained with the neurofilament marker -III tubulin. The results show that there 
are consistently fewer motoneurons present in KD cultures than in WT control cultures 
and that the motoneurons that are present in the KD cultures are more clustered than 
those in WT cultures (Figure 4.3A). Thus, as shown in Figure 4.3B when the number of 
motoneurons is expressed as a percentage of total cell number per coverslip, 
significantly fewer motoneurons survive in KD cultures than in WT cultures (p<0.001). 
Whilst WT cultures consist of 42% motoneurons (+/- 1.11 % SEM, n = 40 fields from 3 
different cultures), KD cultures consist of only 29% motoneurons (+/- 1.27 % SEM, n = 
40 fields from 3 different cultures). Thus approximately 1.5 times more motoneurons 
survive at 7 DIV in WT cultures than in KD cultures. 
4.2.2 Treatment with an inhibitor of ER stress improves motoneuron survival in 
WT and KD cultures 
Salubrinal is a well-established inhibitor of ER stress (Kessel et al, 2006). A range of 
Salubrinal concentrations was first tested on WT cultures in order to ensure that 
Salubrinal did not have a detrimental effect on primary motoneurons under normal 
conditions. 
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Figure 4.3: Motoneuron survival in WT and KD cultures under basal conditions 
Primary motoneurons were cultured from WT and KD embryos at E13. Cultures were 
treated with 50 M DHT (final concentration 500 nM) at 4 DIV and were fixed in 4% 
PFA at 7 DIV. Cultures were immunostained for -III tubulin (green) and the nuclear 
marker DAPI (blue) to determine motoneuron number and total cell number, 
respectively. Typical example images of WT and KD cultures are shown in Ai) and ii), 
respectively. There are fewer motoneurons present in KD cultures, and the 
motoneurons that are present are more clustered than motoneurons in WT cultures.  
When the number of motoneurons present in each culture is expressed as a 
percentage of total cell number (B) significantly fewer motoneurons survive in KD 
cultures (p < 0.005). Data was acquired from 40 different fields, from at least 3 different 
cultures for each genotype.  
Error bars show the standard error of mean. Scale Bar in A) = 45 m.  
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Figure 4.3 
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The concentrations ranged between 1 M and 100 M (final concentrations 10 nM – 
100 nM). There was no significant difference observed in motoneuron survival in 
cultures treated with different concentrations of Salubrinal and so 50 M Salubrinal, 
which has been used previously in primary cultures, was used in the following 
experiments (Kessel 2006). Thus at 6 DIV, motoneurons cultures were treated with 50 
M Salubrinal (final concentration = 500 nM) for 24 hours. 
Following treatment with 24 hour Salubrinal (500 nM) there was an increase in the 
number of motoneurons in both WT and KD cultures, with more -III tubulin-positive 
cells, with 2 or more processes, in Salubrinal-treated cultures compared to untreated 
cultures (Figure 4.4A).  Salubrinal treatment also appears to decrease motoneuron 
clustering in KD cultures (Figure 4.4Aii). When the percentage of -III tubulin-positive 
cells, with 2 or more processes, is expressed as a percentage of total cell number, the 
number of motoneurons in Salubrinal-treated KD cultures is 48%, which is approx. 
115% (+/- 2.85 % SEM, n=40 fields from 3 different cultures), relative to WT cultures 
that have not been treated with Salubrinal, and approximately 178% relative to KD 
cultures that have not been treated with Salubrinal (Figure 4.4B). This increase in 
motoneuron survival in KD cultures following Salubrinal treatment is significant (p< 
0.005). When WT cultures were treated with Salubrinal, the percentage of 
motoneurons increased to 53.4%, which is 127% (+/- 1.42 % SEM, n = 40 fields from 3 
different cultures) relative to WT cultures that had not been treated with Salubrinal 
(Figure 4.4B). This increase in survival is also significant (p = 0.043) Thus, Salubrinal 
treatment appears to be beneficial to both WT and KD motoneurons.  
To summarize, 30% fewer KD motoneurons survive at 7 DIV compared to WT cultures. 
However, following treatment with Salubrinal there is a significant increase in 
motoneuron survival in WT and KD cultures so that motoneuron survival in Salubrinal-
treated KD and WT cultures is not significantly different. 
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Figure 4.4: Treatment with Salubrinal improves the survival of KD motoneurons 
Primary motoneuron cultures from WT and KD embryos were treated with 5 M DHT at 
4 DIV and fixed at 7 DIV in 4% PFA before being stained for -III tubulin (green) and 
the nuclear marker DAPI (blue). In some cases cultures were also treated with 50 mM 
Salubrinal at 6 DIV. Example images of DHT-treated WT and KD cultures in the 
absence and presence of Salubrinal are shown in Ai) and ii), respectively. Salubrinal 
decreases motoneuron clustering and increase motoneuron number in KD cultures.  
When the number of motoneurons is expressed as a percentage of total cell number 
(B) Salubrinal treatment results in a significant increase in motoneuron survival in both 
WT and KD cultures (p < 0.05 and < 0.005, respectively). The data is the mean from 40 
different fields from at least 3 different cultures. Error bars show the standard error of 
mean. Scale bars in A) = 30 m 
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Figure 4.4 
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4.2.3 KD motoneurons have an increased vulnerability to ER stressors that 
deplete ER Ca2+ such as Thapsigargin (TG). 
Primary WT and KD ventral motoneuron cultures were treated at 6 DIV for 24 hours 
with various concentrations of Thapsigargin (TG) ranging from 10 nM to 1 M. The 
cultures were fixed at DIV 7 and stained for MAP2 and DAPI to assess motoneuron 
survival. In WT cultures, TG begins to have a detrimental effect on motoneuron survival 
at 1 M, whereas survival of KD motoneurons decreases most noticeably at 300 nM. 
Therefore a concentration of 300 nM (Figure 4.5), which has been used previously in 
primary cultures, was used in the following experiments (Rahman et al, 1996). 
Following the treatment of cultures with TG for 24 hours there are visible changes in 
both WT and KD motoneurons. WT motoneurons are more clustered following TG 
treatment whilst the number of KD motoneurons appears to decrease dramatically – as 
demonstrated by a lower number of -III tubulin-positive cells (Figure 4.6A). 
When the number of motoneurons in each culture is expressed as a percentage of total 
cell number, it shows that treatment with 300 nM TG for 24 hours results in decreased 
in motoneuron survival in both WT and KD cultures (Figure 4.6B). In WT cultures, TG 
treatment results in a decrease in motoneuron survival, from 42% in untreated cultures 
to 33% in TG-treated cultures i.e. the survival of TG-treated WT motoneurons, relative 
to WT motoneurons that are not exposed to TG, is 91% (+/- 1.11 SEM, n=40 fields 
from 3 different cultures). This decrease in motoneuron survival, although only 9%, is 
significant (p=0.05). In contrast, KD motoneuron cultures are more vulnerable to TG 
treatment, so that motoneuron survival decreases from 29% (+/- 1.27 % SEM, n = 40 
fields from 3 different cultures) in untreated conditions to only 12% (+/-1.01% SEM, n = 
40 fields from 3 different cultures) in TG-treated cultures (p=0.0008). Thus, relative to 
WT motoneurons that are not exposed to TG, TG - treated KD motoneuron survival is 
71 % lower, which is a significant decrease (p= 0.0002). Furthermore, the difference in 
survival between TG-treated WT and KD motoneurons is significant (p=0.003). 
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Figure 4.5 Effects of different concentrations of Thapsigargin on ER Ca2+ in WT 
and KD primary motoneurons. 
Primary ventral motoneuron cultures from WT and KD embryos were treated at 4 DIV 
with 5 M DHT and were then fixed at 7 DIV in 4% PFA. The cultures were 
immunostained for -III tubulin (green) and stained with DAPI (blue). In some cases, at 
6 DIV, cultures were also treated with various concentrations of Thapsigargin (TG) 
ranging from 10 nM to 1M.  
The Bar Chart summarizes the results obtained when the number of motoneurons 
surviving at 7 DIV is expressed relative to the number of motoneurons present in 
untreated WT cultures. A significant decrease in KD motoneuron survival is observed 
when cultures are treated with 300 nM and 1 M TG. A significant decrease in WT 
motoneuron survival is only observed following treatment of cultures with 1 M TG (p < 
0.005). Error bars show the standard error of mean. 
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Figure 4.5 
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Figure 4.6: KD motoneurons are more vulnerable to ER stress than WT 
motoneurons: the effect of Thapsigargin 
Primary motoneuron cultures from WT and KD E13 embryos were treated with 5 M 
DHT at DIV 4 and fixed in 4% PFA at 7DIV before being stained for -III tubulin (green) 
and the nuclear marker DAPI (blue). In some cases, at 6DIV, the cultures were also 
treated with 300 nM Thapsigargin (TG). Examples of immunostained DHT-treated WT 
and KD cultures in the absence and presence of TG are shown in Ai) and ii), 
respectively. TG increases motoneuron clustering in WT cultures and decreases 
motoneuron survival in KD cultures. The number of surviving motoneurons in each 
culture was expressed as a percentage of total number of cells present, which was 
then expressed relative to the percentage of motoneurons in untreated WT cultures. 
(B) TG treatment results in a significant decrease in motoneuron survival in KD cultures 
(p < 0.01). Mean motoneuron survival was determined by examining 40 different fields 
from at least 3 different cultures. 
Error bars show the standard error of mean. Scale bars in A) = 30 M 
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Figure 4.6 
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4.2.4 Treatment with an inhibitor of ER stress rescues motoneurons from TG-
induced death 
Treatment with Thapsigargin for 24 hours results in axonal clustering in WT cultures 
and a significant loss of motoneurons in KD cultures (Figure 4.6). To determine if this 
effect was due to the known ER stress-inducing effects of TG, the effects of Salubrinal, 
an ER stress inhibitor, on TG-induced stress was examined. When motoneurons were 
treated with Salubrinal (50 M) as well as TG (300 nM), a decrease in motoneuron 
clustering was observed, although it was not eliminated (Figure 4.7A). However, a 
dramatic increase in motoneuron survival was observed in KD cultures treated with TG 
and Salubrinal. Thus, significantly fewer KD and WT motoneurons died in cultures 
treated with Salubrinal in addition to TG than TG-only treated cultures (Figure 4.7B). In 
TG-treated WT cultures 45.0 % (+/- 0.82 % SEM, n = 40 fields from 3 different cultures) 
of motoneurons survived following treatment with Salubrinal, an increase of 
approximately 12% compared to TG only-treated cultures (p< 0.001).  Relative to 
untreated WT cultures, TG-treated WT motoneuron survival is 9 % lower, but in the 
presence of Salubrinal in addition to TG, survival is 7 % higher (Figure 4.7B). In TG-
treated KD cultures however, the increase in motoneuron survival observed following 
treatment with Salubrinal is even greater, so that motoneuron survival increases by 
37.6 % to 44.6 % (+/- 0.77 % SEM, n= 40 fields from 3 different cultures). This increase 
is significant (p<0.001). Relative to untreated WT cultures, TG-treated KD motoneuron 
survival is 71 % lower, but in the presence of Salubrinal in addition to TG, survival is 
6% higher (Figure 4.7B). Importantly, there is no difference in survival between TG-
treated WT and TG-treated KD motoneurons in the presence of Salubrinal. 
4.2.5 KD motoneurons are less vulnerable to Ca2+-independent ER stress 
To examine whether KD motoneurons are also more vulnerable to Ca2+-independent 
ER stress than WT motoneurons, the cultures were treated with Tunicamycin, an 
established inducer of Ca2+-independent ER stress. 
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Figure 4.7: Salubrinal treatment prevents KD motoneuron vulnerability to 
Thapsigargin 
Primary motoneuron cultures from WT and KD E13 embryos were treated with 5 M 
DHT at 4 DIV and 300 nM Thapsigargin (TG) at 6 DIV. Cultures were then fixed at 7 
DIV in 4% PFA and immunostained for -III tubulin (green) and DAPI (blue). In some 
cases, cultures were also treated with 50 M Salubrinal at 6 DIV. Example images of 
DHT and TG- treated WT and KD cultures in the absence and presence of Salubrinal 
are shown in Ai) and ii), respectively. There does not appear to be a noticeable 
difference between TG-treated WT cultures and Salubrinal + TG-treated WT cultures. 
However in TG-treated KD cultures there appears to be an increase in motoneuron 
survival following Salubrinal treatment. 
When the number of motoneurons is expressed as a percentage of total cell number 
and then expressed relative to the percentage of motoneurons in untreated WT 
cultures (B), Salubrinal treatment results in significant increases in motoneuron survival 
in  both TG-treated WT and TG-treated KD cultures (p < 0.005 in both cases). 
Motoneuron survival is based on 40 different fields from at least 3 different cultures. 
Error bars show the standard error of mean. Scale bars in A) = 30 m 
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Figure 4.7 
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Following 24 hour treatment of WT and KD cultures with Tunicamycin, cultures were 
immunostained for -III tubulin and the number of motoneurons surviving in WT and 
KD cultures was established (Figure 4.8A). As shown in Figure 4.8B, following 
treatment with Tunicamycin at concentrations ranging from 10 nM – 1 M, there is a 
decrease in motoneuron survival in WT cultures at all concentrations used but only at 1 
M is this decrease significant. Thus following exposure to 1 M Tunicamycin for 24 
hours, WT motoneuron survival decreases by approximately 50 % compared to 
untreated WT cultures (p=0.01). However in KD cultures, motoneuron survival is not 
significantly different in Tunicamycin-treated cultures compared to untreated KD 
cultures at any concentration and is the same as that observed in WT motoneuron 
cultures treated with the highest concentration of Tunicamycin (1 M). 
4.2.6 KD motoneurons undergo ER stress-induced apoptosis 
To examine whether the increase in ER stress that is detected in primary KD 
motoneurons resulted in an increase in ER stress-induced apoptosis, in KD and WT 
cultures, the level of Caspase 12 expression was examined by immunohistochemistry 
and Western Blot analysis. As shown in Figure 4.9A, Cleaved Caspase 12 
immunoreactivity (red) appears to be higher in DHT-treated KD motoneurons than in 
DHT-treated WT controls (Figure 4.9A). Indeed, in WT cultures Caspase 12 staining is 
barely visible whereas there is high intensity staining in KD motoneurons. 
Western Blot analysis of purified, DHT-treated WT and KD motoneuron cultures 
reveals that there is a significantly higher level of Caspase 12 expression in KD 
cultures than in WT controls (p=0.003).  Thus the expression level of Caspase 12 
relative to actin is only 0.694 (+/- 0.06 SEM, n = 3) in WT motoneurons, compared to 
1.588 (+/- 0.28 SEM, n = 3) in KD motoneurons (Figure 4.9C). 
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Figure 4.8: KD motoneurons are resistant to Tunicamycin  
Primary ventral motoneuron cultures from WT and KD embryos were treated at 4 DIV 
with 5 M DHT and were then fixed at 7 DIV in 4% PFA. The cultures were 
immunostained for -III tubulin (green) and stained with DAPI (blue). In some cases, at 
6 DIV cultures were also treated with various concentrations of Tunicamycin (TM) 
ranging from 10 nM to 1M. Examples of DHT - treated WT and KD cultures in the 
absence and presence of 1 M TM are shown in Ai) and ii), respectively.  
When the number of motoneurons surviving at 7 DIV is expressed relative to the 
number of motoneurons present in untreated WT cultures (B), only the highest 
concentration of TM (1 M) results in a significant decrease in motoneuron survival in 
WT cultures ( p < 0.01). However there is no significant decrease in KD motoneuron 
survival at any concentration tested. Motoneuron survival was measured in 40 different 
fields from at least 3 different cultures. Error bars show the standard error of mean. 
Scale bars in A) = 30 m 
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Figure 4.8 
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Figure 4.9: Caspase 12 expression is higher in KD primary motoneurons 
Primary motoneuron cultures from WT and KD embryos were treated at 4 DIV with 5 
M DHT. In some cultures the cells were fixed at 7 DIV in 4% PFA before being 
immunostained for -III tubulin (green), Caspase 12 (red) and DAPI (blue). Example 
images of WT and KD motoneuron cultures are shown in Ai) and ii), respectively. There 
appears to be much higher Caspase 12 immunoreactivity in KD motoneurons than in 
WT motoneurons. 
In other cultures the cells were homogenized at 7 DIV and processed for Western blot 
analysis of Caspase 12. An example blot is shown in B). The blot shows that there is a 
higher level of expression of Caspase 12 in KD motoneurons compared to WT controls.  
Quantification of the blot was achieved by expressing the optical density of the 
Caspase 12 bands relative to that of the corresponding Actin band, which was given a 
value of 1.0. The result is shown in Bar Chart C). There is a significantly higher level of 
Caspase 12 in KD motoneurons compared to the WT controls (P < 0.005). Values are 
based on the average of three different cultures from three different embryos. The blot 
was repeated twice. Error bars show the standard error of mean. Scale bars in A) = 30 
m 
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Figure 4.9 
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4.2.7 Treatment with an inhibitor of ER stress reduces ER stress-induced 
apoptosis in KD motoneurons 
To establish whether the increase in Caspase 12 expression detected in DHT-treated 
KD motoneurons was indeed due to ER stress, the cultures were treated with 
Salubrinal, an ER stress inhibitor. The level of Caspase 12 expression was determined 
by immunohistochemistry and Western blot analysis. Following 24 hour Salubrinal (50 
M) treatment, Caspase 12 immunoreactivity appears to decrease in primary KD 
ventral motoneurons (Figure 4.10A) so that a similar level of Caspase 12 
immunoreactivity is observed in KD and WT Salubrinal-treated cultures. 
Western blot analysis of DHT-treated purified WT and KD motoneurons reveals that 
following 24 hour treatment with Salubrinal there is a significant decrease in Caspase 
12 expression in both WT and KD motoneurons (p=0.042 and 0.0004, respectively). 
The expression level of Caspase 12 decreases by 84.2% in WT motoneurons following 
Salubrinal treatment to 0.11, relative to Actin (+/- 0.18 SEM, n = 3). In KD 
motoneurons, there is a 85% decrease in Caspase 12 expression following Salubrinal 
treatment – with the relative level of Caspase 12 now being 0.24 (+/- 0.21 SEM, n =3). 
Although the expression of Caspase 12 is higher in KD motoneurons than in WT 
controls, this difference is not significant.  
4.2.8 Inhibition of ER stress increases ER calcium levels in KD motoneurons 
Inhibition of ER stress in KD motoneurons by treatment with Salubrinal decreases 
Caspase 12 expression and improves motoneuron survival in KD cultures. To examine 
the effect of Salubrinal on ER Ca2+ levels, which are depleted in untreated KD 
motoneurons (Chapter 3, Section 3.3.4.2), ER Ca2+ levels were examined using Fluo 4-
AM and confocal microscopy to infer ER Ca2+ in primary ventral motoneurons from 
embryonic WT and KD cultures (as described in Chapter 3). As shown in Figure 4.11 
and Chapter 3, (Section 3.3.2.1), there is a significantly lower level of ER Ca2+ in KD 
motoneurons compared to WT controls (p< 0.005). 
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Figure 4.10: Treatment with Salubrinal decreases Caspase 12 expression in KD 
motoneurons 
Primary cultures from WT and KD embryos were treated at 4 DIV with 5 M DHT and 
then fixed at 7 DIV in 4% PFA. The cultures were either immunostained for -III tubulin 
(green), Caspase 12 (red) and DAPI (blue), or processed for Western blot analysis. In 
some cases, the cultures were also treated at 6 DIV with 50 M Salubrinal. Example 
images of immunostained WT and KD cultures are shown in Ai) and ii), respectively. 
Western blot analysis of Caspase 12 expression (B) showed that Salubrinal treatment 
results in a decrease in Caspase 12 expression in both WT and KD motoneurons. The 
level of Caspase 12 was expressed as optical density of the Caspase 12 band relative 
to the optical density of the corresponding Actin band (the loading control), which was 
given a value of 1.0 (C). In both WT and KD motoneurons, Salubrinal results in a 
significant decrease in Caspase 12 expression (p < 0.05 and 0.005, respectively). 
Although Caspase 12 expression is slightly higher in KD motoneurons, this is not 
significant. Values are based on the average of three different cultures from three 
different embryos. Each blot was repeated twice. 
Error bars show the standard error of mean. Scale bars in A) = 30 m 
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Figure 4.10 
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Following 24 hour treatment with Salubrinal, ER Ca2+ increases significantly in KD 
cultures (Figure 4.11). In WT cultures, although ER Ca2+ increases by 12 nM to 152 nM 
(+/- 29 nM SEM, n = 29) this is not significant. In KD motoneurons however, ER Ca2+ 
increases by 59 nM to 69 nM (+/- 11.5 nM SEM, n = 34). This increase in ER Ca2+ is 
significant (p = 0.008). Despite a significant increase in ER Ca2+ in KD motoneurons, 
ER Ca2+ levels in Salubrinal-treated WT motoneurons are significantly higher in than in 
Salubrinal treated KD motoneurons (p= 0.009). 
4.2.9 Caspase 12 expression levels throughout KD progression 
In order to determine whether the increase in ER stress-induced apoptosis observed in 
embryonic KD motoneurons in culture was also present in KD motoneurons in vivo and 
to establish whether ER stress-induced apoptosis was present throughout the disease, 
the pattern and level of Caspase 12 expression was examined in spinal cord sections 
of WT and KD mice at various stages of disease by immunohistochemistry and 
Western blot analysis. 
The pattern of Caspase 12 immunoreactivity in WT and KD spinal cord sections from 
mice at 3, 12 and 18 months of age suggests that the increase in Caspase 12 
expression observed in KD motoneurons at E13 does not persist throughout disease 
progression (Figure 4.12A). At 3 and 12 months of age, there is a clear increase in 
Caspase 12 immunoreactivity in KD motoneurons compared to WT motoneurons. 
However, by 18 months of age, Caspase 12 immunoreactivity in KD motoneurons has 
reduced, so that there is no detectable difference in Caspase 12 immunoreactivity 
between WT and KD motoneurons. 
The expression levels of Caspase 12 in spinal cord tissue from WT and KD mice at P5, 
3, 12 and 18 months of age were also assessed by Western blot analysis. A typical 
Western blot is shown in Figure 4.12 B, which shows that Caspase 12 expression is 
elevated early in disease in KD spinal cord and expression gradually declines as the 
disease progresses. 
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Figure 4.11: Salubrinal treatment increases ER Ca2+ in KD motoneurons 
Motoneuron cultures from E13 WT and KD embryos were examined using confocal 
microscopy at 7 DIV. Fluo 4 AM was used to measure cytosolic Ca2+ following TG-
induced Ca2+ release from the ER, giving an indication ER Ca2+ levels. The 
fluorescence signal was then calibrated using the Ionomycin-induced maximum 
cytosolic Ca2+ fluorescence as described in Chapter 2 (Section 2.6). In all cases, 
cultures were treated at 4 DIV with 5 M DHT and were treated with either 50 M 
Salubrinal at 6 DIV or left untreated. The Bar Chart shows the average ER Ca2+ in WT 
and KD motoneurons (+/- Salubrinal). Salubrinal significantly increases ER Ca2+ in KD 
motoneurons (p < 0.01), although the level of ER Ca2+ is still significantly higher in WT 
motoneurons (p =0.009).  
Error bars show the standard error of mean. The N number varies between 29 and 34, 
from at least three different cultures for each genotype. 
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Figure 4.11 
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Quantification of these Western blots (Figure 4.12 C) reveals that the peak elevation of 
Caspase 12 in KD motoneurons relative to WT controls occurs at P5. At P5 the level of 
Caspase 12 in WT spinal cord tissue, relative to Actin, is 0.93 (+/- 0.17 SEM, n = 3) 
compared to 1.87 (+/- 0.31 SEM, n = 3) in KD spinal cord, an increase of 101% 
(p=0.03). Caspase 12 expression remains elevated in KD spinal cord at 3 months of 
age when Caspase 12 levels in WT spinal cord tissue are 1.25 (+/- 0.12 SEM, n =3) 
compared to 1.74 (+/- 0.18 SEM, n = 3) in KD spinal cord, a difference of 39% ( p < 
0.05). 
By 12 months of age, Caspase 12 levels in KD spinal cord begin to decline, and 
although levels are higher than in WT spinal cord, 1.74 (+/- 0.09 SEM, n = 3) in KD 
spinal cord compared to 1.23 (+/- 0.10 SEM, n = 3) in WT spinal cord, this difference is 
not significant. 
By 18 months of age, Caspase 12 expression in KD spinal cord is significantly higher 
than in 18 month WT spinal cord (p < 0.01), so that Caspase 12 levels are 1.02 (+/- 
0.01 SEM, n = 3) in KD spinal cord compared to 0.70 (+/- 0.08 SEM, n =3) in WT 
tissue, a difference of 45%. 
4.2.10 Results summary 
In this Chapter, ER stress-induced apoptosis has been detected in KD motoneurons 
and its role in KD-associated motoneuron death has been investigated. Motoneuron 
counts in primary WT and KD ventral motoneuron cultures reveal that even under basal 
culture conditions KD motoneuron survival is reduced. Furthermore, treatment of 
cultures with the ER stressor Thapsigargin (TG) has a more detrimental effect on the 
survival of KD motoneurons than WT controls. Treatment of cultures with Salubrinal, 
which inhibits ER stress, rescues KD motoneurons both under basal conditions and in 
the presence of TG.  
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Figure 4.12: Expression of Caspase 12 remains elevated in KD spinal cords 
throughout disease progression 
Transverse sections (10 M) of spinal cords from WT and KD mice at 3 months (pre-
symptomatic), 12 months (symptom onset) and 18 months (end-stage) of age were 
immunostained for -III tubulin (green), Caspase 12 (red) and stained with DAPI (blue). 
Example images are shown in A).  Caspase 12 immunoreactivity (red) appears to be 
higher in KD motoneurons than in WT controls at 3 and 12 months of age although 
there appears to be no detectable difference at 18 months of age. (Scale bars = 25 
m). 
Western blot analysis was carried out to determine expression levels of Caspase 12 in 
WT and KD spinal cords. Spinal cord homogenates were prepared from WT and KD 
mice at P5 (first signs of ER stress in ALS), 3, 12 and 18 months of age. A typical blot 
is shown in B). The blot shows that the level of Caspase 12 expression is higher in KD 
spinal cords than WT controls at P5 and 3 months of age, but there is no clear 
difference at 12 or 18 months of age. Quantification of the blot was achieved by 
expressing the optical density of the Caspase 12 band relative to the optical density of 
the corresponding Actin band, which was given a value of 1.0. The results are 
summarized in the Bar Chart (C), which shows the average values based on mean 
data from three different spinal cords. The results show that the relative level of 
Caspase 12 expression is higher in KD spinal cords than in WT controls at P5, 3 
months and 18 months (p< 0.05, 0.05 and 0.01, respectively) but not at 12 months of 
age. The blot was repeated twice on each set of samples. Error bars show the 
standard error of mean. 
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Figure 4.12 
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When a Ca2+-independent ER stressor, Tunicamycin (TM), is applied to primary 
motoneuron cultures, there is no additional motoneuron death in KD cultures, 
highlighting the specific vulnerability of KD motoneurons to ER Ca2+ depletion. 
When the expression of Caspase 12, a marker of ER stress-induced apoptosis, is 
examined in purified, primary WT and KD motoneurons, Caspase 12 expression in KD 
motoneurons is higher than in WT controls, indicating a higher level of ER stress-
induced apoptosis. Furthermore, treatment of primary motoneurons with Salubrinal, 
which decreases KD motoneuron death, also reduces Caspase 12 expression, so that 
there is only a negligible difference in Caspase 12 expression between WT and KD 
motoneurons. Salubrinal treatment also appears to increase ER Ca2+ in both WT and 
KD cultures.  
Finally, in KD spinal cord tissue, Caspase 12 expression remains higher than WT 
controls throughout disease progression. The peak elevation in Caspase 12 expression 
in KD spinal cord occurs pre-symptomatically, at P5, but remains significantly higher in 
KD spinal cord tissue at disease end-stage. 
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4.3. Discussion 
In this Chapter I investigated whether the ER stress that was observed in KD 
motoneurons in Chapter 3 was associated with an increased vulnerability of KD 
motoneurons to ER stress-induced apoptosis. The results presented in this Chapter 
show that ER stress-induced apoptosis does indeed occur in KD motoneurons both in 
vitro and in vivo, and can be prevented by treatment with ER stress inhibitors. 
4.3.1 Motoneuron death occurs in the AR100 model of Kennedy’s Disease. 
We have previously shown that motoneuron degeneration occurs in vivo in the AR100 
mouse model of KD (Malik et al, 2011). However, the first step in establishing whether 
or not ER stress-induced apoptosis plays a role in the pathology of the AR100 mouse 
model of KD at the embryonic stage is to determine whether or not motoneuron death 
is significantly higher in KD primary cultures than in WT controls. Analysis of 
motoneuron survival reveals that significantly fewer KD motoneurons survive than WT 
motoneurons even under basal conditions. This finding suggests that even during 
embryonic development, KD motoneurons are more vulnerable to cell death and are 
less able to withstand the process of culturing. There also appeared to be increased 
axonal clustering in KD cultures. Indeed, it has been shown previously that cells cluster 
in culture when axonal growth is inhibited (Kimura-Kuroda et al, 2010), which may 
suggest that the growth of embryonic KD motoneurons is impaired and thus the 
reduced survival of KD motoneurons could reflect impaired development. This would 
be consistent with the neurotrophic support deficit discussed in Chapter 1 (Section 3.3). 
4.3.2 The effects of treatment with an inhibitor of ER stress on KD motoneuron 
survival 
In order to correlate the presence of ER stress observed in KD motoneurons (Chapter 
3, Section 3.3.10) with an increased vulnerability to cell death, the effects of inhibition 
of ER stress on motoneuron survival was investigated, by treating the cultures with the 
ER stress inhibitor, Salubrinal. If motoneurons are rescued following the inhibition of 
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ER stress, it would indicate that ER stress is, at least in part, involved in the increased 
death of motoneurons observed in KD cultures. The results show that following 
Salubrinal treatment, motoneuron survival improved in both WT and KD cultures so 
that the number of motoneurons in WT and KD cultures was not significantly different. 
This finding has several implications. The first is that even in WT cultures, the culturing 
process induces a degree of ER stress since Salubrinal treatment increases 
motoneuron survival. The second implication is that ER stress plays a role in KD 
pathology and occurs in addition to ER stress associated with the culturing process, as 
motoneuron survival improved to a greater extent in KD cultures than in WT cultures. 
Indeed, treatment of KD cultures with Salubrinal significantly rescued KD motoneurons 
from cell death, so that there was no longer a difference in motoneuron survival 
between WT and KD cultures. These findings show that the inhibition of ER stress 
alone is enough to rescue the death of embryonic KD motoneurons, and suggests that 
triggers of apoptosis other than ER stress do not contribute to KD motoneuron death as 
much as ER stress does, at least during embryonic development. This finding, 
combined with the fact that ER stress is present in KD motoneurons even during 
embryonic development, strongly suggests that the occurrence of ER stress is an 
important trigger of disease pathology in KD. 
4.3.3 Vulnerability of KD motoneurons to ER stressors 
As well as being a trigger per se, the increased presence of ER stress in KD 
motoneurons may result in these cells being more vulnerable to ER stressors and not 
being able to restore ER homeostasis in response to further ER stress. In order to 
investigate this, the effects of the ER stressor, Thapsigargin (TG), on WT and KD 
motoneurons was examined. In both WT and KD cultures, motoneuron survival 
decreased following 24 hour treatment with 300 nM TG for 24 hours. However, the 
effects of treatment were more severe in KD cultures. This suggests that the ER stress 
that is present in KD motoneurons even under basal conditions increases their 
vulnerability to additional insults such as TG-induced ER Ca2+ depletion. Furthermore, 
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KD motoneurons appear to be more vulnerable to ER Ca2+ depletion than other causes 
of ER stress. When Tunicamycin (TM), which interferes with post-translational 
modification of proteins, was applied to WT and KD cultures for 24 hours there was no 
significant decrease in motoneuron survival in KD cultures. Indeed, at higher 
concentrations of TM, WT motoneurons seem to be affected to a greater extent than 
KD motoneurons. This may suggest that the normal site of action of TM (peptidoglycan 
synthesis) is affected in KD. Alternatively, it may be that the effects of TM are not as 
substantial in KD motoneurons because there is already a greater basal level of ER 
stress and apoptosis occurring and so the effects of TM are concealed by pre-existing 
pathology. 
4.3.4 Inhibition of ER stress reduces the vulnerability of KD motoneurons 
Treatment with Salubrinal, a pharmacological inhibitor of ER stress, reduced the 
vulnerability of KD motoneurons to ER Ca2+ depletion. Indeed, Salubrinal eliminated 
basal levels of ER stress and negated effects of TG, so that there was no difference 
between WT and KD motoneuron survival following Salubrinal treatment in the 
absence and presence of TG. Furthermore, motoneuron survival was still higher in KD 
cultures treated with both TG and SAL than in untreated cultures. This suggests that 
the inhibition of ER stress is very effective at preventing ER stress in KD motoneurons. 
4.3.5 ER stress-induced apoptosis in KD motoneurons 
In Chapter 3, ER Ca2+ depletion and ER stress were found to occur in motoneurons 
from the AR100 model of KD. The results presented in this Chapter established that 
this ER stress is associated with an increased vulnerability to motoneuron death. The 
increased death of KD motoneurons is likely to be downstream of ER stress, as 
inhibition of ER stress with Salubrinal improves motoneuron survival. The results 
presented in this Chapter also suggest that ER stress-induced apoptosis is a result of 
the ER Ca2+depletion observed in KD motoneurons in Chapter 3 (Section 3.3.4.2). 
Whilst TG treatment caused significant motoneuron death in KD motoneurons, 
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Tunicamycin, which causes ER stress independently of Ca2+, did not increase KD 
motoneuron death. In order to confirm that ER Ca2+depletion is a cause of ER stress 
and subsequent ER stress-induced apoptosis in KD motoneurons, the expression of 
Caspase 12, a mediator of ER stress-induced apoptosis, which is activated 
downstream of Ca2+release from the ER, was assessed both in embryonic KD 
motoneurons in vitro and in spinal cords of KD (AR100) mice at various stages of 
disease. Briefly, following the release of Ca2+from the ER, the protease Calpain is 
activated (Nakagawa et al, 2000) and cleaves Caspase 12. Caspase 12 then activates 
Caspase 3 and apoptosis ensues. Western blot analysis of Caspase 12 expression in 
WT and KD purified ventral motoneurons, showed that Caspase 12 levels were 
significantly higher in KD motoneurons than in WT controls. This suggests that 
Caspase 12 activation increases in KD motoneurons downstream of the ER Ca2+ 
depletion observed in KD motoneurons in Chapter 3 (Section 3.3.4.2). Furthermore, 
following treatment with Salubrinal, which increases motoneuron survival and ER Ca2+, 
Caspase 12 expression in both WT and KD motoneurons decreased. This finding 
suggests that Salubrinal increases ER Ca2+, despite acting at the level of the Unfolded 
Protein Response (UPR). This finding suggests that there is a two-way relationship 
between ER Ca2+ and ER stress i.e. they can be both a cause and a result of each 
other. This possibility will be discussed in more detail in Chapter 6.  
Taken together, the results presented in this Chapter show that treatment with 
Salubrinal increases ER Ca2+, decreases ER stress and decreases ER stress-induced 
apoptosis in KD cultures, thereby improving KD motoneuron survival. These findings 
suggest that motoneuron death in KD may occur as a result of a sequence of events at 
the ER. Thus ER Ca2+depletion leads to the activation of Caspase 12 and initiation of 
the UPR. This results in ER stress-induced apoptosis, due to a combination of 
Caspase 12 activation and pro-apoptotic proteins, which are expressed downstream of 
the UPR. If this proposal is correct, it suggests that prevention of ER Ca2+ depletion 
210 
 
may be an effective therapeutic target in the treatment of KD. This possibility will be 
discussed in more detail in Chapter 6. 
4.3.6 Caspase 12 expression in spinal cord of KD mice changes during disease 
progression 
In order to establish whether ER stress-induced apoptosis observed in KD embryonic 
motoneurons in vitro, was a feature of disease pathology in vivo, Caspase 12 
expression in spinal cord tissue from KD mice was assessed at various stages of 
disease. This analysis may also indicate if elevated levels of ER stress-induced 
apoptosis act exclusively as an initial disease trigger, or remain with disease 
progression. The results showed that at all stages of the disease, from E13 until end 
stage, Caspase 12 expression was elevated in KD motoneurons and spinal cords 
compared to WT, age-matched controls. As was the case with ER stress markers 
examined in Chapter 3 (Section 3.3.10), the peak increase in Caspase 12 expression 
occurred at P5, in keeping with the possibility that ER stress acts as an early disease 
trigger. However, unlike previous ER stress markers, Caspase 12 was significantly 
elevated in KD spinal cord tissue compared to WT tissue at disease end-stage and the 
smallest difference in Caspase 12 expression between WT and KD spinal cord tissue 
occurred at 12 months, at symptom onset. This implies that ER stress may have 
different roles in KD pathology, occurring at two different stages. There appears to be 
an initial/early stage that occurs during embryonic development and remains until 
approximately 3 months of age. ER stress at this pre-symptomatic stage could be an 
initial disease trigger and give rise to an underlying vulnerability in KD motoneurons.  
The second occurrence of ER stress-induced apoptosis however, could be a 
combination of KD motoneuron vulnerability together with the effects of aging. Aging 
alone is not sufficient to cause ER stress-induced apoptosis since the level of Caspase 
12 in WT spinal cord tissue does not change as dramatically with age as it does in KD 
spinal cord tissue. Therefore additional factors, caused by KD pathology must play a 
role in Caspase 12 elevation in KD motoneurons at end-stage. Thus, the AR mutation 
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associated with KD may cause early changes that have subsequent, long term, 
negative effects on the vulnerability of motoneurons to other factors that accumulate 
with age and which have been implicated in the pathogenesis of other 
neurodegenerative disorders. Such factors include mitochondrial dysfunction, impaired 
axonal transport and protein aggregation (Paradies et al, 2011, Tashiro & Komiya 
1994, Lindner and Demarez 2009). Mitochondrial dysfunction is strongly implicated in 
the process of aging. It has been suggested that reactive oxygen species (ROS), which 
are produced downstream of respiratory chain activity, have been shown to attack 
protein and lipid constituents of the mitochondrial membrane as well as mitochondrial 
DNA (Pak et al, 2003). With age, ROS-associated mitochondrial mutations are 
suggested to increase, resulting in impairment in respiratory chain function and a 
consequential increase in ROS production and mitochondrial DNA mutations (Larsson 
et al, 2010). This has been shown to occur during the aging process in various tissue 
types including the brain and skeletal muscle (Larsson 2010). An underlying 
pathological mechanism such as ER stress could render motoneurons more vulnerable 
to this natural phenomenon of aging. 
Impairments in axonal transport have also been shown to occur with age (Tahsiro & 
Komiya 1994). For example, a longitudinal study of the rat sciatic nerve revealed that 
as rats aged, the rate of slow axonal transport decreased and the proteolysis of 
retarded proteins, particularly neurofilament proteins, was found to accelerate (Tashiro 
& Komiya 1994). In another set of experiments the expression of Dynein, which is an 
essential motor protein involved in axonal transport (Carter et al, 2011), was found to 
decrease over time in neuroblastoma cells and result in the accumulation of Tau 
(Kimura et al, 2007). The impairment of axonal transport can result in other 
pathological features of aging such as protein aggregation (Lindner and Demarez 
2009). Such protein aggregation would increase the demand on the ER and thus the 
presence of ER stress could result in vulnerability to causes of protein aggregation, 
such as axonal transport impairment. 
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As well as factors that accumulate with age, the early occurrence of ER stress may 
also affect the vulnerability of KD motoneurons to factors that occur downstream of the 
Androgen Receptor (AR) mutation. For example, nuclear inclusions of the AR, which 
have been found to occur in KD but are not necessarily associated with pathology 
(Adachi et al, 2007), could also result in degeneration of motoneurons. Nuclear 
inclusions have been found to occur in KD, but are not restricted to cell types that are 
affected by the disease (Adachi et al, 2007). It could therefore be the case that only cell 
types with an underlying vulnerability are affected by the presence of nuclear 
inclusions. Such vulnerability could be triggered by ER stress. Therefore, as well as 
acting as an initial disease trigger, ER stress may also serve as a mechanism by which 
motoneurons are rendered more vulnerable to deleterious age-related factors as the 
disease progresses. 
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CHAPTER 5: RESULTS 3 – MITOCHONDRIAL 
DYSFUNCTION IN KD MOTONEURONS 
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5.1. Introduction 
In Chapters 3 and 4, the presence of ER Ca2+ depletion, ER stress and ER stress-
induced apoptosis in primary KD motoneurons was confirmed, suggesting that ER 
stress makes a contribution to motoneuron degeneration associated with Kennedy’s 
Disease. Changes in the ER such as ER Ca2+ depletion have been shown previously to 
have downstream effects on mitochondrial function (Romagnoli et al, 2008). In this 
Chapter, mitochondrial function and biogenesis in primary KD motoneurons are 
therefore investigated in order to determine downstream effects of ER stress in KD as 
well as the role of mitochondrial dysfunction per se. 
5.1 Mitochondrial structure & function 
5.1.1.1 Structure 
Mitochondria are dynamic organelles that are constantly being transported around the 
cell, changing in size, shape and number (Hollenbeck et al, 2005).  Depending on the 
cell type they can appear as spheres, rod-like structures or filamentous bodies (Krauss 
et al, 2001). Their general function in all cells is to produce energy via the electron 
transport chain (ETC) and to play an essential role in programmed cell death (Krauss 
et al, 2001). Mitochondria also have several other cell-specific functions including; 
steroid synthesis, neuronal signalling, membrane potential regulation, monitoring cell 
differentiation and building and breaking down products (Krauss et al, 2001), some of 
which will be discussed in more detail below 
The hallmark structure of mitochondria, which was first identified in the 1950s using 
electron microscopy (Palade 1953) is depicted in Figure 5.1. The outer membrane 
consists of a phospholipid bilayer that contains protein structures referred to as Porins. 
Porins are permeable to molecules that are less than or equal to 10 kDa in size, which 
is the maximum size of ions, adenosine triphosphate (ATP), adenosine diphosphate 
(ADP) and nutrient molecules (Schirmer et al, 1998). The protein-to-lipid ratio of the 
outer membrane is approximately 50:50 (Krauss 2001). The inner membrane however 
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has a protein-to-lipid ratio of approximately 80:20 (Krauss 2001). It consists of folds 
that convolute into the mitochondrial matrix and are referred to as cristae. These 
cristae increase the membrane surface area and are permeable to O2, CO2 and H2O 
only (Mannella 2006). 
The inner membrane acts as an electrical insulator and chemical barrier and is the site 
of the ETC and ATP synthetase (Krauss et al, 2001). The ETC is a group of complexes 
at which separate redox reactions occur. It couples the transfer of electrons between 
electron donors (reduced Nicotinamide Adenine Dinucleotide - NADH) and acceptors 
(for example, O2) to the transfer of H+ ions across the mitochondrial membrane from 
the matrix into the mitochondrial intermembrane space. This creates a proton gradient 
that generates chemical energy in the form of ATP (Dimroth et al, 2000). 
The matrix, which is the internal space of mitochondria, contains a mixture of different 
enzymes such as those involved in the synthesis of ATP as well as mitochondrial 
ribosomes, tRNAs and mitochondrial DNA (Krauss et al, 2001).  Enzymes in the 
mitochondrial matrix are also major components of pathways required for 
carbohydrate, lipid and amino acid oxidation as well as urea and haem biosynthesis 
(Krauss 2001). 
5.1.1.2 Function 
Mitochondria have a wide variety of functions contributing to normal cell function and 
death. A major function of mitochondria is energy conversion, which is achieved via 
several processes occurring in the mitochondrial inner membrane and matrix. 
One of these processes is the coupling of aerobic respiration to the production of ATP - 
the vital energy unit of cells (Knowles 1980). H+ ions are generated as a product of 
oxidative reactions in ETC complexes in the mitochondrial inner membrane (Dimroth et 
al, 2000). 
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Figure 5.1 Hallmark mitochondrial structure  
In general terms mitochondria consist of a double phospholipid membrane (outer and 
inner) enclosing a matrix that contains mitochondrial DNA as well as enzymes involved 
in various essential processes such as ATP synthesis and carbohydrate, lipid and 
amino acid oxidation. The inner membrane contains protein complexes that form the 
electron transport chain (ETC) and convolutes into the matrix, forming cristae that 
increase the membrane surface area. 
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The release of H+ ions into the mitochondrial intermembrane space creates an H+ 
electrochemical gradient, which drives the return of H+ ions into the mitochondrial 
matrix (Dimroth et al, 2000). This transportation of H+ into the matrix occurs via 
ATPsynthetase, which uses the potential energy of the transport to synthesize ATP 
(Dimroth et al, 2000). In addition to aerobic respiration, mitochondria utilize other 
processes to produce energy. For example, pyruvate, which is a product of glycolysis, 
is transported into the mitochondrial matrix where it is then oxidized by the pyruvate 
dehydrogenase complex and combined with Co-enzyme A (CoA) to produce CO2, 
acetyl CoA and NADH (Reed 2001). Acetyl-CoA is the primary substrate for the Citric 
Acid Cycle in the matrix, which generates electrons for the ETC as well as GTP, which 
is readily converted into ATP by nucleoside diphospho-kinase (Weiland et al, 1991). 
Thus mitochondria have a vital role in the conversion of metabolic by-products into 
units of energy. 
As well as energy conversion, mitochondria also have an important role in the 
regulation of cellular Ca2+ signalling. Mitochondria act as a Ca2+ buffer when the 
intracellular Ca2+ concentration exceeds 1 M (Krauss et al, 2001). Ca2+ enters 
mitochondria through a uniporter, whilst Ca2+ efflux from the mitochondria is regulated 
by an electroneutral antiport with either H+ or Na+, depending on the cell type (Krauss 
et al, 2001). Under stable conditions, both of these Ca2+ transporters have a low level 
of activity and act together to produce a balanced mitochondrial Ca2+ cycle (Saris 
2005). In the event that the level of cytosolic Ca2+ increases, the uniporter becomes 
more active and the uptake of Ca2+ into the mitochondrial matrix exceeds the expulsion 
of Ca2+, resulting in a net uptake of Ca2+ (Saris 2005). An increase in Ca2+ in 
mitochondria has several effects. For example, the permeability transition pore is 
activated, followed by a decrease in mitochondrial membrane potential, resulting in 
transient stimulation of the proton pumping respiratory chain (Huser & Davies 2007). 
This process is known as the uncoupling effect and causes an increase in pH in the 
matrix. As well as being detrimental to mitochondrial function, Ca2+ is also essential for 
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various mitochondrial enzymes such as pyruvate dehydrogenase phosphatase (Behal 
et al, 1993) and isocitrate dehydrogenase (Denton 2009), thus the uptake of Ca2+ has 
both extra-mitochondrial and intra-mitochondrial effects. 
Since mitochondria act as Ca2+ buffers, they also play a vital role in the synchronicity of 
neuronal signalling (Talbot et al, 2003).  Indeed, the inhibition of mitochondrial Ca2+ 
uptake and subsequent mitochondrial membrane depolarization in motoneurons, 
results in an increase in asynchronous neurotransmitter release during low frequency 
stimulation. This occurs in parallel with a greater increase in intracellular Ca2+ 
concentration (Talbot et al, 2003). These results suggest that mitochondria are 
therefore also able to sequester Ca2+ in order to prevent asynchronous 
neurotransmitter release. 
Mitochondria also have an essential role in apoptosis as well as processes that are 
required for cell survival. Mitochondrial permeablization and the consequential release 
of pro-apoptotic factors have been shown to precede or accompany the execution of 
apoptosis (Gulbins et al, 2003). The increase in mitochondrial permeability is caused 
by the opening of the mitochondrial permeability transition pore (PTP), which is a 
protein complex in the mitochondrial membranes (Gulbins et al, 2003). The PTP 
consists of a voltage-dependent anion channel (VDAC) and an adenine nucleotide 
translocase (ANT) in the inner mitochondrial membrane (Zamzani & Kroemer 2001). It 
has been suggested that following pro-apoptotic stimuli, B-cell CLL/lymphoma 2 (Bcl-2) 
proteins, such as Bcl2-associated X protein (Bax), interact with the VDAC and ANT, 
resulting in the formation of a large pore that allows mitochondrial pro-apoptotic 
proteins, such as Cytochrome C, to be released into the cytoplasm (Narita et al, 1998). 
Conversely, anti-apoptotic signals prevent opening of the pore and thus prevent the 
release of pro-apoptotic proteins (Marzo et al, 1998). Once pro-apoptotic proteins are 
released into the cytosol they initiate apoptosis, block anti-apoptotic proteins and 
cleave nuclear DNA (Gulbins et al, 2003). As well as the release of proteins, opening of 
the PTP also results in the influx of ions and water into the mitochondria, which results 
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in the swelling and eventual rupturing of mitochondria that is associated with apoptosis 
(Van der Heiden et al, 1997). The release of pro-apoptotic proteins from the 
mitochondria as well as interactions with regulatory proteins such as Bcl-2, place the 
mitochondria in a prime position to regulate apoptosis. As well as the removal of 
physiologically unwanted cells, apoptosis also plays a vital role in development (Naruse 
& Keino 1995). Thus mitochondrial regulation of apoptosis is also a vital component of 
embryonic development. 
As well as general functions, mitochondria also have functions that are cell - or tissue-
specific. In brown adipose tissue for example, mitochondria produce heat, which is an 
essential event in thermogenesis (Mozo et al, 2005). Mitochondria are able to produce 
heat due to the fact that H+ has a pathway through which it can enter the matrix 
without resulting in the production of ATP (Mozo et al, 2005). This is known as a proton 
‘leak’ or mitochondrial uncoupling and the unharnessed potential energy that is created 
by this process is released as heat. This H+ - facilitated diffusion pathway is mediated 
by a proton channel called Thermogenin, or UCP1 (Mozo et al, 2005). UCP1 is 
expressed primarily in brown adipose tissue (Ricquier & Bouillaud 2000), which is why 
this heat-producing function is specific to this tissue type.  
Mitochondria also have a tissue-specific role in steroid synthesis in the adrenal cortex. 
The synthesis of steroids requires the activation of various oxidative enzymes located 
in the mitochondria and ER in cells that constitute the adrenal cortex (Chung et al, 
1997). In the mitochondria, Cytochrome P450 Cholesterol side chain cleavage enzyme 
(CYP11A1) converts cholesterol into pregnenolone, which is then processed further in 
the ER (Hall 1985). 
5.1.2 Mitochondrial biogenesis 
In general terms, mitochondrial biogenesis is the process by which mitochondrial 
content, turnover and number are regulated in order to maintain homeostatic demands. 
The process requires communication between the nuclear genome and the 
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mitochondrial genome as mitochondrial proteins are encoded by both genomes (for 
review see Hock & Kralli 2009). Such ‘inter-genome’ communication is carried out by 
various proteins including Nuclear Respiratory Factors (NRF) 1 and 2, cyclic-AMP 
response element binding protein (CREB) and Transcription Factor A of Mitochondria 
(TFAM). These proteins regulate transcription of essential mitochondrial proteins that 
are encoded by genes in the nuclear genome, such as those that comprise the electron 
transport chain (ETC), (Herzig et al, 2000, Li et al, 1999, Scarpulla 2002). Upstream of 
these regulatory proteins is the transcriptional co-activator; Peroxisome Proliferator-
activated receptor  co-activator 1, or PGC1, which will be used as an indicator of 
mitochondrial biogenesis in this Chapter (for review see Ventura-Clapier 2008). 
5.1.2.1 PGC1 
There are three PGC1 isoforms, namely  and  however PGC1 will be the focus 
of this Chapter as it has been frequently associated with health and disease (Frink & 
Kelly 2006). The PGC1 gene is located on chromosome 5 in mice and chromosome 4 
in humans (Puigserver et al, 1998). The murine gene encodes a protein that is 797 
amino acids in length and is located within the nucleus (Puigserver et al, 1998). PGC1 
is highly expressed in tissues that have a high demand for oxidative metabolism, such 
as skeletal and cardiac smooth muscle (Puigserver et al, 1998). However, relatively 
high levels of PGC1 are also found in the central nervous system (Puigserver et al, 
1998). 
5.1.2.2 Regulation of PGC1 expression and activity 
A large number of signalling pathways have been found to regulate the expression and 
activity of PGC1 (for review see Ventura-Clapier et al, 2008). Ca2+ and other second 
messengers for example, have been found to exert transcriptional control over the 
PGC1 gene. For example, in skeletal muscle a prolonged period of contraction results 
in a prolonged elevation of cytosolic Ca2+, which activates the Ca2+-dependent 
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phosphatase, Calcineurin (CaN) as well as the Ca2+-calmodulin-dependent kinase 
CaMK (Heineke & Molkentin 2006). CaN has been shown to control the expression of 
PGC1in muscle (Handschin et al, 2003). CaN-mediated activation of the PGC1 
promoter is dependent on Myocyte Enhancer Factor 2 (MEF2) as well as Histone 
Deacetylases (HDAC). Resistance to HDAC in mice has been shown to result in a 
decrease in the number of mitochondria (Czubryt et al, 2003), whilst deletion of MEF2 
in mice is also accompanied by a reduction in mitochondrial number (Naya et al, 2002). 
These results indicate that CaN and MEF2 play a major role in the regulation of 
PGC1 However they are not sufficient to regulate the expression of PGC1 as their 
disruption does not completely eliminate PGC1 expression. As described above, 
prolonged Ca2+ elevation also results in the activation of CaMK. CaMK activation 
requires the presence of cAMP response element binding protein (CREB), which has 
also been suggested to regulate the expression of PGC1 (Wu et al, 2006). For 
example, a strong positive correlation between CREB activation, PGC1 expression 
and mitochondrial protein content has been observed in murine cardiac tissue (Wu et 
al, 2006, Watson et al, 2007). 
As well as Ca2+, other second messengers such as those involved in the p38 mitogen-
activated protein kinase (MAPK) pathway have also been suggested to regulate 
PGC1 expression. However, unlike the downstream effects of elevated Ca2+, MAPK 
activation has been suggested to have a negative regulatory effect over PGC1 
transcription (Wall et al, 2006). Indeed, the overexpression of the MAPK upstream 
Kinase 6 (MKK6) is accompanied by a reduction in oxidative respiration, which is 
indicative of compromised mitochondrial function and/or number (Wall et al, 2006). 
In addition to second messenger regulation, PGC1 transcription has also been 
suggested to be controlled indirectly by thyroid hormones (Wrutniak-Cabello et al, 
2001). The precise effect that thyroid hormones have on PGC1 expression however 
remains unclear. In some cases, the treatment of rats with thyroid hormone appears to 
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result in increased cardiac oxygen consumption and elevated PGC1 expression 
(Goldenthal et al, 2004). However other studies report that thyroid hormone treatment 
has no effect on the level of PGC1 expression (Irrcher et al, 2003). 
Cyclin-dependent kinases (CDKs), which are involved in the cell cycle, have also been 
found to regulate PGC1 transcription (for review see Ventura-Clapier et al, 2008). 
Gene expression profiling studies have shown that CDK9 (a RNA polymerase kinase) 
for example, decreases the expression of PGC1 and some of its downstream 
effectors (Sano et al, 2004). 
As well as transcriptional regulation, PGC1 is also subject to post-translational 
modification, which alters its activity. There are various forms of post-translational 
modification. For example, PGC1 has been shown to undergo p38MAPK-induced 
phosphorylation, which is thought to be a mechanism by which the effects of cytokines 
are regulated (Knutti et al, 2001). The activity of PGC1 has also been suggested to be 
positively regulated by deacetylation, which is catalysed by the NAD+-dependent 
SIRT1 deacetylase (Rodgers et al, 2005). The third post-translational modification that 
is thought to regulate PGC1 activity is arginine methylation, which is catalysed by the 
protein arginine methyl transferase-1, or PRMT1 (Teyssier et al, 2005). This proposed 
mechanism of modification has been supported by the fact that mutations of arginine 
residues in the c-terminal of the PGC1 protein result in reduced expression of various 
PGC1 target genes (Teyssier et al, 2005). 
Thus PGC1 regulation is both complex and varied, making its level of expression and 
activity vulnerable to a wide range of pathological mechanisms. 
5.1.3 Pharmacological manipulation of mitochondrial biogenesis 
In order to establish the role that disturbances in mitochondrial biogenesis have in 
neurodegenerative disease pathology, the effects of pharmacological induction of 
biogenesis have been examined. There are various drugs that can be used to induce 
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biogenesis, including Resveratrol and Bezafibrate, which are used in the experiments 
described in this Chapter.  
5.1.3.1 Resveratrol 
Resveratrol is a naturally occurring polyphenol that is found in red wine, peanuts and 
grapes (Sanders et al, 2000, Siemann et al, 1992). It has been shown to increase 
levels of PGC1 thereby increasing mitochondrial biogenesis (Lagouge et al, 2006). 
Resveratrol has therefore often been considered as a potentially useful therapeutic tool 
for neurodegenerative disorders in which mitochondrial biogenesis is impaired (see 
below Section 5.1.3.2). One of the suggested mechanisms by which Resveratrol is able 
to increase the activity of PGC1 is via its interaction with the protein Silent Mating 
Type Information Regulation 2 Homolog 1, or  SIRT1 (Lagouge et al, 2006). Under 
normal circumstances SIRT1 physically interacts with and deacetylates PGC1 and 
multiple lysine sites, which results in an increase in PGC1 activity (Rodgers et al, 
2005). Resveratrol is thought to increase SIRT1 activity (Borra et al, 2005) and in doing 
so is also thought to increase the deacetylation and hence activity of PGC1.  However 
this finding is controversial in light of recent evidence, which suggests that Resveratrol 
may not affect SIRT1 activity (Pacholec et al 2010). Indeed, when the level of native 
SIRT1 substrates such as p53 were measured using ELISA and Western Blot analysis, 
the level of SIRT1 activity appeared to be unaffected by the presence of Resveratrol 
(Pacholec et al 2010). Interestingly, Reseveratrol did increase the levels of fluophore-
tagged substrates, which explains previous findings (Pacholec et al 2010). 
Resveratrol has also been found to increase the expression of PGC1 (Bastin et al, 
2011). In human fibroblasts for example, exposure to 75 M Resveratrol results in a 
significant increase in PGC1 expression, compared to fibroblasts treated with a 
vehicle drug, as revealed by Western blot analysis (Bastin et al, 2011).  
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However, the effects of Resveratrol appear to vary substantially, with studies reporting 
both protective and toxic effects of the drug. For example, treatment of obese and 
insulin-resistant mice with Resveratrol results in increased mitochondrial biogenesis 
and appears to protect mice against the metabolic disease (Lagouge et al, 2006). In 
another study, Resveratrol treatment appears to protect neurons and improve 
functional recovery in a rat model of spinal cord injury (Liu et al, 2010). However, in 
some studies, Resveratrol treatment results in apoptosis. For example, when a 
hormone-sensitive prostate cancer cell line is treated with Resveratrol, viability is 
reduced and cells appear to have apoptotic morphology (Morris et al, 2002). The effect 
of Resveratrol on KD motoneurons is therefore difficult to predict. Whilst neuronal cells 
appear to benefit from Resveratrol treatment, treatment of cells in which the Androgen 
Receptor is affected, may be detrimental to survival. 
5.1.3.2 Bezafibrate 
Another pharmacological agent that has been previously used to induce mitochondrial 
biogenesis is Bezafibrate. Bezafibrate (2-[4-[2-(4-chlorobenzamido)ethyl]phenoxy]-2-
methylpropanoic acid) is a synthetic ligand for peroxisome proliferator-activated -
receptors (PPARs) that is commonly used for the treatment of hyperlipidaemia, since it 
can  lower levels of low-density lipoproteins (LDLs) and triglycerides, whilst increasing 
high-density lipoproteins (HDLs) in the blood (Goldenberg et al, 2008). Like 
Resveratrol, Bezafibrate has been shown to increase PGC1 activity (Goldenberg et 
al, 2008). The increase in activity occurs as a result of PPAR activation, which 
increases deacetylation of PGC1 (for review see Goldenberg et al, 2008). The effect 
of Bezafibrate exposure on PGC1 expression levels is currently unclear. 
5.1.4 Mitochondrial dysfunction and Neurodegenerative Diseases 
Mitochondrial dysfunction has been found to play a role in the pathogenesis of various 
neurodegenerative disorders such as Motor Neuron Diseases (MNDs) and Poly-CAG 
repeat Disorders (Afifi et al, 1966, Browne 2008). Since KD is both an MND and Poly-
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CAG repeat disorder, it can therefore be suggested that mitochondrial dysfunction is 
also likely to occur in KD. 
 
5.1.4.1 Mitochondrial dysfunction in Motor Neurone Diseases (MNDs) 
Mitochondrial dysfunction has been suggested to play a role in the pathogenesis of 
MNDs such as Amyotrophic Lateral Sclerosis (ALS). The first indications of 
mitochondrial disruption in ALS came from post-mortem skeletal muscle tissue of 
sporadic ALS (sALS) patients in the 1960s (Afifi et al, 1966). These autopsies revealed 
subsarcolemmal aggregations of mitochondria in both skeletal muscle and 
intramuscular nerves, which are not present in healthy individuals (Afifi et al, 1966, 
Atsumi et al, 1981). Mitochondrial morphological abnormalities were also later 
observed in anterior horn post-mortem samples from sALS patients (Sasaki & Iwata 
1996). 
Consistent with the presence of abnormal morphology, evidence suggests that 
mitochondrial function appears to be disrupted in ALS. Abnormalities in respiratory 
function for example, have been implicated by mitochondrial DNA (mtDNA) frame-shift 
mutations that decrease the activity of complexes I and IV of the mitochondrial 
respiratory chain in the spinal cord and skeletal muscle of sALS patients (Wiedemann 
et al, 2000). Although this strongly suggests that changes in ETC complex activities 
play a role in ALS pathology, it does not confirm whether or not mitochondrial 
dysfunction is a disease trigger or a secondary effect of other pathological 
mechanisms. In order to establish the time point at which mitochondrial dysfunction 
occurs, cell lines and mouse models of ALS, which over-express a mutant SOD1 G93A 
protein (SOD1G93A) have been investigated. Several studies have found that not only is 
the expression of SOD1G93A associated with morphological changes in mitochondria, 
but also with the disruption of mitochondrial function. For example, in neuroblastoma 
cells transfected with SOD1G93A cytosolic Ca2+ levels are increased, which could be 
indicative of disrupted mitochondrial Ca2+ buffering, and mitochondrial depolarization, 
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which is an indicator of increased mitochondrial membrane permeability (Carri et al, 
1997). This finding has been replicated in the SOD1G93A model of ALS (Bilsland et al, 
2008) and thus is a consistent effect of the over-expression of SOD1G93A. 
In keeping with findings from patient post-mortem tissue, reductions in ETC complex 
activity have also been found in SOD1G93A mice. The magnitude of the reduction in 
complex activity also appears to increase with disease progression (Jung et al, 2002, 
Mattiazzi et al, 2002). This decrease in activity of the ETC results in an impairment in 
mitochondrial Ca2+ loading and a sustained decreased capacity to consume oxygen 
and synthesize ATP (Mattiazzi et al, 2002). Importantly, these defects appear in 
SOD1G93A mice pre-symptomatically, indicating that mitochondrial dysfunction has an 
early and therefore potentially causal role in ALS pathogenesis. 
As well as functional impairment, mitochondrial biogenesis is also likely to be disrupted 
in ALS. Although the levels of PGC1 expression and activity have yet to be 
extensively studied in ALS pathology, the various mechanisms of PGC1 regulation, 
such as Ca2+ signalling in skeletal muscle (Handschin et al, 2003) have been found to 
be affected in ALS (for review see Appel 2011) 
The mechanism by which expression of mutant SOD1 results in mitochondrial 
dysfunction has yet to be fully established. However several theories have been 
proposed based on the fact that SOD1 is localized to the mitochondria (Higgins et al, 
2002). Under normal circumstances, SOD1 is thought to localize to the mitochondrial 
intermembrane space (Mattiazzi et al, 2002). Mutant SOD1 is thought to remain 
localized to the mitochondrial matrix where it forms large aggregates (Vijayvergiya et 
al, 2005). One of the suggested mechanisms by which mSOD1 aggregates result in 
mitochondrial abnormalities is based on observations made during early stages of 
mitochondrial vacuolization is ALS. Mutant SOD1 fragments have been observed 
within the vacuoles and peroxisomes appear to fuse with these vacuolated 
mitochondria, which are thought to result in expansion of the mitochondrial outer 
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membrane (Higgins et al, 2003).  A possible outcome of this event is that mitochondria 
become porous and allow Cytochrome C and other pro-apoptotic proteins to leak out of 
the mitochondria and into the cytosol (Higgins et al, 2003).  Alternatively, it has been 
suggested that mSOD1 accumulates progressively on the outer membrane of the 
mitochondria and results in ‘blockage’ of the mitochondrial translational machinery, 
leading to mitochondrial dysfunction (Liu et al, 2004). This theory remains controversial 
however, since Wild-Type SOD1 also appears to localize to mitochondria as part of its 
normal function (Higgins et al, 2002). 
5.1.4.2 Mitochondrial dysfunction in CAG-repeat disorders 
The first indications that mitochondrial and energetic impairment are present in 
Huntington’s Disease (HD) have come from the significant weight loss observed in HD 
patients despite a maintained caloric intake (for review see Browne 2008). Indeed, PET 
scans of these patients reveal that there is pre-symptomatic decrease in glucose 
utilization, which is suggestive of mitochondrial disturbances (Browne 2008).  
Extensive studies have revealed that there are indeed several aspects of mitochondrial 
function that are disturbed in HD. For example, post-mortem striatum samples from HD 
patients in advanced stages of the disease reveal that complexes II, III and IV of the 
respiratory chain have a lower level of in vitro activity compared to healthy controls (Gu 
et al, 1996, Browne et al, 1997). This decrease in activity however is not replicated in 
samples of striatum (which is affected in HD) from pre-symptomatic patients, 
suggesting that respiratory chain impairment is not a trigger of HD (Guidetti et al, 
2001). Indeed, there appears to be no difference in levels of activity of these 
complexes in mice expressing the full length mutant Huntingtin protein or in primary 
motoneurons from HD mice in vitro (Guidetti et al, 2001, Oliveria et al, 2007). The 
disturbance of complex activity only appears to emerge when primary neurons are 
challenged with Ca2+-induced stress indicating that respiratory chain disturbances 
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could give rise to an underlying vulnerability as opposed to directly triggering HD 
(Oliveria et al, 2007). 
Mitochondrial Ca2+ handling has also been suggested to be affected in HD. For 
example, in striatal neurons from HD rats there appears to be a susceptibility to cellular 
Ca2+ loads that is indicative of diminished mitochondrial Ca2+ buffering capacity (Panov 
et al, 1999). Furthermore, the extent of this susceptibility appears to increase with an 
increasing number of Huntingtin CAG repeats, which is positively correlated with 
symptom severity (Panov et al, 1999). 
Another function of mitochondria that is disturbed in HD is ATP production. However, 
the role of changes in ATP production in HD is controversial, with both increases and 
decreases being reported. For example, in synaptossomal fractions from the HdH150 
mouse model of HD, ATP levels are lower than in WT controls (Orr et al, 2008). 
However, this decrease has been explained by disturbances in mitochondrial trafficking 
as opposed to disruption of ATP synthesis per se (Orr et al, 2008). In contrast, ATP 
levels are higher in the N171-82Q model of HD, which is likely to be due to a higher 
level of glycolysis that is observed in this model (Olah et al, 2008). Therefore the exact 
effect of the CAG-repeat mutation on ATP production in mitochondria remains unclear. 
The mechanism by which the CAG expansion in the Huntingtin gene can disrupt 
mitochondrial function has yet to be determined however several proposals have been 
made that include both direct and indirect effects of the mutation on mitochondria. 
Evidence for a direct effect includes the fact that the mutant Huntingtin protein 
physically associates with mitochondria (Panov et al, 2002). The site of association is 
not clear however, with some groups reporting association of the protein with the outer 
membrane of mitochondria (Choo et al, 2004), whilst other groups report the presence 
of mutant Huntingtin fragments inside the mitochondria (Yu et al, 2003). A key process 
that is thought to be affected downstream of this interaction is mitochondrial trafficking 
(Trushina et al, 2004). It has been suggested that the presence of mutant Huntingtin 
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aggregates physically blocks the mitochondrial trafficking pathway (Chang et al, 2006). 
Alternatively, the aggregates have been proposed to sequester the trafficking 
machinery that is required for the normal trafficking of mitochondria (Trushina et al, 
2004). Consequences of impaired mitochondrial trafficking include a disruption of 
cellular ATP supply, which is of particular significance in long neuronal cells, which 
require high amounts of energy to traffic cargo over long distances (Wang et al, 2008).  
As well as mitochondrial function being disrupted, mitochondrial number also appears 
to decrease in HD, suggesting that mitochondrial biogenesis is also impaired (McGill & 
Beal 2006). Indeed in the N171-82Q mouse model of HD, there is reduced PGC1 
expression in the striatum compared to WT control mice (Weydt et al, 2006). 
Furthermore, in HD patient post-mortem brain tissue, microarray expression analysis 
reveals that the expression of 24 out of 26 PGC1 target genes are reduced (Weydt et 
al, 2006). PGC1 activity has also been found to be reduced in muscle tissue from HD 
mice and myoblasts from HD patients (Chaturvedi et al, 2009). Furthermore, 
adenoviral-mediated delivery of PGC1 to murine muscle tissue increased expression 
of oxidative muscle fibre markers and heightened b-guanidinopropionic acid (GPA – a 
catabolic stressor) – induced responses (Chaturvedi et al, 2009).  Thus the interference 
of PGC1 expression and activity could play a pivotal role in HD pathology. 
5.1.5 Mitochondrial dysfunction in Kennedy’s Disease 
In view of the involvement of mitochondrial disturbances in MNDs and CAG-repeat 
disorders, it is not surprising that mitochondrial dysfunction has also been suggested to 
contribute to KD pathogenesis. At present however, the vast majority of evidence for 
the involvement of mitochondrial dysfunction in KD pathology has been obtained from 
in vitro experiments from the use of mutant AR-transfected cell lines as opposed to 
transgenic models and patient spinal cord biopsy tissue. In the motoneuron-derived cell 
line MN-1 for example, the expression of a mutant AR protein containing 65 CAG 
repeats results in mitochondrial membrane depolarization and decreases PGC1 
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expression (Ranganathan et al, 2009). Mitochondrial-dependent apoptosis was also 
found to accompany the mitochondrial dysfunction observed in these cells 
(Ranganathan et al, 2009). For instance, activation of the mitochondrial-dependent 
apoptotic pathway, which can be inferred by measuring levels of active Caspase 9, is 
elevated by approximately 50% in these cells  compared to control cells containing a 
AR protein with a normal number of CAG-repeats (Ranganathan et al, 2009). 
Furthermore, MN-1 cells containing the mutant AR protein appear to be protected by 
the application of the mitochondrial modulator; cyclosporine A, which prevents opening 
of the mitochondrial membrane transition pore, confirming further that mitochondrial 
dysfunction is a cause of apoptosis in these cells (Ranganathan et al, 2009). 
The experiments described in this Chapter will expand on the above findings and 
measure mitochondrial membrane potential and PGC1 expression in primary 
motoneurons from the AR100 model of KD. The effects of pharmacologically-induced 
increases in mitochondrial biogenesis on motoneuron survival will also be examined. 
This will allow the magnitude of the effect of inhibiting ER stress and increasing 
mitochondrial biogenesis on KD motoneurons to be compared and thus to establish 
which is more likely to form the basis of a successful therapeutic strategy. 
5.1.6 Hypothesis & Aims 
Since mitochondrial dysfunction has been shown to play a role in the pathogenesis of 
various neurodegenerative disorders and ER Ca2+ depletion has also been shown 
previously to jeopardize mitochondrial function (Romagnoli et al, 2008), mitochondrial 
dysfunction is likely to play a role in the pathogenesis of KD. 
In this Chapter, mitochondrial function and biogenesis in primary KD motoneurons will 
be investigated. In the event that mitochondrial biogenesis is impaired in primary KD 
motoneurons, the effect of pharmacological induction on primary KD motoneuron 
survival will be investigated in order to further establish the role of mitochondrial 
impairment in KD pathogenesis. 
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5.2. Results 
The possibility that mitochondrial dysfunction was a feature of KD pathology at early 
stages of disease progression was investigated by measuring mitochondrial membrane 
potential in embryonic primary KD motoneurons. 
5.2.1 TMRM reliably measures mitochondrial membrane potential 
In order to determine whether or not TMRM reliably measures mitochondrial membrane 
potential, 1 M carbonyl cyanide-trifluoromethoxyphenyl hydrazone (FCCP) is applied 
to cultures and the average mitochondrial fluorescence in motoneurons is measured 
(see Chapter 2, Section 2.6.7 for details). In untreated WT primary motoneurons the 
mean arbitrary TMRM fluorescence intensity is 1387.75 (+/- 83.2 SEM, n = 25). 
However in FCCP-treated WT primary motoneurons the average fluorescence intensity 
decreases by 80% (+/- 5.4% SEM, n = 15). This decrease is significant (p < 0.001) and 
is indicative of mitochondrial membrane depolarization (Figure 5.2B). 
5.2.2 The mitochondrial membrane potential is depolarised in primary KD 
motoneurons 
The mitochondrial membrane potential is depolarized in primary KD motoneurons 
compared to WT controls. Indeed confocal images reveal that TMRM fluorescence is 
stronger in WT primary motoneurons than in KD motoneurons (Figure 5.2A). When this 
fluorescence is quantified, the average TMRM fluorescence value in KD motoneurons 
is 36.1% lower (+/- 12% SEM, n = 26) than the average mitochondrial fluorescence in 
WT motoneurons, which is indicative of mitochondrial membrane depolarization. This is 
not as low as the fluorescence in FCCP-treated WT motoneurons, but is still 
significantly lower than the value for untreated WT motoneurons (p = 0.003). 
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Figure 5.2 Mitochondria are depolarized in KD ventral horn motoneurons 
compared to WT controls 
Primary WT and KD motoneuron cultures were imaged at 7 DIV. Cultures were  treated 
with 5 M DHT (final concentration 50 nM) at 4 DIV. Cultures were incubated at 37oC 
with TMRM, diluted in a 1 M Ca2+ recording medium, prior to imaging. After 30 
minutes of incubation, cultures were washed with, and subsequently imaged in, fresh 
TMRM-containing recording medium. Cultures were kept at 37oC throughout the 
protocol. Ai) and Aii) show example fluorescent images taken from the experiment. 
TMRM is shown in red. The Bar chart (B) summarizes TMRM fluorescence in DHT- 
treated WT and KD motoneuron cultures, as well as FCCP-treated WT cultures, which 
are a positive control for mitochondrial depolarization. Values are expressed relative to 
the average TMRM fluorescence in WT motoneurons (100.00).  
Error bars = standard error of mean, scale bars = 35 m 
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Figure 5.2 
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5.2.3 PGC1 expression is lower in primary KD motoneurons than in WT controls 
The expression of PGC1, an inducer of mitochondrial biogenesis, was examined in 
WT and KD cultures by immunohistochemistry and Western blot analysis. 
Mitochondrial biogenesis was investigated in KD motoneurons following previous 
findings that mitochondrial biogenesis is impaired in other MNDs and Poly-CAG repeat 
disorders (Handschin 2003, McGill & Beal) 
Immunostaining of WT and KD primary motoneuron cultures for PGC1 at 7 DIV 
reveals that PGC1 immunoreactivity is stronger in WT primary motoneurons than in 
KD motoneurons (Figure 5.3A). This suggests that PGC1 expression is higher in WT 
motoneurons.  
The level of expression of PGC1 was also quantified by Western blot analysis. A 
typical blot is shown in Figure 5.3B. 
Assessment of the optical density of the Western blot (Figure 5.3C) reveals that the 
level of PGC1 is 155% lower in KD primary motoneurons than in WT controls. In WT 
motoneurons, the PGC1 expression level relative to the loading control, Actin (1.0), is 
1.25 (+/- 0.06 SEM, n=3), whereas in KD motoneurons it is 0.49 (+/- 0.02 SEM, n=3).  
This reduction in PGC1 levels in KD motoneurons is significant (p= 0.034). 
5.2.4 The effects of pharmacological induction of mitochondrial biogenesis on 
PGC1 expression in KD primary motoneurons 
Since the results show that mitochondrial biogenesis is reduced in KD motoneurons, 
the effects of pharmacological induction of mitochondrial biogenesis, using Resveratrol, 
were investigated. 
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Figure 5.3 PGC1 expression in WT and KD ventral horn motoneurons 
WT and KD motoneuron cultures were immunostained for PGC1 (red) and co-stained 
for -III tubulin (green – a neuronal marker) and DAPI (blue, a nuclear marker). Images 
showing the typical patterns of PGC1 immunoreactivity in DHT-treated WT and KD 
motoneuron cultures are shown in Ai) and ii), respectively. Levels of PGC1 in WT and 
KD motoneuron cultures were also analysed by Western blot. A representative 
Western blot is shown in (B). Optical density analysis was performed and protein levels 
were expressed relative to the house-keeping protein, Actin, which was used as a 
loading control and given a value of 1.0. As shown in the bar chart (C), PGC1 
expression is significantly reduced in embryonic KD motoneurons compared to WT 
controls (p < 0.05).  
(Error Bars = standard error of mean, scale bars = 50 m) 
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Figure 5.3 
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The expression of PGC1, was examined in WT and KD cultures in the absence and 
presence of 50 M Resveratrol by immunohistochemistry and Western blot analysis.  
Immunohistochemistry reveals that following treatment of cultures with Resveratrol 
PGC1 immunoreactivity increases in KD motoneurons (Figure 5.4A) in contrast to WT 
motoneurons in which there is no noticeable change in PGC1 immunoreactivity 
following Resveratrol treatment.  
Levels of PGC1 after 50 M Resveratrol exposure were also examined by Western 
blot analysis. A typical blot is shown in Figure 5.4B. Assessment of the optical density 
of the Western blot (Figure 5.4C) reveals that the level of PGC1 is 15% lower in KD 
primary motoneurons than in WT controls compared to 155% lower in KD motoneurons 
that had not been exposed to Resveratrol (see Figure 5.3). In WT motoneurons, the 
PGC1 expression level relative to Actin (1.0) is 1.37 (+/- 0.08 SEM, n=3), whereas in 
KD motoneurons it is 1.165 (+/- 0.09 SEM, n=3). This difference is not significant. 
5.2.5 Pharmacological induction of mitochondrial biogenesis increases 
motoneuron survival in KD ventral horn cultures 
When motoneuron survival is calculated by expressing the number of -III tubulin 
positive cells with more than two processes as a percentage of total cell number (DAPI-
positive), the results show that treatment with Resveratrol increases motoneuron 
survival in both WT and KD cultures (Figure 5.5B). Following 24 hour Resveratrol 
exposure (50 M), the percentage of motoneurons in WT cultures increases from 
approximately 42% to 49.6 % (+/- 1.47% SEM, n =40), an increase of almost 8%. In KD 
cultures however, the percentage of motoneurons increases by approximately 19% 
following Resveratrol treatment to 47.9% (+/- 1.32% SEM, n = 40). This increase is 
significant (p=0.023). Following Resveratrol treatment there is no longer a significant 
difference in motoneuron survival between WT and KD cultures. 
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Figure 5.4 The effect of Resveratrol on PGC1 expression in WT and KD ventral 
horn cultures 
DHT-treated WT and KD motoneuron cultures were immunostained at 7 DIV for 
PGC1 (red) and co-stained for -III tubulin (green – a neuronal marker) and DAPI 
(blue, a nuclear marker). In some cases cultures were treated at 6 DIV with 
Resveratrol. Images showing the typical patterns of PGC1 immunoreactivity in the 
absence and presence of Resveratrol in WT and KD motoneuron cultures are shown in 
Ai) and ii), respectively. Levels of PGC1 in WT and KD motoneuron cultures in the 
absence and presence of resveratrol were also analysed by Western blot. A 
representative Western blot is shown in (B). Optical density analysis was performed 
and protein levels were expressed relative to the house-keeping protein, Actin, which 
was used as a loading control and given a value of 1.0. As shown in the Bar chart (C), 
PGC1 expression is significantly reduced in embryonic KD motoneurons compared to 
WT controls (p < 0.05) but there is no significant difference in expression following 
Resveratrol exposure.  
(Error Bars = standard error of mean, scale bars = 50 m) 
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Figure 5.4 
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Figure 5.5 The effect of Resveratrol on motoneuron survival in WT and KD 
ventral horn cultures 
DHT-treated WT and KD motoneuron cultures were immunostained at 7 DIV for 
PGC1 (red) and co-stained for -III tubulin (green – a neuronal marker) and DAPI 
(blue, a nuclear marker). The motoneuron survival was calculated by expressing the 
number of -III tubulin-positive cells, with more than 2 processes, as a percentage of 
total cell number (DAPI-positive). The Bar chart shows motoneuron survival in DHT-
treated WT and KD ventral horn cultures in the absence and presence of Resveratrol. 
Motoneuron survival is significantly lower in KD cultures compared to WT cultures in 
the absence of Resveratrol (p < 0.01), however after Resveratrol exposure the 
difference in survival of motoneurons between WT and KD cultures is negligible. 
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Figure 5.5 
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5.2.6 Resveratrol treatment decreases total cell number in WT and KD cultures 
When the total number of DAPI-positive cells (blue) is counted in WT and KD ventral 
horn cultures in the absence and presence of Resveratrol, it appears that Resveratrol 
treatment decreases the total cell number in both WT and KD cultures (Figure 5.6). In 
DHT-treated WT cultures not treated with Resveratrol, the average total cell number 
per field is 260 (+/- 15 SEM, n = 40), however, following Resveratrol treatment, this 
decreases to 201 (+/- 11 SEM, n = 40), which, although a decrease of approximately 
23%, is not a significant decrease. In DHT-treated KD cultures not treated with 
Resveratrol, the average total cell number per field is 231 (+/- 17 SEM, n = 40). 
Following Resveratrol treatment, this decreases by 54% to 105 (+/- 7 SEM, n = 40). 
This decrease is significant (p = 0.008). In the absence of Resveratrol treatment, there 
is only a negligible difference in total cell number between WT and KD cultures. 
However, following Resveratrol treatment, the difference in total cell number between 
WT and KD cultures becomes significant (p=0.01).  
5.2.7 The effects of induction of mitochondrial biogenesis on mitochondrial 
function: Resveratrol treatment depolarizes mitochondrial membrane potential in 
KD motoneurons 
The effects of treatment with Resveratrol on mitochondrial function were examined next 
by assessment of mitochondrial membrane potential. Measurements of TMRM 
fluorescence in DHT-treated WT and KD primary motoneuron cultures that are either 
treated at 6 DIV with Resveratrol or left untreated, showed that Resveratrol exposure 
depolarizes the mitochondrial membrane in both WT and KD motoneurons (Figure 5.7). 
In WT cultures the average TMRM fluorescence in motoneurons decreases to 1267, 
which is 91% (+/- 23% SEM, n = 28) of the average value for untreated WT 
motoneurons. 
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Figure 5.6 The effect of Resveratrol on total cell number in KD and WT ventral 
horn cultures. 
DHT-treated WT and KD motoneuron cultures were immunostained at 7 DIV for 
PGC1 (red) and co-stained for -III tubulin (green – a neuronal marker) and DAPI 
(blue, a nuclear marker). In some cases cultures were treated at 6 DIV for 24 hours 
with Resveratrol. The total cell number (DAPI-positive) was then counted for each field 
used in the motoneuron survival assessment in Figure 5.4. The bar chart summarizes 
the total number of cells in each culture. The total number of cells is significantly lower 
in DHT-treated KD cultures than in DHT-treated WT cultures (p < 0.01). This difference 
becomes greater after 24 hours exposure of cultures to Resveratrol (p < 0.01). 
(Error Bars = standard error of mean) 
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Figure 5.6 
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Figure 5.7 The effect of Resveratrol on mitochondrial membrane potential in WT 
and KD ventral horn motoneurons 
Primary WT and KD motoneuron cultures were examined at 7 DIV. All cultures were 
treated with 5 M DHT (final concentration 50 nM) at 4 DIV and some were treated at 6 
DIV with 50 M Resveratrol. Cultures were incubated at 37 oC with TMRM, diluted in a 
1 M Ca2+ recording medium, prior to imaging. After 30 minutes of incubation cultures 
were washed with, and subsequently imaged in, fresh TMRM-containing recording 
medium. Cultures were kept at 37oC throughout the protocol. The Bar chart 
summarizes TMRM fluorescence in DHT- treated WT and KD motoneuron cultures in 
the absence and presence of Resveratrol, as well as FCCP-treated WT cultures, which 
are a positive control for mitochondrial depolarization. Values are expressed relative to 
the average TMRM fluorescence in WT motoneurons (100.00). Treatment with 
Resveratrol decreases TMRM fluorescence in WT and KD motoneurons although the 
decease is not significant in either genotype. 
Error bars = standard error of mean 
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Figure 5.7 
 
 
 
 
 
 
 
 
 
247 
 
In KD cultures however, the average TMRM fluorescence value decreases to 634 after 
Resveratrol exposure, which is 70% (+/- 17% SEM, n =23) of the average value for 
untreated KD motoneurons. The decrease in TMRM fluorescence in Resveratrol-
treated KD cultures compared to KD cultures that are not exposed to Resveratrol is 
significant (p=0.05). 
5.2.8 Resveratrol causes nuclear condensation and fragmentation in KD 
motoneurons 
Treatment with Resveratrol results in nuclear condensation and fragmentation in 
primary KD motoneurons. When WT cultures are treated with Resveratrol, there is no 
noticeable change in nuclear morphology, size or DAPI staining density (Figure 5.8A). 
However, in KD cultures, motoneuron nuclei have a more fragmented appearance 
following Resveratrol treatment and DAPI staining is more intense (Figure 5.8B). 
5.2.9 The effects of Bezafibrate – an alternative inducer of mitochondrial 
biogenesis on KD motoneurons 
In view of the complicated effects of Resveratrol on KD motoneuron survival and 
viability, an alternative pharmacological inducer of mitochondrial biogenesis was 
examined next by treatment of WT and KD motoneuron cultures with Bezafibrate. 
The expression of PGC1 and motoneuron survival were examined in WT and KD 
cultures in the absence and presence of 50 M Bezafibrate using 
immunohistochemistry. Western blot analysis was not undertaken as a suitable 
antibody was not available. 
When WT and KD primary motoneuron cultures are immunostained for PGC1 at 7 
DIV, PGC1 immunoreactivity (red) increases in KD motoneurons following 24 hour 
Bezafibrate treatment (Figure 5.9A). In WT motoneurons Bezafibrate treatment does 
not result in a noticeable change in PGC1 immunoreactivity. 
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Figure 5.8 The effect of Resveratrol on nuclear morphology in KD and WT ventral 
horn motoneurons 
DHT-treated WT and KD motoneuron cultures were immunostained at 7 DIV for 
PGC1 (red) and co-stained for -III tubulin (green – a neuronal marker) and DAPI 
(blue, a nuclear marker). In some cases cultures were treated at 6 DIV with 
Resveratrol. The images Ai) and ii), show typical examples of WT and KD 
motoneurons, respectively. Image B) shows nuclear morphology in KD motoneurons in 
more detail. 
(Scale bars = 45 m) 
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Figure 5.8 
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5.2.9.2 Motoneuron counts 
The effects of treatment with Bezafibrate on motoneuron survival were examined. 
Motoneuron survival was determined by counting the number of -III tubulin positive 
cells, with more than two processes, as a percentage of total cell number (DAPI-
positive). The results show that 24 hour Bezafibrate treatment increases motoneuron 
survival in KD cultures (Figure 5.9B). Following Bezafibrate treatment, the percentage 
of motoneurons in WT cultures is 40.6 % (+/- 2.3% SEM, n =40),. In KD cultures 
however, the percentage of motoneurons in culture increases by approximately 16% 
following Bezafibrate treatment to 34.62% (+/- 4.6% SEM, n = 40). This increase is 
significant (p=0.04). Following Bezafibrate treatment there is no longer a significant 
difference in motoneuron survival between WT and KD cultures.  
5.2.10 Results summary 
The results in this Chapter strongly suggest that mitochondrial dysfunction is present in 
motoneurons from the AR100 mouse model of Kennedy’s Disease from an early stage 
of development. Functional impairment of mitochondria is indicated by mitochondrial 
membrane depolarization, whilst a decrease in mitochondrial biogenesis is inferred by 
a decrease in PGC1 expression in primary KD motoneurons. When primary 
motoneuron cultures are treated with Resveratrol, which increases PGC1 expression 
and hence mitochondrial biogenesis, motoneuron survival is increased in KD cultures 
although the total cell number decreases and the mitochondrial membrane is 
depolarized. When cultures are treated with an alternative inducer of mitochondrial 
biogenesis, Bezafibrate, KD motoneuron survival significantly improves, however not to 
the extent observed following treatment with Resveratrol. 
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Figure 5.9 The effect of Bezafibrate on PGC1 expression and motoneuron 
survival in WT and KD ventral horn cultures 
DHT-treated WT and KD motoneuron cultures were immunostained at 7 DIV for 
PGC1 (red) and co-stained for -III tubulin (green – a neuronal marker) and DAPI 
(blue, a nuclear marker). In some cases cultures were treated at 6 DIV with Bezafibrate 
(50 M) for 24 hours. Images showing the typical patterns of PGC1 immunoreactivity 
in the absence and presence of Bezafibrate exposure in WT and KD motoneuron 
cultures are shown in Ai) and ii), respectively. The bar chart (B) shows the percentage 
of motoneurons in DHT-treated WT and KD ventral horn cultures in the absence and 
presence of Bezafibrate. The percentage of motoneurons is significantly lower in KD 
cultures compared to WT cultures in the absence of Bezafibrate (p < 0.01), however in 
cultures treated with Bezafibrate there is a significant increase in KD motoneuron 
survival, so that there is no significant difference in motoneuron survival between KD 
and WT cultures. 
(Error Bars = standard error of mean, scale bars = 50 m) 
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Figure 5.9 
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5.3. Discussion 
5.3.1 Mitochondria in KD primary motoneurons are depolarized relative to WT 
controls 
When DHT-treated WT and KD primary embryonic motoneurons were imaged using 
TMRM at 7 DIV, the results revealed that the level of mitochondrial fluorescence in KD 
motoneurons was significantly lower than in WT motoneurons. This indicates that, 
relative to WT motoneurons, the mitochondria in KD motoneurons are depolarized. In 
order to ensure that the protocol and conditions used in this study reliably measure 
mitochondrial membrane potential, 1 M FCCP, which fully depolarizes mitochondria, 
was applied to motoneurons as a control. Following application of FCCP, mitochondrial 
fluorescence decreased significantly, indicating that fluorescence decreases as the 
mitochondrial membrane becomes depolarized. The finding that mitochondria in KD 
motoneurons were depolarized compliments present findings of mitochondrial 
dysfunction in both Motor Neuron Diseases, such as ALS, and CAG-repeat disorders, 
such as Huntington’s disease (Mattiazzi et al, 2002, Guidetti et al, 2001). Furthermore, 
previous studies that have investigated mitochondrial function in KD have shown that 
mitochondria become depolarized in MN-1 cell lines expressing a mutant Androgen 
Receptor (AR) gene (Ranganathan et al, 2009). 
Mitochondrial depolarization in KD motoneurons is indicative of mitochondrial 
dysfunction and increased permeability of the mitochondrial membrane and thus is 
associated with an increased risk of apoptosis (for review see Green & Reed 1998). 
There are several possible causes of mitochondrial depolarization. The most 
interesting cause in the context of this Thesis is ER stress. It has been suggested that 
ER stress results in the accumulation of intracellular Ca2+, which is then buffered by the 
mitochondria, resulting in increased Ca2+ levels in the mitochondrial matrix (Deniaud et 
al, 2007). Increased levels of Ca2+ in the mitochondrial matrix can subsequently lead to 
increased permeability of the mitochondrial outer membrane, which can lead to 
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depolarization and the release of pro-apoptotic proteins such as Cytochrome C (Utt 
2002). Thus it is possible that ER stress, which occurs in KD motoneurons as shown in 
Chapter 3, occurs upstream of the mitochondrial depolarization shown in this Chapter.  
5.3.2 PGC1 expression is lower in KD motoneurons, indicative of decreased 
mitochondrial biogenesis 
The level of expression of peroxisome proliferator-activated receptor  co-activator 1  
(PGC1) has been shown to be a useful indicator of levels of mitochondrial biogenesis 
(Knutti and Kralli 2001). In order to determine PGC1 expression levels in KD 
motoneurons, primary DHT-treated WT and KD motoneuron cultures were 
immunostained with an antibody against PGC1 at 7 DIV. The results show that the 
level of PGC1 immunoreactivity in primary KD motoneurons was lower than in WT 
motoneurons. In addition, in order to confirm the decreased expression quantitatively, 
the level of PGC1 was measured in purified DHT-treated WT and KD motoneurons at 
7 DIV using Western blot analysis. Optical density analysis of the blot reveals that, 
relative to the control protein Actin, PGC1 expression was significantly lower in DHT-
treated KD motoneurons than in DHT-treated WT motoneurons. This reduced PGC1 
expression in KD motoneurons strongly suggests that mitochondrial biogenesis is 
impaired in KD motoneurons. Indeed, it has already been shown that in cell lines 
expressing the mutant AR protein, mitochondrial biogenesis is impaired as indicated by 
reduced PGC1 expression (Ranganathan et al, 2009).  
5.3.3 Resveratrol increases PGC1expression and improves KD motoneuron 
survival but has variable effects on total cell survival 
In order to assess the consequence of impaired mitochondrial biogenesis in KD 
pathogenesis the effects of pharmacological induction of mitochondrial biogenesis were 
examined. One such pharmacological inducer, which has been considered previously 
as a possible tool for increasing mitochondrial biogenesis in Huntington’s Disease, is 
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Resveratrol (Ho et al, 2010). Primary DHT-treated WT and KD motoneuron cultures 
were therefore treated for 24 hours with 50 M Resveratrol and both PGC1 
expression and motoneuron survival were determined. The results showed that 
Resveratrol treatment significantly increased the level of expression of PGC1 in KD 
motoneurons so that there was no longer a difference in PGC1 expression between 
WT and KD motoneurons. This suggests that increasing the expression of PGC1 by 
treatment with Resveratrol is sufficient to overcome the reduction of mitochondrial 
biogenesis induced by expression of the mutant AR in KD motoneurons.  
Analysis of motoneuron survival in WT and KD cultures exposed to Resveratrol 
showed that there was a significant increase in the percentage of motoneurons in 
culture so that the level of motoneuron survival in KD cultures was the same as that 
observed in WT cultures. This dramatic improvement in survival is inconsistent with the 
modest increase in PGC1 expression observed in KD motoneurons. In order to 
address this issue, the total number of cells present in each culture was determined. 
The results show that Resveratrol treatment significantly decreased total cell survival in 
KD cultures. This result, in combination with the fact that motoneuron percentage 
increases, suggests that the decrease in total cell number in KD cultures is a result of a 
greater level of non-motoneuron cell death than motoneuron death. This suggests that 
Resveratrol could also have toxic effects over cells. Indeed, it has been shown 
previously that treatment of prostate cancer cells with Resveratrol resulted in cell death 
(Morris et al, 2002).  
5.3.4 Effects of resveratrol on mitochondrial membrane potential 
Although Resveratrol treatment appears to increase the survival of KD motoneurons, 
despite only modestly increasing PGC1 expression, it is important to determine the 
viability of the surviving motoneurons. In order to do this, mitochondrial membrane 
potential was assessed in DHT-treated WT and KD motoneurons that were exposed to 
Resveratrol for 24 hours. It appears that Resveratrol treatment decreases 
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mitochondrial membrane potential in DHT-treated WT and KD motoneurons, although 
the magnitude of the decrease in both genotypes is not significant. Since Resveratrol 
treatment does not improve the deficits in mitochondrial membrane potential in KD 
motoneurons, it is possible that the quantity of mitochondria as opposed to their 
function is a more potent determinant of motoneuron survival, since Resveratrol 
treatment did increase KD motoneuron survival. 
5.3.5 Resveratrol treatment results in nuclear condensation and fragmentation in 
KD primary motoneurons 
In keeping with the finding that Resveratrol treatment increases KD motoneuron 
survival without improving the deficits in mitochondrial function, the nuclei of surviving 
KD motoneurons were condensed and fragmented following Resveratrol treatment, 
which is indicative of apoptosis (Skalka et al, 1976). This effect is not observed in WT 
cultures. Resveratrol has been shown previously to depolarize the mitochondrial 
membrane in prostate cancer cells (Aziz et al, 2006). As is the case with KD, prostate 
cancer involves changes in AR function (Culig et al, 2001). This could suggest that AR 
function influences the effects of Resveratrol. Indeed, an interaction between 
Resveratrol and the Androgen Receptor has been suggested previously. For example, 
Resveratrol treatment was found to suppress AR transcriptional activity in HeLa cells 
(Shi et al, 2009).  
5.3.6 Bezafibrate increases PGC1expression and improves KD motoneuron 
survival 
The effects of Resveratrol on primary KD motoneuron survival and mitochondrial 
function were complicated and the role of mitochondrial dysfunction in KD 
pathogenesis is difficult to determine on the basis of these results. Therefore the 
effects of an alternative inducer of mitochondrial biogenesis, Bezafibrate, on primary 
KD motoneurons were investigated. When DHT-treated WT and KD motoneurons were 
treated for 24 hours with Bezafibrate, both PGC1 expression and motoneuron survival 
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increased in KD cultures, with no observable effect in DHT- treated WT cultures. As 
was the case with Resveratrol treatment, Bezafibrate significantly increased the level of 
PGC1 expression in primary KD motoneurons, but had only a modest effect on 
motoneuron survival. This result, in combination with the fact that improving 
mitochondrial biogenesis does not appear to improve mitochondrial function in KD 
motoneurons, suggests that mitochondrial biogenesis does not play as significant a 
role as ER stress does in KD pathogenesis (Chapter 4), although comparisons 
between ER and mitochondrial deficits need to be approached with caution. This will be 
discussed further in Chapter 6. 
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CHAPTER 6: DISCUSSION 
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ER stress has been previously shown to play a major role in the pathogenesis of both 
Motor Neuron Diseases (MNDs), such as Amyotrophic Lateral Sclerosis (ALS), and 
Poly-Q repeat disorders, such as Huntington’s Disease (HD) (Saxena et al, 2009, 
Reijonen et al, 2008). In the case of ALS, markers of ER stress including BiP and 
CHOP, have been found to be elevated in motoneurons in SOD1G93A mice that model 
the disease (Saxena et al, 2009) as well as in patient spinal cord autopsy tissue (Atkin 
2008). Furthermore, inhibition of ER stress with Salubrinal, significantly improves 
SOD1G93A motoneuron survival in SOD1 mice and in vitro (Saxena et al, 2008). 
Likewise, BiP and CHOP have also been found to be elevated in cell lines transfected 
with a mutant Huntingtin protein compared to cell lines that had been transfected with a 
control protein (Reijonen 2009). Salubrinal treatment was also found to improve the 
survival of these cells, suggesting that ER stress, at least in part, accounts for the 
observed cell death.  
Despite the strong evidence to suggest that ER stress is likely to play a major, causal 
role in the pathogenesis of both MNDs and Poly-Q disorders, the role of ER stress in 
the pathogenesis of Kennedy’s Disease (KD), has yet to be established.  
In the experiments described in this Thesis, I have shown that both ER Ca2+ depletion 
and ER stress are present in embryonic, primary motoneurons from the AR100 mouse 
model of KD. I have also monitored the presence of ER stress in KD spinal cord tissue 
at various stages of disease progression. The results here have shown the presence of 
ER stress in KD motoneurons even during early embryonic development. These 
findings suggest that ER stress may play a causal role, as opposed to a secondary 
effect, in KD pathogenesis. Indeed, the relative magnitude of ER stress was at its 
greatest in pre-symptomatic KD mice at early stages of disease, indicating that ER 
stress is more likely to have an early role in disease pathology and is less likely to be a 
secondary effect of alternative pathological mechanisms. 
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When cellular Ca2+ handling in Wild-Type (WT) and KD primary motoneurons was 
investigated, it was found that the highest level of cytosolic Ca2+ was present in DHT-
treated KD primary motoneurons, whilst the lowest level of basal cytosolic Ca2+ was 
present in DHT-treated WT motoneurons. This suggests that KD motoneurons are 
potentially more vulnerable to excitotoxic insults than WT motoneurons, which has 
been found to be the case in other Motor Neuron Disorders. In the case of ALS, for 
example, an elevation in cytosolic Ca2+ has been shown to render motoneurons more 
vulnerable to stimuli that increase intracellular Ca2+ (Appel et al, 2001). This increased 
vulnerability arises from the fact that elevated cytosolic Ca2+ is associated with the 
activation of apoptotic pathways (Demaurex et al, 2003, Dykens 1994, Lang et al, 
2002). Indeed, increases in cytosolic Ca2+ have been found to result in self-propagating 
cycles that increase cytosolic Ca2+ levels further and thus trigger apoptosis. For 
instance, elevated cytosolic Ca2+ in neurons appears to be accompanied by an 
increased production of free radicals (Dykens 1994), which results in the activation of 
several pathways that converge and result in further elevation of cytosolic Ca2+ . For 
example, free radical production alters glial cell-mediated removal of glutamate and in 
doing so, activates glutamatergic receptors, which act as Ca2+ channels and 
consequentially increase cytosolic Ca2+. In addition, the production of free radicals also 
results in increased lipid peroxidation (Kakkar et al, 1992), increasing cytosolic Ca2+ as 
a by-product. Cytosolic Ca2+ triggers apoptosis when sequestered by mitochondria, 
which is discussed in detail below (Vindis 2005). Thus any underlying pathology which 
elevates cytosolic Ca2+ renders cells vulnerable to stimuli that increase Ca2+ further. 
The fact that the embryonic KD motoneurons examined in this study had a higher level 
of cytosolic Ca2+ than their WT counterparts, could suggest that embryonic KD 
motoneurons are more vulnerable to increases in Ca2+. 
The level of ER Ca2+ in untreated and DHT-treated WT and KD primary motoneurons 
was inferred by measuring the Thapsigargin-induced increase in cytosolic Ca2+ that 
occurred when motoneurons were imaged in a Ca2+-free recording medium. The 
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results showed that the lowest level of inferred ER Ca2+ was present in DHT-treated KD 
motoneurons, whilst the highest level of ER Ca2+ was present in DHT-treated WT 
motoneurons. These findings suggest that ER stress is more likely to occur in KD 
motoneurons than WT controls since ER function is dependent on ER Ca2+ (Paschen & 
Doutheil 1999). Furthermore, DHT treatment had different effects on WT and KD 
primary motoneurons. Whilst exposure to DHT slightly increased ER Ca2+ in WT 
motoneurons, it significantly reduced ER Ca2+ in KD motoneurons. Thus DHT treatment 
appeared to be detrimental to KD motoneurons in as much as it appears to deplete the 
ER of Ca2+.  Reduced ER Ca2+ can be detrimental to cell survival since ER function is 
Ca2+-dependent and the release of Ca2+ from the ER is one of the triggers of apoptosis 
(Demaurex 2003). Indeed, it has been shown that the release of Ca2+ from the ER 
activates pro-apoptotic proteins, such as Bcl-2-associated X protein (BAX) and Bcl-2 
homologous antagonist killer (BAK), that initiate mitochondrial dysfunction, which in 
turn triggers apoptosis (Scorrano et al, 2003). The pattern of the effect of DHT 
treatment on ER Ca2+ observed in this study reflects the pattern of KD symptom 
manifestation observed in patients i.e. symptoms only occur in males who possess 
high levels of the AR ligand testosterone (Katsuno et al, 2006). These findings, 
together with the fact that ER Ca2+ depletion occurs in KD motoneurons at such an 
early time point, suggest that ER dysfunction may be a trigger of KD, or at the very 
least, is one of the very earliest manifestations of KD pathology.  
Store-operated Ca2+ (SOC) influx occurs following ER Ca2+ depletion as an attempt to 
restore ER Ca2+ homeostasis. This process was therefore examined in untreated and 
DHT-treated WT and KD motoneurons. I found that the highest level of SOC influx was 
detected in DHT-treated KD motoneurons, whilst the lowest level was observed in 
DHT-treated WT motoneurons. This is consistent with the trends observed for ER Ca2+ 
since a lower level of ER Ca2+ is accompanied by a higher level of SOC influx in order 
to compensate for the deficit in ER Ca2+ (Smani et al, 2004). Furthermore, I observed 
that DHT treatment had opposing effects on SOC influx in WT and KD primary 
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motoneurons. In WT motoneurons, DHT treatment decreased SOC influx whilst DHT 
treatment increased SOC influx in KD motoneurons, again suggesting that DHT is 
detrimental to KD motoneurons. An increase in SOC influx can be considered to 
represent a detrimental change to cells for two reasons. The first is that increases in 
SOC influx are associated with ER Ca2+ depletion (Zhang 2004) and, as discussed 
above, the release of Ca2+ from the ER is one of many triggers of apoptosis (Scorrano 
et al, 2003). Secondly, increases in SOC influx result in an increase in cytosolic Ca2+ in 
an attempt to facilitate re-filling of ER Ca2+ (Smani 2004). However, if a pre-existing, 
underlying pathology is present, which depletes the ER of Ca2+ then it is possible that 
as a result an increased SOC influx, cytosolic Ca2+ remains elevated in diseased 
motoneurons. As discussed above, elevated cytosolic Ca2+ is detrimental to the 
survival of cells. 
The kinetics of the responses in cytosolic Ca2+ to both Thapsigargin application and 
Ca2+ introduction into the medium was also examined in order to reveal more about the 
disruption in cellular Ca2+ handling observed in primary KD motoneurons. I found that in 
the case of the Thapsigargin-induced increase in cytosolic Ca2+, the peak of the 
increase in cytosolic Ca2+ in WT and KD motoneurons was reached within a similar 
time frame. However, the response to Thapsigargin was of a more transient nature in 
KD motoneurons than in WT controls. This could suggest that the mechanism by which 
calcium is expelled from the cytosol, for example, the plasma membrane calcium pump 
(PMCA) is more active in KD primary motoneurons than in WT controls. The nature of 
the response to Ca2+ introduction however, suggests that increased PMCA activity is 
unlikely. In KD motoneurons the cytosolic Ca2+ response to Ca2+ introduction was more 
prolonged than in WT controls. It is therefore more likely that the transient nature of the 
cytosolic Ca2+ increase in KD motoneurons in response to Thapsigargin was due to the 
fact that there is a lower starting level of Ca2+ in the ER, so that it is depleted of Ca2+ 
more rapidly and the response duration is therefore shorter. 
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Experiments were also undertaken in primary motoneurons from mice of each sex, 
since KD manifests exclusively in males, and female carriers of the mutation remain 
asymptomatic (Katsuno et al, 2006). It was therefore important to determine whether or 
not the differences observed in ER Ca2+ handling were due to differences in ligand 
availability (i.e. DHT) or inherent differences between male and female AR proteins. 
Under the same treatment conditions, there appeared to be very little difference in 
basal Ca2+, ER Ca2+ or SOC influx between male and female primary KD motoneurons. 
This finding suggests that the differences in Ca2+ handling that were observed between 
WT and KD motoneurons were not determined by sex differences. These results 
strongly suggest that the manifestation of KD is not dependent on inherent differences 
in the AR protein between the sexes, but the availability of the AR ligand and thus AR 
activation.  
It was also important to establish whether or not alterations in ER Ca2+ were directly 
linked to mutant AR activation in the KD mice. The expression of the 
Sarco/Endoplasmic Reticulum ATPase (SERCA) pump is controlled downstream of AR 
activation and is the route by which Ca2+ enters the ER lumen (Foradori et al, 2008). It 
could therefore provide a link between mutations in the AR receptor and changes in ER 
Ca2+. I found that the level of expression of the SERCA2b pump was significantly lower 
in primary KD motoneurons than in WT controls. A lower level of expression of the 
SERCA pump could mean that there is reduced sequestration of Ca2+ from the cytosol 
into the ER lumen, giving rise to increased cytosolic Ca2+ level and lower ER Ca2+. 
However this was not enough to attribute ER Ca2+ depletion to reduced SERCA2b 
expression in DHT-treated KD primary motoneurons because the activity of the 
SERCA2b pump had not been determined and the expression and activity of proteins 
involved in Ca2+ release from the ER, such as the Inositol trisphosphate (IP3) and 
Ryanodine receptor had not been examined. Future experiments should therefore aim 
to investigate the expression and activity levels of such proteins. 
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These experiments establish the presence of ER Ca2+ depletion in KD motoneurons, 
suggesting that ER stress is an early feature of KD pathogenesis. To assess whether 
or not ER stress was occurring in DHT-treated KD motoneurons as a result of ER Ca2+ 
depletion, I examined various markers of the Unfolded Protein Response (UPR). 
Western blot analysis and immunohistochemistry revealed that all of the ER stress 
markers examined, including Binding immunoglobulin protein (BiP), Activating 
Transcription Factor (ATF4) and C/EBP Homologous Protein (CHOP), were all 
significantly elevated in DHT-treated KD motoneurons compared to DHT-treated WT 
controls. These findings therefore suggest that the extent of ER stress was greater in 
KD embryonic primary motoneurons in culture than in WT controls. WT motoneurons 
did not appear to be completely free of ER stress however, possibly due to the effects 
of the culturing process. Indeed, all ER stress markers were also present at detectable 
levels in DHT-treated WT motoneurons. Importantly however, the expression of ER 
stress markers in KD motoneurons was significantly higher than in WT motoneurons. 
KD motoneurons can therefore be considered to have either a higher level of basal ER 
stress, or may be more vulnerable to ER stress-induced by the culturing process. 
The fact that ER stress appeared to be elevated in primary KD motoneurons at such an 
early stage of development, suggested that ER stress was more likely to play a causal 
role in KD pathogenesis as opposed to being a secondary effect of another pathogenic 
mechanism. KD is a multifactorial, progressive disease (Katsuno et al, 2006) and so as 
the disease progresses, it becomes difficult to identify and differentiate between 
pathological triggers and secondary effects. The fact that ER stress was found to occur 
in KD motoneurons prior to birth makes it a strong candidate as an early disease 
trigger. 
Although ER stress was present in KD motoneurons during embryonic development, 
whether it remained a feature of disease at later stages of disease progression was 
also examined. The time points investigated included postnatal day 5 (P5), 3, 12, and 
18 months of age. P5 was selected on the basis that it is the earliest time point at 
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which ER stress was found to occur in the SOD1G93A mouse model of ALS (Saxena et 
al, 2009). Three months of age represents a pre-symptomatic stage of disease in 
AR100 mice, whilst 12 months and 18 months of age are the median time points of 
symptom onset and disease end-stage, respectively (Sopher et al, 2004). 
Examination of markers of ER stress in spinal cord tissue revealed that the expression 
of each ER stress marker measured i.e. BiP, ATF4 and CHOP, was higher in KD spinal 
cord tissue than in WT control tissue at all disease stages, although significant 
differences were predominantly observed at pre-symptomatic disease stages. This 
suggests that the predominant role of ER stress in KD pathogenesis is as an early 
pathological event, although its presence appears to persist throughout the disease. 
The fact that the difference in expression of ER stress markers between WT and KD 
spinal cord tissue decreased with disease progression could be due to the fact that the 
survival of KD motoneurons was lower than the survival of WT motoneurons. Western 
blot analysis did not give an indication of the level of expression in individual 
motoneurons, but the tissue sample as a whole. Therefore, if there are fewer KD 
motoneurons expressing a high level of ER stress marker, the total level of expression 
could be the same as the level of expression from a larger number of WT motoneurons 
expressing a lower level of ER stress marker. Alternatively, the level of ER stress 
markers may increase in WT spinal cord tissue as a natural effect of aging, which has 
previously been suggested to occur (Naidoo et al, 2009). Indeed, at such a late stage 
in mice, it could be the case that aging-induced ER stress conceals underlying 
pathological effects in KD mice. 
Although all of the ER stress markers examined in this study were elevated in KD 
spinal cords compared to WT controls, subtle differences in the expression pattern of 
the markers revealed more about the role of ER stress in KD pathogenesis. For 
example, whilst there was no difference in the expression of BiP between WT and KD 
spinal cord tissue and 12 months and 18 months of age, the difference in the 
expression levels of CHOP between WT and KD spinal cord tissue still appeared to be 
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significant at 12 months of age and substantial (although not significant) at 18 months 
of age. These findings therefore suggest that pro-apoptotic, or downstream markers of 
the UPR remain elevated later into disease progression. Whether or not this means 
that there is a skew in transcription towards pro-apoptotic factors at later disease 
stages however, requires further investigation of the expression of other UPR 
mediators. 
Establishing the presence of ER stress however, does not confirm its role in 
motoneuron degeneration. I therefore attempted to clarify this role by examining the 
relationship between ER stress and motoneuron survival in KD motoneurons. Firstly, 
whether embryonic motoneuron survival was lower in basal culture conditions in KD 
cultures than that of WT controls was examined. Motoneuron counts indicated that the 
survival of KD motoneurons was significantly lower than that of WT motoneurons. This 
suggests that KD motoneuron survival was indeed reduced in the model of KD used in 
this lab.  
These experiments establish that embryonic KD motoneuron survival was significantly 
reduced and that markers of ER stress are significantly elevated in embryonic KD 
motoneurons. In order to determine whether or not ER stress results in motoneuron 
degeneration in the AR100 mouse model of KD, the expression level of Caspase 12, a 
marker of ER stress-induced apoptosis (Nakagawa et al, 2000), was examined. In 
addition, the effects of inhibiting ER stress on Caspase 12 expression, ER Ca2+ and 
motoneuron survival was determined. The results showed that the level of expression 
of Caspase 12 was significantly higher in embryonic, purified KD motoneurons than in 
WT controls. This suggests that there was a greater amount of ER stress-induced 
apoptosis occurring in KD motoneurons and indicates that KD motoneurons are not 
able to overcome ER stress. This could be due to the fact that the UPR is disturbed, or 
that the cause of ER stress, i.e. the presence of the mutated CAG-repeat expansion in 
the AR gene, is fervent, or a combination of the two.  
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Examination of spinal cord tissue revealed that the expression of active Caspase 12 
remains elevated in KD spinal cord relative to WT control tissue at all stages of disease 
progression. The peak increase in Caspase 12 expression was observed in pre-
symptomatic spinal cord tissue, which then declined with disease progression. 
Interestingly, even at disease end-stage, there was a significantly higher level of 
expression of Caspase 12 in KD spinal cord tissue relative to WT control tissue. This 
could suggest that as the disease progresses transcription is skewed towards pro-
apoptotic factors, possibly as a result of the combined effects of KD pathogenesis and 
aging. 
These findings do not however confirm that ER stress-induced apoptosis results in KD 
motoneuron degeneration. The occurrence of ER stress-induced apoptosis can only be 
correlated with decreased motoneuron survival at this point. Therefore the possibility 
that ER stress-induced apoptosis plays a key role in KD motoneuron degeneration was 
investigated by studying the effects of ER stress inhibitors on motoneuron survival. 
In order to inhibit ER stress, motoneuron cultures were treated with Salubrinal, which 
prevents dephosphorylation of eIF2(Boyce et al, 2005). I found that Salubrinal 
improved the survival of both WT and KD motoneurons, with the percentage of 
motoneurons in culture increasing significantly. Following Salubrinal exposure, there 
was no longer a significant difference in the survival of motoneurons in WT and KD 
cultures. These findings not only suggest that ER stress-induced apoptosis plays a key 
role in KD motoneuron death, but that the inhibition of this pathway is sufficient to 
rescue motoneurons; ER stress therefore plays a major role in KD motoneuron 
degeneration. In keeping with the improvement in KD motoneuron survival, the level of 
expression of Caspase 12 in KD motoneurons was also significantly reduced by 
Salubrinal, confirming that inhibition of ER stress rescues motoneurons, possibly 
through the prevention of ER stress-induced apoptosis.  
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At this point it is important to acknowledge that the relationship between ER Ca2+ 
depletion and ER stress can be a two-way interaction. Thus, as well as ER Ca2+ 
depletion resulting in ER stress, ER stress can result in ER Ca2+ depletion. Inhibition of 
ER stress was also found to result in an increase in inferred ER Ca2+ in WT and KD 
motoneurons. Given that Salubrinal treatment also decreased Caspase 12 expression, 
it appears that there is a cycle between ER Ca2+, ER stress and ER stress-induced 
apoptosis. Whilst ER Ca2+ depletion can result in ER stress and therefore ER stress-
induced apoptosis, ER stress can also result in ER Ca2+ depletion which can in turn 
result in activation of Caspase 12 and hence ER stress-induced apoptosis. This toxic, 
propagative cycle appears to be broken by treatment with Salubrinal. 
Another possibility examined in this Thesis was whether or not KD motoneurons are 
inherently more vulnerable to triggers of ER stress. This possibility was examined by 
treating WT and KD cultures with two pharmacological agents that induce ER stress via 
different mechanisms. The first agent was Thapsigargin, and the second agent was 
Tunicamycin, which interferes with post-translational modification of proteins, 
specifically N-glycosylation (Brandish et al, 1996). Interestingly, DHT-treated KD 
motoneuron survival was significantly reduced following exposure to Thapsigargin but 
not following exposure to Tunicamycin at any concentration. This finding suggests that 
KD motoneurons are more vulnerable to ER Ca2+ depletion than to other triggers of ER 
stress, such as alterations in protein structure. However, whether or not ER Ca2+ 
depletion is the major cause of ER stress in KD cannot be determined without 
investigating the role of other causes of ER stress such as ATP and glucose depletion 
(Xu 2005). 
Simultaneous treatment of motoneuron cultures with Thapsigargin and Salubrinal 
revealed that the vulnerability of KD motoneurons to ER Ca2+ depletion was prevented 
by the inhibition of ER stress. Following treatment of DHT- and Thapsigargin-treated 
KD motoneuron cultures with Salubrinal, the survival of KD motoneurons was similar to 
the level of survival observed in DHT-treated WT cultures. This result suggests that 
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treatment of KD motoneurons with Salubrinal is sufficient to eliminate the increased 
vulnerability of KD motoneurons to Thapsigargin treatment 
As well as ER stress, mitochondrial dysfunction has also been found to play a major 
role in the pathogenesis of ALS (Manfredi et al, 2005, Shi et al, 2010) and Huntington’s 
Disease (Oliveira et al, 2010). In the case of ALS for example, both morphological and 
biochemical abnormalities have been found in ALS patient forebrain biopsy tissue and 
the mutant SOD1 mouse model of ALS (Manfredi et al, 2005). Likewise, various 
aspects of mitochondrial function have been found to be disturbed in several mouse 
models of HD. For example, in the R6/2 and YAC128 models of HD, the Ca2+ loading 
capacity of mitochondria in forebrain neurons appeared to be reduced under basal 
conditions, whilst the Ca2+ loading capacity of forebrain mitochondria from the Hdh 150 
knock-in model of HD appeared to be vulnerable to NMDA receptor activation, thus 
cytosolic Ca2+elevation (Oliveira et al, 2007). This strongly suggests that mitochondrial 
deficits play an important role in the pathology of several mouse models of HD. Activity 
of essential mitochondrial proteins such as Complex IV/Cytochrome C Oxidase and 
Aconitase, have also been found to be reduced in the R6/2 mouse model of HD, thus 
the respiratory chain and the Citric Acid cycle also appear to be impaired in HD  
(Tabrizi et al, 2000).  
However, as is the case with ER stress, the role of mitochondrial dysfunction in animal 
models of KD has not been established and evidence of mitochondrial dysfunction in 
KD is predominantly restricted to mutant AR-transfected cell lines (Ranganathan et al, 
2009). In another set of experiments I therefore aimed to determine whether or not 
mitochondrial dysfunction occurred in primary DHT-treated KD motoneurons and 
whether or not mitochondrial dysfunction played a more dominant role than ER stress 
in KD pathogenesis. TMRM fluorescence and PGC1 expression analysis suggested 
that mitochondrial depolarization and impaired mitochondrial biogenesis were present 
in embryonic DHT-treated KD primary motoneurons, respectively. The effects of 
pharmacologically inducing mitochondrial biogenesis on DHT-treated KD primary 
270 
 
motoneuron survival were examined next to determine the importance of impaired 
biogenesis in KD pathology. Although treatment with the mitochondrial biogenesis 
inducer, Resveratrol, appeared to improve DHT-treated KD motoneuron survival, the 
morphology of surviving motoneurons and TMRM fluorescence suggested that there 
was no improvement in motoneuron viability. For instance, following 24 hour 
Resveratrol exposure, KD motoneuron nuclei appeared condensed and fragmented 
and mitochondria remained depolarized. This could suggest that the number of 
mitochondria is a more dominant determinant of motoneuron survival than 
mitochondrial dysfunction in KD motoneurons. It could also suggest however that 
mitochondrial dysfunction does not play a major role in KD pathogenesis. Indeed it has 
been suggested that such mitochondrial dysfunction occurs downstream of ER Ca2+ 
depletion (Arduino et al, 2004) and thus targeting such depletion and consequential ER 
stress could form the basis of a more effective therapy than improving mitochondrial 
biogenesis. It could also be suggested that the most effective therapy for KD would be 
a therapy that targets both ER stress and mitochondrial dysfunction. 
The results presented in this Thesis provide evidence for the presence of ER Ca2+ 
depletion and ER stress in embryonic motoneurons from the AR100 mouse model of 
KD. This early presence of ER stress strongly suggests that ER stress plays an early, 
key role in KD pathology and is not a secondary effect of the disease process. The 
beneficial effects of inhibition of ER stress on KD motoneuron survival also suggest 
that ER stress plays a direct role in the degeneration of motoneurons in KD. 
Furthermore, following treatment of cultures with Salubrinal, there was no longer a 
difference in the survival between WT and KD motoneurons. This suggests that the 
occurrence of ER stress almost completely accounts for the motoneuron degeneration 
that occurs in embryonic KD motoneurons.  
With respect to the initial aims of this Thesis, the above experiments have: 
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1. Established an early, potentially causative role of ER stress in the pathogenesis 
of KD. 
2. Established an early elevation of markers of ER stress in the spinal cord of KD 
mice that decreases with disease progression. 
3. Confirmed that ER stress is related to the motoneuron degeneration observed 
in KD. 
4. Confirmed that mitochondrial dysfunction is an early pathological feature of KD. 
It is therefore possible that therapeutic approaches that aim to target ER stress, for 
example, treatment with Salubrinal, may be a possible therapeutic approach for the 
treatment of KD. Such an approach may be particularly effective if used in combination 
with other agents that target additional pathological mechanisms that are likely to be 
involved in this progressive neurodegenerative disease. 
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APPENDIX 
Solutions & Reagents 
1.1Primary ventral horn motoneuron culture solutions 
1.1.1 Complete Neurobasal Medium (per 150 ml) 
 143.75 ml Neurobasal medium (Gibco) 
 3 ml B27 supplement (Gibco BRL) 
 3 ml Heat-activated Horse Serum (Sigma) 
 1.5 ml Penicillin/Streptomycin (0.6g Penicillin and 1g Streptomycin in 1 litre) 
 125 l 0.5mM L-glutamine 
 75 l 25uM 2-mercaptoethanol (Sigma) 
 1.5 l 10ng/ml CNTF (R&D systems) 
 0.5 l 100pg/ml GDNF (R&D systems) 
 0.5 l BDNF (R&D systems) 
1.1.2 0.25 %Trypsin 
 Preparation: 2.5 % w/v solution 
- 25 mg trypsin powder (Sigma) in 1 ml Phosphate-Buffered Saline (PBS). 
Stored at -20oC, defrosted and used at 37oC. 
1.1.3 Bovine serum albumin (BSA) 
 4% BSA 
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Preparation:  BSA powder (Sigma) in l L15 medium (Gibco). Stored at -20oC, 
used at room temperature 
 
1.1.4 Deoxyribonuclease 1 (DNAse 1) 
DNAse 1 is an enzyme that catalyzes the hydrolytic cleavage of phosphodiester 
linkages in the DNA backbone thus degrading unwanted single- and double-stranded 
DNA (Vitolo et al, 1999).  
Preparation: 1 mg of DNase powder (Sigma) in 1 ml Neurobasal medium 
(Gibco BRL). Aliquoted and stored at -20oC, used at room temperature. 
1.1.5 Optiprep 
Optiprep is a density gradient medium that has been used previously to purify primary 
ventral motoneurons (Gingras et al, 2007). The high density of Optiprep facilitates the 
fractionation of motoneurons by encouraging flotation from an area of relatively high 
density through either a continuous or discontinuous gradient. 
Preparation: 10.4% Optiprep solution in 10 mM Trycine and 4% Glucose w/v 
(Nycomed) in clear L15 (Gibco) medium 
1.1.6 Polyornithine 
Polyornithine is used to coat the coverslips with a negative charge prior to culturing 
thus attracting the positively charged phospholipid membranes of cells growing in 
culture. 
 Preparation: 1.5mg/ml in sterile water. Used at 1 in 1000 in sterile water 
(Baxter) 
1.1.7 Laminin (already prepared by Sigma – 1mg/ml) 
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Coverslips are coated with Laminin prior to culturing. Laminin is an extracellular matrix 
glycoprotein, which guides and promotes the growth and differentiation of neuronal 
cells (Luckenbill-Edds1997). 
 Preparation: Dilute in L15 medium at 1 in 200 
1.2 Genotyping Solutions & Reagents 
1.2.1 Rapid Digestion Buffer (RDB); for the digestion of embryonic tail biopsies 
 10 mM Tris-HCl (pH 8.3) 
 50 mM KCl 
 0.1 mg/ml Gelatin 
 0.45% NP40 
 0.45% Tween-20 
1.2.2 10 X Electrophoresis Buffer (10X TBE) 
 1 L double distilled water 
 108 g Tris Base 
 40 mls 0.5M EDTA (pH8.0) 
1.3 Confocal microscopy solutions 
1.3.1 Confocal recording medium  
Table 1 summarizes the recipe for confocal recording medium. The amounts given are 
in grams per litre of distilled water. In addition to the components below, 50 l of 1 M 
CaCl2 is added to 50 ml of recording medium when a 1 mM Ca
2+ recording medium is 
required. 
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Table 1 
 Molecular Weight Grams/Litre Final conc. 
NaCl 58.44 7.305 125 mM 
KCl 74.55 0.372 5 mM 
Na3PO4.12H2O 380.12 0.380 1 mM 
MgSO4.7H2O 246.48 0.246 1 mM 
D-Glucose 180.16 1.000 1g/L 
Hepes 238.3 4.766 20 mM 
 
1.3.2 Fluo 4-AM – non-ratiometric/single wave calcium indicator 
Per 1 ml of 1 mM Ca2+ confocal recording medium:  5 l 1M Fluo 4-AM 
(Invitrogen) + 2 l of 10% Pluronic acid. 
1.3.3 Fura 2–ratiometric calcium indicator 
Per 1 ml of Ca2+ confocal recording medium: 5 l 1mM Fura 2 (Invitrogen) + 2 l 
of 10% Pluronic acid 
1.3.4 Thapsigargin  
 10 l of 1mM Thapsigargin (in DMSO) per 1 ml of calcium-free recording 
medium (to produce a final concentration of 1 M in the imaging chamber) 
1.3.5 Ionomycin  
 50 l of per 1 ml of 1 mM Ca2+ recording medium (to produce a final 
 concentration of 5 M in the imaging chamber 
1.3.6 10 mM Ca2+ recording medium  
 10 ml of 1mM Ca2+ per 1 ml of calcium-free recording medium (producing a final 
 concentration of 1 M in the imaging chamber 
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1.4 Western blot solutions 
1.4.1 Bovine serum albumin (BSA) standard solutions 
BSA controls are used to obtain protein standards to which samples of interest are 
calibrated. 
Preparation: 2, 1, 0.5, 0.25 and 0.125 mg of BSA in 1 ml homogenizing buffer to 
make control solutions of 2, 1, 0.5, 0.25 and 0.125 mg/ml 
1.4.2 Culture tissue and P5 spinal cord homogenising buffer 
500 ml Tris buffer: 
- 0.302g Tris Base (5 mM in 500 mls), and 0.394g Tris HCl (5 mM in 500 
mls) 
-400 ml distilled water 
-Make up to a pH of 6.8 by adding NaOH 
 2% SDS (10g) 
 2 mM EDTA (0.372g) 
 2 mM EGTA (0.468g) 
1.4.3 Resolving gel  
For the purposes of the proteins being identified, 7.5 % and 10.5 % gels were made, 
which are suitable for detecting proteins in the range of 25-200 kDa and 15-100 kDa, 
respectively (according to manufacturer’s instructions). 
In the case of the 7.5% gel the preparation was as follows: 
 2.5 ml Protogel resolving buffer (stored at room temperature) 
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 4.935 ml dH2O (stored at room temperature) 
 2.5 ml 30 % acrylamide (stored at room temperature) 
 50 l 10 % ammonium persulphate (stored at -20oC) 
 5 l TEMED (stored at room temperature) 
1.4.4 Stacking gel 
 4.137 ml Protogel stacking buffer (stored at room temperature) 
 833 l 30% acrylamide 
 25 l 10% ammonium persulphate  
 5 l Tetramethylethylenediamine (TEMED)   
The stacking gel sets very quickly following the addition of ammonium persulphate and 
TEMED, and therefore care was taken to add these reagents to the gel solution just 
prior to it being poured into the combs (see section 2.7.3).    
1.4.5 Running buffer 
 100 ml Stock running buffer (National diagnostic, stored at room temperature) 
  - 0.25 M Tris 
  - 1.92 M Glycine 
  - 1% SDS 
 900 ml dH2O  
1.4.6 Transfer buffer  
100 ml Stock transfer buffer (National diagnostic, stored at room temperature), 
per litre dH2O: 
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-Glycine  29.3 g 
-TRIS base  58.1 g 
-SDS   3.75 g  
 200 ml Methanol 
 700 ml dH2O 
1.4.7 Blocking solution 
Approximately 10 ml of blocking solution is required per blot 
 95% PBS + 0.1% Tween 
 5% milk 
1.5 Immunohistochemistry 
1.5.1 Blocking solution 
 92% PBS + 0.1% Triton X 
 5% Milk 
 3% Animal serum (depending on host of secondary antibody) 
1.6 Immunostaining and Western Blot Antibodies (Table 2) 
The antibodies used in this study for immunohistochemistry (IHC) and western blot 
analysis (WB) are summarized in Table 2. 
 
 
 
 
279 
 
 
Table 2: Antibodies 
Antibody IHC 
concentration 
WB 
concentration 
Purpose Supplier Reference 
Neuronal Antibodies  
-III tubulin 
anti-rabbit 
1 in 1000 N/A Neuronal marker Abcam 
18207 
Chen et al, 
2010 
MAP2 anti-
mouse 
1 in 1000 N/A Neuronal marker Abcam 
11267 
Orlova et al, 
2010 
Chicken 
Peripherin 
1 in 1000 N/A Ventral motoneuron 
marker 
EnCor Errante et al, 
1994 
Nuclear Stain  
DAPI 1 in 2000 N/A Nuclear stain Sigma D8417 Collins, 1997 
UPR/ER stress markers  
BiP anti-
rabbit 
1 in 500-1000 1 in 1000 ER chaperone 
protein 
Abcam 
21685 
Chai et al, 
2010 
Phospho-
eIF2 anti-
rabbit 
1 in 100 1 in 1000 UPR activation Abcam 
19288 
Not available 
ATF4 anti-
mouse 
1 in 500 1 in 1500 UPR activation Abcam 
50546 
Ouyang et al, 
2011 
CHOP anti-
mouse 
1 in 500 1 in 500 Pro-apoptotic 
protein downstream 
of UPR 
Abcam 
11419 
Nishina et al, 
2010 
 
Caspase 12 
anti-rabbit 
1 in 500 1 in 1000 ER stress-induced 
apoptosis 
Abcam 
62484 
Chen et al, 
2010 
ER calcium pump  
SERCA 
anti-rabbit 
1 in 400 1 in 1000 ER calcium pump Abcam 3625 Babai et al, 
2010 
Mitochondrial Biogenesis  
PGC1anti
-mouse 
1 in 500 1 in 1000 Inducer of 
mitochondrial 
biogenesis 
Abcam 
54481 
Kim et al, 
2010 
Loading control  
 Actin anti-
mouse 
N/A 1 in 5000 Western blot 
loading control 
Abcam 8226 Xu et al, 
2011 
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